Carbohydrate conjugates as delivery agents for oligonucleotides
Carbohydrate-conjugated siRNA agents efficiently target liver cells by leveraging asialoglycoprotein receptors, addressing the challenge of in vivo delivery and treatment of liver diseases.
Patent Information
- Application Number
- JP2022186311
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2008-09-16
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2028-12-04
AI Technical Summary
There is a need for improved in vivo delivery of oligonucleotide therapeutics, particularly siRNA agents, that can efficiently target specific cells such as liver parenchymal cells and macrophages, and effectively treat conditions like hepatitis and liver disorders by conjugating them with receptor-specific ligands.
Conjugating siRNA agents with carbohydrate ligands such as monosaccharides, disaccharides, or polysaccharides, specifically targeting liver cells by exploiting the high affinity of asialoglycoprotein receptors, and using cleavable linking groups to enhance intracellular delivery.
The carbohydrate-conjugated siRNA agents effectively target and silence genes in liver cells, providing therapeutic benefits for hepatitis and other liver disorders by enhancing delivery and reducing extracellular degradation.
Smart Images

Figure 0007590395000186 
Figure 0007590395000187 
Figure 0007590395000188
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 60 / 992,309, filed December 4, 2007; U.S. Provisional Patent Application No. 61 / 013,597, filed December 13, 2007; U.S. Provisional Patent Application No. 61 / 127,751, filed May 14, 2008; U.S. Provisional Patent Application No. 61 / 091,093, filed August 22, 2008; and U.S. Provisional Patent Application No. 61 / 097,261, filed September 16, 2008. [Technical Field]
[0002] The present invention relates to the field of therapeutic agent delivery using carbohydrate conjugates. In particular, the present invention provides novel carbohydrate conjugates and iRNA agents comprising these conjugates that are advantageous for in vivo delivery of iRNA agents, as well as iRNA compositions suitable for in vivo therapeutic use. Furthermore, the present invention provides methods for making these compositions and methods for using these compositions to introduce these iRNA agents into cells, for example, for the treatment of various disease states. [Background technology]
[0003] Oligonucleotide compounds have important therapeutic applications in medicine. Oligonucleotides can be used to silence genes that cause certain diseases. Gene silencing prevents the production of proteins by inhibiting translation. Importantly, gene silencing agents are promising alternatives to traditional small organic compounds that inhibit the function of disease-associated proteins. siRNA, antisense RNA, and microRNA are oligonucleotides that prevent the production of proteins through gene silencing.
[0004] RNA interference, or "RNAi," is a term first coined by Fire and colleagues to describe the observation that double-stranded RNA (dsRNA) can block gene expression (Non-Patent Document 1). Short dsRNAs direct gene-specific posttranscriptional silencing in many organisms, including vertebrates, providing a new tool for studying gene function. RNAi is mediated by the RNA-induced silencing complex (RISC), a sequence-specific multicomponent nuclease that destroys messenger RNAs homologous to the silencing trigger. RISC is known to contain short RNAs (approximately 22 nucleotides) derived from the double-stranded RNA trigger, but the protein components of this activity are unknown.
[0005] siRNA compounds are promising agents for a variety of diagnostic and therapeutic purposes. They can be used to identify gene functions. Furthermore, siRNA compounds offer great potential as a new type of pharmaceutical that acts by silencing disease-causing genes. Research is currently underway to develop interfering RNA therapeutics for the treatment of many diseases, including central neurological disorders, inflammatory diseases, metabolic disorders, tumors, infectious diseases, and eye diseases.
[0006] siRNAs have been shown to be highly effective as potential antiviral therapeutics, and many examples have been published recently. siRNA molecules directed against targets in the viral genome dramatically reduce viral titers by several orders of magnitude in animal models of influenza (Non-Patent Documents 2-3), respiratory syncytial virus (RSV) (Non-Patent Document 4), hepatitis B virus (HBV) (Non-Patent Document 5), hepatitis C virus (Non-Patent Documents 6-7), and SARS coronavirus (Non-Patent Document 8).
[0007] Antisense technology refers to the complementary hybridization of relatively short oligonucleotides to mRNA or DNA, such that the normal essential functions of intracellular nucleic acids, such as mRNA or DNA, are disrupted (e.g., protein synthesis). Hybridization is the sequence-specific hydrogen bonding of the oligonucleotide to the RNA or single-stranded DNA via Watson-Crick base pairing. Such base pairs are said to be complementary to each other.
[0008] Cohen (Non-Patent Document 9) discusses two types of naturally occurring events that alter the expression level of target sequences. The first, hybridization arrest, describes a termination event in which an oligonucleotide inhibitor binds to a target nucleic acid, thereby preventing essential proteins (most often ribosomes) from binding to the nucleic acid due to simple steric hindrance. Methylphosphonate oligonucleotides (Non-Patent Document 10) and α-anomeric oligonucleotides are the two most widely studied antisense agents, which are thought to interfere with nucleic acid function by hybridization arrest.
[0009] Another way that antisense oligonucleotides alter the expression level of target sequences is through hybridization to target mRNA followed by enzymatic cleavage of the target RNA by intracellular RNase H. 2'-deoxyribofuranosyl oligonucleotides or oligonucleotide analogs hybridize to the target RNA, and the resulting duplex activates the RNase H enzyme, cleaving the RNA strand and thereby disrupting the normal function of the RNA. Phosphorothioate oligonucleotides are the most prominent example of antisense drugs that act through this type of antisense termination event.
[0010] The opportunity to use these and other nucleic acid-based therapeutics holds great promise, providing solutions to medical problems that currently cannot be addressed by traditional medicine. The locations and sequences of an increasing number of disease-associated genes are being identified, and clinical trials of nucleic acid-based therapeutics for a variety of diseases are currently underway.
[0011] Despite the progress in the application of oligonucleotides and oligonucleotide analogs as therapeutic agents, there is still a need for oligonucleotides with improved pharmacological properties (for example, serum stability, delivery to appropriate organs or cells, and transmembrane delivery).In efforts to improve the transmembrane delivery of nucleic acids and oligonucleotides, protein carriers, antibody carriers, liposomal delivery systems, electroporation, direct injection, cell fusion, viral vectors, and calcium phosphate-mediated transformation have been utilized.However, most of these techniques are limited by the cell types that can transmembrane transport and the conditions required to achieve such transport.
[0012] Efficient delivery to cells in vivo requires specific targeting and substantial protection from the extracellular environment, particularly serum proteins. One way to achieve specific targeting is to conjugate a targeting moiety to the iRNA agent. The targeting moiety serves to target the iRNA agent to the desired target site. One way that a targeting moiety can improve delivery is through receptor-mediated endocytosis activity. This uptake mechanism involves the movement of an iRNA agent bound to a membrane receptor into the interior of a membrane-enclosed region via invagination of a membrane structure or fusion of the delivery system with the cell membrane. This process is initiated by activation of a cell surface or membrane receptor after a specific ligand binds to the receptor. Many receptor-mediated endocytosis systems are known and have been studied, including those that recognize sugars (e.g., galactose, mannose, mannose-6-phosphate), peptides, and proteins (e.g., transferrin, asialoglycoprotein, vitamin B12, insulin, and epidermal growth factor (EGF)). The asialoglycoprotein receptor (ASGP-R) is a high-capacity receptor that is highly abundant in hepatocytes. ASGP-R exhibits a 50-fold higher affinity for N-acetyl-D-galactosamine (GalNAc) than for D-Gal. Previous studies have shown that while multivalency is necessary to achieve nM affinity, adequate spacing between sugars is also crucial.
[0013] The mannose receptor, which has a high affinity for D-mannose, is another important carbohydrate-based ligand-receptor pair. The mannose receptor is highly expressed in certain cell types, such as macrophages and possibly dendritic cells. Mannose conjugates and mannosylated drug carriers have been successfully used to target drug molecules to these cells. See, for example, Non-Patent Documents 11-14.
[0014] Lipophilic moieties such as cholesterol or fatty acids, when conjugated to highly hydrophilic molecules such as nucleic acids, can significantly improve plasma protein binding and consequently increase circulatory half-life. Furthermore, binding to specific plasma proteins, such as lipoproteins, has been shown to increase uptake in specific tissues expressing the corresponding lipoprotein receptors (e.g., LDL receptor, HDL receptor, or scavenger receptor SR-B1). See, for example, Non-Patent Documents 15-16. Lipophilic conjugates can also be used in combination with targeting ligands to improve intracellular trafficking of targeted delivery approaches. [Prior art documents] [Non-patent literature]
[0015] [Non-Patent Document 1] Fire et al. (1998) Nature 391,806-811; Elbashir et al. (2001) Genes Dev.15,188-200 [Non-patent document 2] 2Ge et al. (2004) Proc.Natl.Acd.Sci.USA,101,8676-8681;Tompkins et al. (2004) Proc.Natl.Acd.Sci.USA,101,8682-8686 [Non-patent document 3] Thomas et al. (2005) Expert Opin. Biol. Ther. 5, 495-505 [Non-patent document 4] Bitko et al. (2005) Nat.Med.11,50-55 [Non-patent document 5] Morrissey et al. (2005) Nat.Biotechnol.23,1002-1007 [Non-patent document 6] Kapadia(2003) Proc.Natl.Acad.Sci.USA,100,2014-2018 [Non-Patent Document 7] Wilson et al. (2003) Proc. Natl. Acad. Sci. USA, 100, 2783-2788 [Non-patent document 8] Li et al. (2005) Nat.Med.11,944-951 [Non-Patent Document 9] Oligonucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Inc., 1989, Boca Raton, Fla. [Non-Patent Document 10] Miller et al. (1987) Anti-Cancer Drug Design, 2, 117-128 [Non-Patent Document 11] Biessen et al. (1996) J.Biol.Chem.271,28024-28030 [Non-Patent Document 12] Kinzel et al. (2003) J. Peptide Sci. 9, 375-385 [Non-Patent Document 13] Barratt et al. (1986) Biochim.Biophys.Acta 862,153-64 [Non-Patent Document 14] Diebold et al. (2002) Somat.Cell Mol.Genetics 27,65-74 [Non-Patent Document 15] Bijsterbosch, MK, Rump, ET et al. (2000) Nucleic Acids Res. 28, 2717-25 [Non-Patent Document 16] Wolfrum, C., Shi, S. et al. (2007) 25, 1149-57 Summary of the Invention [Problem to be solved by the invention]
[0016] There is a clear need for new iRNA agents conjugated to receptor-specific ligands and methods for preparing them that address the shortcomings of in vivo delivery of oligonucleotide therapeutics, as described above. The present invention is directed to this critical objective. [Means for solving the problem]
[0017] In one aspect, the invention provides an iRNA agent conjugated to at least one carbohydrate ligand, e.g., a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide. These carbohydrate-conjugated iRNA agents specifically target liver parenchymal cells. In one embodiment, the iRNA agent includes two or more carbohydrate ligands, preferably two or three. In one embodiment, the iRNA agent includes one or more galactose moieties. In another embodiment, the iRNA agent includes at least one (e.g., two or three or more) lactose molecules (lactose is glucose linked to galactose). In another embodiment, the iRNA agent includes at least one (e.g., two or three or more) N-acetyl-galactosamine (GalNAc), N-Ac-glucosamine (GluNAc), or mannose (e.g., mannose-6-phosphate). In one embodiment, the iRNA agent includes at least one mannose ligand, and the iRNA agent targets macrophages.
[0018] In one aspect, the invention features an iRNA agent that includes a carbohydrate ligand, the presence of which can increase delivery of the iRNA agent to the liver. Thus, an iRNA agent that includes a carbohydrate ligand can be useful for targeting genes whose expression in the liver is undesirable. For example, an iRNA agent that includes a carbohydrate ligand can target nucleic acid expression by a hepatitis virus (e.g., hepatitis C, hepatitis B, hepatitis A, hepatitis D, hepatitis E, hepatitis F, hepatitis G, or hepatitis H).
[0019] In one embodiment, the carbohydrate-conjugated iRNA agent targets a gene of the Hepatitis C virus. In another embodiment, an iRNA agent that targets a gene of the Hepatitis C virus can be administered to a person who has hepatitis (e.g., acute hepatitis or chronic hepatitis), i.e., inflammation of the liver, or is at risk of developing liver inflammation. A person who is a candidate for treatment with a carbohydrate-conjugated iRNA agent, e.g., an iRNA agent that targets a gene of HCV, may exhibit symptoms indicative of HCV infection, such as jaundice, abdominal pain, enlarged liver, and fatigue.
[0020] In one embodiment, the carbohydrate-conjugated iRNA agent targets the 5' core region of HCV, which is immediately downstream of the ribosomal toe-print spanning the initiating methionine. In another embodiment, the iRNA agent targets any one of the nonstructural proteins of HCV (e.g., NS3, NS4A, NS4B, NS5A, or NS5B). In another embodiment, the iRNA agent targets the E1, E2, or C gene of HCV.
[0021] In another embodiment, the carbohydrate-conjugated iRNA agent targets hepatitis B virus (HBV), and the iRNA agent has a sequence substantially similar to that of a gene of HBV, e.g., the protein X (HBx) gene of HBV.
[0022] Carbohydrate-conjugated iRNA agents can also be used to treat other liver disorders, including disorders characterized by unwanted cell proliferation, hematological disorders, metabolic disorders, and disorders characterized by inflammation. Liver proliferative disorders can be, for example, benign or malignant, e.g., cancer (e.g., hepatocellular carcinoma (HCC), liver metastasis, or hepatoblastoma). Liver hematological or inflammatory disorders can be, for example, disorders involving clotting factors, complement-mediated inflammation, or fibrosis. Liver metabolic diseases include dyslipidemia and abnormal glucose regulation. In one embodiment, a liver disorder is treated by administering one or more iRNA agents having a sequence substantially identical to a sequence in a gene involved in the liver disorder.
[0023] In one embodiment, the carbohydrate-conjugated iRNA agent targets a nucleic acid expressed in the liver, eg, ApoB RNA, c-jun RNA, β-catenin RNA, or glucose-6-phosphate mRNA.
[0024] For example, for the treatment of glucose metabolism-related disorders, such as diabetes (e.g., type 2 diabetes), an iRNA targeting glucose-6-phosphate can be administered to a subject to inhibit hepatic glucose production. This iRNA agent can be administered to an individual at risk of this disorder to delay the onset of the disorder or the symptoms of the disorder. [Brief explanation of the drawings]
[0025] [Figure 1] Conjugation of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to the 3'-end (I) and 5'-end (II) of double-stranded nucleic acids and the 3'-end (III) and 5'-end (IV) of single-stranded nucleic acids. The double-stranded nucleic acid may have two 3'-overhangs, one overhang at the sense or antisense 3'-end, or no overhang; Q is O or S. [Figure 2] Conjugation of sugars (monosaccharides) to nucleic acids: (V) the 3'-end of both strands (sense and antisense or guide strands); (VI) the 3'-end of one strand (sense or antisense) and the 5'-end of the second, complementary strand; and (VII) conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to the 5'-end of both strands. Double-stranded nucleic acids can have two 3'-overhangs, one overhang at the 3'-end of the sense or antisense, or no overhangs. [Figure 3]Conjugation of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to the 3'-end and 5'-end of one strand (sense or antisense / guide strand). Double-stranded nucleic acids can have two 3'-overhangs, one overhang at the 3'-end of the sense or antisense, or no overhangs. [Figure 4] Sugar (monosaccharide) conjugation to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to the 3'-end (IX) and 5'-end (X) of the sense or antisense strand; q = 0 to 10. The double-stranded nucleic acid may have two 3'-overhangs, one overhang at the sense or antisense 3'-end, or no overhangs. [Figure 5] Conjugation of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to the 3'- and 5'-ends (XI), 3'- and 5'-ends (XII), and 5'-ends (XIII) of oligonucleotides; q = 0–10. [Figure 6] Conjugation of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to nucleic acids separated by an additional spacer: XIV - 3'-end conjugates with alkyl spacers and / or PEG spacers double-stranded nucleic acids; XV - 5'-end conjugates with alkyl spacers and / or PEG spacers; XVI and XVII - corresponding 3'-end conjugates and 5'-end conjugates of single-stranded nucleic acids / oligonucleotides. A and B represent alkyl spacers or PEG spacers and combinations thereof, and Q' = CH2, O, S, SS, NH, or NMe. Double-stranded nucleic acids may have two 3'-overhangs, one overhang at the sense or antisense 3'-end, or no overhang. [Figure 7] Hybrid conjugates of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. and a second selected ligand to a double-stranded nucleic acid: XX - sequential conjugation at the 3'-end; XXI - 3'-end ligand and 5'-end pteroic acid analog on the sense or antisense strand; XXII - 5'-end ligand and 3'-end pteroic acid analog on the sense or antisense strand; XXIII - pteroic acid analog on the sense or antisense strand 5'-end and a preferred ligand on the antisense or sense strand 3'-end, or vice versa; XXIV - sequential conjugation of a selected ligand and a pteroic acid analog to the 5'-end of the sense or antisense strand of a double-stranded nucleic acid. L is a selected ligand. [Figure 8] Hybrid conjugates of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. and a second selected ligand to a single-stranded nucleic acid: XXV - 3'- or 5'-end sequential conjugation; XXVI - 3'- or 5'-end ligand and 5'- or 3'-pteroic acid analog. L is the ligand of choice. [Figure 9] Conjugation of sugars (monosaccharides) to nucleic acids. Conjugation of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to lipids or lipid-like molecules with spacers / tethers (XIII) and lipids or lipid-like molecules without spacers / tethers (XIX). [Figure 10]Sugar binding to nucleic acids. Triantennary galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. are conjugated to the 3'-end (XX) and 5'-end (XXI) of double-stranded nucleic acids and the 3'-end (XXII) and 5'-end (XXIII) of single-stranded nucleic acids. The double-stranded nucleic acid may have two 3'-overhangs, one overhang at the sense or antisense 3'-end, or no overhang; Q is O or S. [Figure 11] Sugar (monosaccharide) attachment to nucleic acids. (XXIV) at the 3'-end of both strands (sense and antisense or guide strands); (XXV) at the 3'-end of one strand (sense or antisense) and the 5'-end of the second, complementary strand; and (XXVI) at the 5'-end of both strands. See Figure 1 for definitions of R, X, Y, Z, and Q. Double-stranded nucleic acids may have two 3'-overhangs, one overhang at the sense or antisense 3'-end, or no overhangs. Similarly, the monoantennary sugar moiety(s) in Figures 3-9 are replaced with the triantennary sugar moiety(s) described in Figures 10 and 11. [Figure 12] Conjugation of oligosaccharides to nucleic acids. Conjugation of analogs or derivatives of galactose, N-acetylgalactosamine, mannose, glucose, glucosamine, fucose, lactose, etc. to the 3'-end (XXVII) and 5'-end (XXVIII) of double-stranded nucleic acids and the 3'-end (XXIX) and 5'-end (XXX) of single-stranded nucleic acids. The double-stranded nucleic acid may have two 3'-overhangs, one overhang at the sense or antisense 3'-end, or no overhang; Q is O or S. Similarly, the sugar moiety(s) in Figures 2-9 are replaced with the oligosaccharide moieties described in Figure 12. [Figure 13] A triantennary GalNAc double-stranded oligonucleotide conjugate with a cleavable disulfide bond. [Figure 14] A triantennary GalNAc double-stranded oligonucleotide conjugate with a cleavable disulfide bond. [Figure 15] In vivo apoB gene silencing of galactose-siRNA conjugates. [Figure 16] Structure of cholesterol and (GalNAc)3 linked together via a phosphate bond. [Figure 17] Glycolipid-siRNA conjugate strategy. [Figure 18] Binding affinity and multivalency of the asialoglycoprotein receptor. [Figure 19] Synthesis of hyperbranched conjugates from simple monomers. [Figure 20] Glycolipid-siRNA conjugates for loading and liver targeting of LDL and HDL. [Figure 21] Glycolipid-siRNA conjugates: synthesis. [Figure 22] Monomers for carbohydrate conjugation to siRNA. [Figure 23] Synthesis of GalNAc building blocks. [Figure 24] Synthesis of GalNAc building blocks (II). [Figure 25] GalNAc cluster for liver targeting. [Figure 26] Carbohydrate (GalNAc) cluster for conjugation to siRNA. [Figure 27] Multivalent GalNAc-siRNA conjugates. [Figure 28] Carbohydrate building blocks for 5' conjugation. [Figure 29] Synthesis of mannose conjugate building blocks. [Figure 30] Building blocks for post-synthetic carbohydrate conjugates. [Figure 31]Comparison of gene silencing by cholesterol-conjugated siRNA and cholesterol-(GalNAc)3-conjugated siRNA. [Figure 32] Comparison of the duration of effect on serum cholesterol levels by cholesterol-conjugated siRNA and cholesterol-(GalNAc)3-conjugated siRNA. [Figure 33] Comparison of Cy3-labeled siRNA uptake by cholesterol-conjugated siRNA and cholesterol-(GalNAc)3-conjugated siRNA. [Figure 34] Schematic of conjugate design considerations. [Figure 35] Schematic of the conjugate design. [Figure 36] Two-branched and three-branched conjugates. [Figure 37] Two different conjugates of the present invention. [Figure 38] Some exemplary arrangements of disulfide bonds in conjugates. [Figure 39] In vivo silencing of FVII by carbohydrate-conjugated siRNA. [Figure 40] In vivo silencing of FVII by carbohydrate-conjugated siRNA. [Figure 41] In vivo silencing of ApoB by carbohydrate-conjugated siRNA. [Figure 42] In vivo silencing of ApoB by carbohydrate-conjugated siRNA. [Figure 43] In vitro silencing of ApoB by carbohydrate-conjugated siRNA. [Figure 44] Competition between carbohydrate-conjugated siRNA and the ASGR ligand asialofetuin (ASF) during in vitro uptake. [Figure 45] In vitro receptor binding and uptake of carbohydrate conjugates. [Figure 46] Galactose conjugates and in vivo gene silencing. DETAILED DESCRIPTION OF THE INVENTION
[0026] The present invention is based on the discovery that conjugating a carbohydrate moiety to an iRNA agent can optimize one or more properties of the iRNA agent. Often, the carbohydrate moiety is attached to a modified subunit of the iRNA agent. For example, the ribose sugar of one or more ribonucleotide subunits of the iRNA agent can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier to which a carbohydrate ligand is attached. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose-replacement modified subunit (RRMS). The cyclic carrier can be a carbocyclic ring system (i.e., all ring atoms are carbon atoms) or a heterocyclic ring system (i.e., one or more ring atoms can be a heteroatom, e.g., nitrogen, oxygen, sulfur). The cyclic carrier can be a monocyclic ring system or contain two or more rings (e.g., fused rings). The cyclic carrier can be a fully saturated ring system or contain one or more double bonds.
[0027] The carrier further comprises (i) at least one "backbone attachment point," preferably two "backbone attachment points," and (ii) at least one "tethering attachment point." As used herein, a "backbone attachment point" refers to a functional group (e.g., a hydroxyl group), or generally an available bond, suitable for incorporation of the carrier into the backbone of a ribonucleic acid (e.g., a phosphate backbone, or a modified phosphate backbone (e.g., a sulfur-containing backbone)). In some embodiments, a "tethering attachment point" (TAP) refers to a ring atom, e.g., a carbon atom or heteroatom (different from the atom providing the backbone attachment point), of the cyclic carrier to which the selected moiety is attached. This moiety can be, for example, a carbohydrate (e.g., a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, and polysaccharide). Optionally, the selected moiety is connected to the cyclic carrier by an intervening tether. Thus, cyclic carriers often contain functional groups (e.g., amino groups) suitable for the incorporation or tethering of another chemical entity (e.g., a ligand to a constituent ring), or generally provide bonds suitable for the incorporation or tethering of another chemical entity (e.g., a ligand to a constituent ring).
[0028] In one aspect, the invention features a compound having the structure shown in formula (CI): [ka] During the ceremony, A and B, each occurrence independently, are hydrogen, a protecting group, an optionally substituted aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, polyethylene glycol (PEG), a phosphate, a diphosphate, a triphosphate, a phosphonate, a phosphonothioate, a phosphonodithioate, a phosphorothioate, a phosphorothiolate, a phosphorodithioate, a phosphorothiolothionate, a phosphodiester, a phosphotriester, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -P(Z 1 )(Z 2 )-O-nucleoside, or -P(Z 1 )(Z 2 )-O-oligonucleotide (wherein Z 1and Z 2 is, independently for each occurrence, O, S, N(alkyl), or optionally substituted alkyl; J1 and J2 are independently selected for each occurrence from O, S, NR N , optionally substituted alkyl, OC(O)NH, NHC(O)O, C(O)NH, NHC(O), OC(O), C(O)O, OC(O)O, NHC(O)NH, NHC(S)NH, OC(S)NH, OP(N(R P )2)O, or OP(N(R P )2) and The carrier in formula (CI) is a cyclic group or an acyclic group; the cyclic group is preferably selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and decalin; the acyclic group is preferably selected from a serinol skeleton or a diethanolamine skeleton.
[0029] In a preferred embodiment, the ligand is a carbohydrate, eg, a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, polysaccharide.
[0030] In one embodiment, the compound is a pyrroline ring system as shown in formula (CII): [ka] During the ceremony, E is absent or is C(O), C(O)O, C(O)NH, C(S), C(S)NH, SO, SO2, or SO2NH; R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 are independently H, -CH2OR a , or OR band R a and R b is, each occurrence independently, hydrogen, a hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethylene glycol (PEG), phosphate, diphosphate, triphosphate, phosphonate, phosphonothioate, phosphonodithioate, phosphorothioate, phosphorothiolate, phosphorodithioate, phosphorothiolothionate, phosphodiester, phosphotriester, activated phosphate group, activated phosphite group, phosphoramidite, solid support, -P(Z 1 )(Z 2 )-O-nucleoside, or -P(Z 1 )(Z 2 )-O-oligonucleotide, -P(Z 1 )(O-Linker-R L )-O-nucleoside, or -P(Z 1 )(O-Linker-R L )-O-oligonucleotide; R 30 is, independently for each occurrence, -linker-R L or R 31 and; R L is hydrogen or a ligand; R 31 is C(O)CH(N(R 32 )2)(CH2) h N(R 32 )2; R 32 are independently expressed as H and -R L , -linker-R L , or R 31 and; Z 1 is, independently for each occurrence, O or S; Z 2 is, independently for each occurrence, O, S, N(alkyl), or optionally substituted alkyl; and h is, independently for each occurrence, 1 to 20.
[0031] For pyrroline-based click-carriers, R 11 Ga-CH2OR a Dekatsu R 3 OR b or R 11 Ga-CH2OR a Dekatsu R 9 OR b or R 11 Ga-CH2OR a Dekatsu R 17 OR b or R 13 Ga-CH2OR a Dekatsu R 11 OR b or R 13 Ga-CH2OR a Dekatsu R 15 OR b or R 13 Ga-CH2OR a Dekatsu R 17 OR b In one embodiment, CHOR a and OR b For 4-hydroxyproline based carriers, R 11 Ga-CH2OR a Dekatsu R 17 OR b Thus, pyrroline-based compounds and 4-hydroxyproline-based compounds may contain bonds (e.g., carbon-carbon bonds) where bond rotation is restricted about that particular bond (e.g., restrictions imposed by the presence of a ring). Thus, CHOR a and OR bmay be cis or trans relative to each other in any of the combinations described above. Thus, all cis / trans isomers are expressly included. The compounds may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, and diastereomeric mixtures. All such isomeric forms of the compounds are expressly included (e.g., CH2OR a and OR b Both centers bearing the R configuration can have the R configuration; both can have the S configuration; or one center can have the R configuration and the other center can have the R configuration, and vice versa).
[0032] In one embodiment, R 11 CH2OR a Dekatsu R 9 OR b is.
[0033] In one embodiment, R b is a solid support.
[0034] In one embodiment, the carrier of formula (CII) is a phosphoramidite, i.e., R a or R b In one embodiment, one of R is -P(O-alkyl)N(alkyl), for example, -P(OCHCHCN)N(i-propyl). b is -P(O-alkyl)N(alkyl)2.
[0035] In embodiments, the compound is a ribose ring system as shown in formula (CIII): [ka] During the ceremony, X is O, S, or NR N , or CR P 2 and; B is, independently at each occurrence, hydrogen, an optionally substituted natural or unnatural nucleobase, -linker-R L an optionally substituted natural nucleobase or -linker-R L an optionally substituted non-natural nucleobase linked to R 1 , R 2 , R 3 , R 4 , and R 5 are independently expressed as H, OR 6 ,F,N(R N )2, or -J-linker-R L and; J is absent, O, S, NR N , OC(O)NH, NHC(O)O, C(O)NH, NHC(O), NHSO, NHSO2, NHSO2NH, OC(O), C(O)O, OC(O)O, NHC(O)NH, NHC(S)NH, OC(S)NH, OP(N(R P )2)O, or OP(N(R P )2) and; R 6 is, each occurrence independently, hydrogen, a hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethylene glycol (PEG), phosphate, diphosphate, triphosphate, phosphonate, phosphonothioate, phosphonodithioate, phosphorothioate, phosphorothiolate, phosphorodithioate, phosphorothiolothionate, phosphodiester, phosphotriester, activated phosphate group, activated phosphite group, phosphoramidite, solid support, -P(Z 1 )(Z 2 )-O-nucleosides, -P(Z 1 )(Z 2 )-O-oligonucleotide, -P(Z 1 )(Z 2 )-formula (CIII), -P(Z 1 )(O-Linker-R L)-O-nucleosides, -P(Z 1 )(O-Linker-R L )-O-oligonucleotide, or -P(Z 1 )(O-Linker-R L )-O- is of formula (CIII); R N is, independently for each occurrence, H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted heteroaryl, or an amino protecting group; R P is, independently for each occurrence, H, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted heteroaryl; R L is hydrogen or a ligand; Z 1 and Z 2 is, independently for each occurrence, O, S, N(alkyl), or optionally substituted alkyl; However, R L exists at least once and R L is a ligand at least once.
[0036] In one embodiment, the carrier in formula (CI) is an acyclic group and is referred to as an "acyclic carrier." Preferred acyclic carriers can have the structure shown in formula (CIV) or formula (CV) below.
[0037] In one embodiment, the compound is an acyclic carrier having the structure shown in formula (CIV): [ka] During the ceremony, W is either absent or composed of O, S, and N(R N )(wherein, R Nis independently for each occurrence H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted heteroaryl, or an amino protecting group; E is absent or is C(O), C(O)O, C(O)NH, C(S), C(S)NH, SO, SO2, or SO2NH; R a and R b is, each occurrence independently, hydrogen, a hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethylene glycol (PEG), phosphate, diphosphate, triphosphate, phosphonate, phosphonothioate, phosphonodithioate, phosphorothioate, phosphorothiolate, phosphorodithioate, phosphorothiolothionate, phosphodiester, phosphotriester, activated phosphate group, activated phosphite group, phosphoramidite, solid support, -P(Z 1 )(Z 2 )-O-nucleosides, -P(Z 1 )(Z 2 )-O-oligonucleotide, -P(Z 1 )(O-Linker-R L )-O-nucleoside, or -P(Z 1 )(O-Linker-R L )-O-oligonucleotide; R 30 are each independently present as linkers -R L or R 31 and; R L is hydrogen or a ligand; R 31 is -C(O)CH(N(R 32 )2)(CH2) h N(R 32 )2; R 32are independently expressed as H and -R L , -linker-R L , or R 31 and; Z 1 is, independently for each occurrence, O or S; Z 2 is, independently for each occurrence, O, S, N(alkyl), or optionally substituted alkyl; h is, independently for each occurrence, 1 to 20; and r, s, and t are each independently 0, 1, 2, or 3 for each occurrence.
[0038] When r and s are different, the third carbon can be in either the R or S configuration. In a preferred embodiment, x and y are 1 and z is 0 (e.g., the carrier is based on serinol). The acyclic carrier can be optionally substituted, for example, with hydroxy, alkoxy, perhaloalkyl.
[0039] In one embodiment, the compound is an acyclic carrier having the structure shown in formula (CV): [ka] During the ceremony, E is absent or is C(O), C(O)O, C(O)NH, C(S), C(S)NH, SO, SO2, or SO2NH; R a and R bis, each occurrence independently, hydrogen, a hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethylene glycol (PEG), phosphate, diphosphate, triphosphate, phosphonate, phosphonothioate, phosphonodithioate, phosphorothioate, phosphorothiolate, phosphorodithioate, phosphorothiolothionate, phosphodiester, phosphotriester, activated phosphate group, activated phosphite group, phosphoramidite, solid support, -P(Z 1 )(Z 2 )-O-nucleosides, -P(Z 1 )(Z 2 )-O-oligonucleotide, -P(Z 1 )(Z 2 )-Formula (I), -P(Z 1 )(O-Linker-R L )-O-nucleoside, or -P(Z 1 )(O-Linker-R L )-O-oligonucleotide; R 30 are each independently present as linkers -R L or R 31 and; R L is hydrogen or a ligand; R 31 is -C(O)CH(N(R 32 )2)(CH2) h N(R 32 )2; R 32 are independently expressed as H and -R L , -linker-R L , or R 31 and; Z 1 is, independently for each occurrence, O or S; Z 2 is, independently for each occurrence, O, S, N(alkyl), or optionally substituted alkyl; h is, independently for each occurrence, 1 to 20; and r and s are each independently 0, 1, 2, or 3 for each occurrence.
[0040] In addition to the cyclic carriers described herein, the RRMS can include cyclic and acyclic carriers described in co-pending and co-owned U.S. application Ser. Nos. 10 / 916,185 (filed Aug. 10, 2004), 10 / 946,873 (filed Sep. 21, 2004), and 10 / 985,426 (filed Nov. 9, 2004), 10 / 833,934 (filed Aug. 3, 2007), 11 / 115,989 (filed Apr. 27, 2005), and 11 / 119,533 (filed Apr. 29, 2005), the contents of each of which are incorporated herein by reference for all purposes.
[0041] Accordingly, in one aspect, the invention features a monomer having the structure shown in formula (I): [ka] During the ceremony, A and B are each independently O, N(R N ), or S; R N is, independently for each occurrence, H or C1-C6 alkyl; X and Y, each independently for each occurrence, are H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -P(Z')(Z'')O-nucleoside, -P(Z')(Z'')O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, a nucleotide, a nucleoside, -P(Z')(Z'')O-linker-O-P(Z''')(Z''')O-oligonucleotide, an oligonucleotide, -P(Z')(Z'')-Formula (I), -P(Z')(Z'')-, or -linker-R; R is L Gor having the structure shown below: [ka] L G is, independently for each occurrence, a ligand, e.g., a carbohydrate, e.g., a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, polysaccharide; Z', Z'', Z''', and Z'''' are each independently for each occurrence O or S.
[0042] The term "linker" refers to an organic moiety that connects two parts of a compound. A linker is typically a direct bond or an atom, such as oxygen or nitrogen, a unit, such as NR 1, C(O), C(O)NH, SO, SO2, SO2NH, or a chain of atoms such as substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted alkynyl or unsubstituted alkynyl, aryl alkyl, aryl alkenyl, aryl alkynyl, heteroaryl alkyl, heteroaryl alkenyl, heteroaryl alkynyl, heterocyclyl alkyl, heterocyclyl alkenyl, heterocyclyl alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylaryl alkyl, alkylaryl alkenyl, alkylaryl alkynyl, alkenylaryl alkyl, alkenylaryl alkenyl, alkenylaryl alkynyl, alkynylaryl alkyl, alkynylaryl alkenyl, alkynylaryl alkynyl, alkylheteroaryl alkyl ... Heteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylheterocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylheteroaryl (wherein one or more methylenes are selected from the group consisting of O, S, S(O), SO, N(R 8 ), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle; R 8is hydrogen, acyl, aliphatic, or substituted aliphatic. In one embodiment, the linker is 1 to 24 atoms, preferably 4 to 24 atoms, preferably 6 to 18 atoms, more preferably 8 to 18 atoms, and most preferably 8 to 16 atoms.
[0043] In one embodiment, the linker is -[(P-Q''-R) q -X-(P'-Q'''-R') q’ ] q” -T-, During the ceremony, P, R, T, P', R', and T are each independently selected from the group consisting of absent, CO, NH, O, S, OC(O), NHC(O), CH2, CH2NH, CHO; NHCH(R a )C(O), -C(O)-CH(R a )-NH-, CH=NO, [ka] or heterocyclyl; Q'' and Q''' are each independently absent or -(CH2) n -, -C(R 1 )(R 2 )(CH2) n -, -(CH2) n C(R 1 )(R 2 )-, -(CH2CH2O) m CH2CH2-, or -(CH2CH2O) m CH2CH2NH-; X is absent or a cleavable linking group; R a is H or an amino acid side chain; R 1 and R 2 is, each occurrence independently, H, CH3, OH, SH, or N(R N )2; R N is, independently for each occurrence, H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; q, q', and q'' are each independently for each occurrence 0 to 20, wherein the repeat units may be the same or different; n is, independently for each occurrence, 1 to 20; and m is, independently for each occurrence, 0 to 50.
[0044] In one embodiment, the linker comprises at least one cleavable linking group.
[0045] In some embodiments, the linker is a branched linker. The branch point of a branched linker can be at least trivalent, but may also be a tetravalent, pentavalent, or hexavalent atom or group exhibiting such multiple valencies. In some embodiments, the branch point is -C, -CH, -C(CH2-)(CH2-)CH2-, -C(H)(CH2-)CH2-, -N, -N(Q)-C, -OC, -SC, -SS-C, -C(O)N(Q)-C, -OC(O)N(Q)-C, -N(Q)C(O)-C, or -N(Q)C(O)OC, where Q is, independently for each occurrence, H or an optionally substituted alkyl. In other embodiments, the branch point is glycerol or a glycerol derivative.
[0046] Cleavable Linking Group A cleavable linking group is one that is sufficiently stable outside a cell but is cleaved once inside a target cell, releasing the two moieties attached by the linker. In preferred embodiments, the cleavable linking group degrades at least 10 times faster, and preferably at least 100 times faster, inside the target cell or under a first reference condition (which can, for example, be selected to mimic or represent intracellular conditions) than under the subject's blood or under a second reference condition (which can, for example, be selected to mimic or represent conditions found in blood or serum).
[0047] Cleavable linking groups are susceptible to cleavage factors (e.g., pH, redox potential, or the presence of degrading molecules). Generally, cleavage factors are more prevalent or abundant in cells than in serum or blood, with higher levels or activity. Examples of such degrading factors include redox agents that are selective for specific substrates or have no substrate specificity, including oxidases or reductases or reducing agents (e.g., mercaptans present in cells that can degrade redox-cleavable linking groups by reduction); esterases; agents that can create endosomes or acidic environments (e.g., agents that produce a pH of 5 or less); enzymes that can hydrolyze or decompose acid-cleavable linking groups by acting as general acids, peptidases (potentially substrate-specific), and phosphatases.
[0048] Cleavable linking groups (e.g., disulfide bonds) can be sensitive to pH. While the pH of human serum is 7.4, the average intracellular pH is slightly lower, ranging from approximately 7.1 to 7.3. The pH of endosomes is more acidic, ranging from 5.5 to 6.0, and the pH of lysosomes is even more acidic, around 5.0. Some linkers have cleavable linking groups that are cleaved at a preferred pH, thereby releasing the cationic lipid from the ligand intracellularly or into a desired cellular compartment.
[0049] Linker can comprise a cleavable linking group that can be cleaved by specific enzyme.The type of cleavable linking group incorporated into linker can depend on the target cell.For example, liver targeting ligand can be linked to cationic lipid through a linker that comprises an ester group.Liver cells are rich in esterase, therefore, linker is cleaved more effectively in liver cells than in cell types that are not rich in esterase.Other cell types that are rich in esterase include lung, renal cortex and testis.
[0050] Linkers containing peptide bonds can be used when targeting cell types that are rich in peptidases (eg, liver cells and synovial cells).
[0051] In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradation agent (or condition) to cleave the candidate linking group. It may also be desirable to test candidate cleavable linking groups for their ability to resist cleavage in blood or when contacted with other tissues other than the target. Thus, the relative susceptibility to cleavage between first and second conditions can be determined, where the first condition is selected to indicate cleavage within target cells and the second condition is selected to indicate cleavage in other tissues or biological fluids (e.g., blood or serum). Evaluation can be performed in a cell-free system, in cells, in cell culture, in organ or tissue culture, or in whole animals. It may be useful to perform initial evaluations in cell-free or culture conditions and confirm with further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least 2-fold, 4-fold, 10-fold, or 100-fold faster in cells (or under in vitro conditions selected to mimic intracellular conditions) than in blood or serum (or under in vitro conditions selected to mimic extracellular conditions).
[0052] Redox-cleavable linking groups One class of cleavable linking groups is redox-cleavable linking groups, which are cleaved by reduction or oxidation. An example of a reductively cleavable linking group is a disulfide linking group (-SS-). To determine whether a candidate cleavable linking group is suitable and a "reductively cleavable linking group," or, for example, suitable for use with a particular iRNA moiety and a particular targeting agent, one can turn to the methods described herein. For example, candidates can be evaluated by incubating with dithiothreitol (DTT) or other reducing agents using reagents known in the art that mimic the cleavage rate observed in cells (e.g., target cells). Candidates can also be evaluated under conditions selected to mimic blood or serum conditions. In preferred embodiments, candidate compounds are cleaved at a maximum of 10% in blood. In preferred embodiments, useful candidate compounds are degraded at least 2-fold, 4-fold, 10-fold, or 100-fold faster in cells (or under in vitro conditions selected to mimic intracellular conditions) than in blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of the candidate compound can be measured using standard enzyme kinetic assays under conditions selected to mimic the intracellular medium and compared to conditions selected to mimic the extracellular medium.
[0053] Phosphate-based cleavable linking groups Phosphate-based cleavable linking groups are cleaved by agents that decompose or hydrolyze phosphate groups. Examples of agents that cleave phosphate groups within cells include enzymes such as intracellular phosphatases. Examples of phosphate-based linking groups are -OP(O)(ORk)-O-, -OP(S)(ORk)-O-, -OP(S)(SRk)-O-, -SP(O)(ORk)-O-, -OP(O)(ORk)-S-, -SP(O)(ORk)-S-, -OP(S)(ORk)-S-, -SP(S)(ORk)-O-, -OP(O)(Rk)-O-, -OP(S)(Rk)-O-, -SP(O)(Rk)-O-, -SP(S)(Rk)-O-, -SP(O)(Rk)-S-, and -OP(S)(Rk)-S-. Preferred embodiments are -OP(O)(OH)-O-, -OP(S)(OH)-O-, -OP(S)(SH)-O-, -SP(O)(OH)-O-, -OP(O)(OH)-S-, -SP(O)(OH)-S-, -OP(S)(OH)-S-, -SP(S)(OH)-O-, -OP(O)(H)-O-, -OP(S)(H)-O-, -SP(O)(H)-O-, -SP(S)(H)-O-, -SP(O)(H)-S-, and -OP(S)(H)-S-. A preferred embodiment is -OP(O)(OH)-O-. These candidates can be evaluated using methods similar to those described above.
[0054] Acid-cleavable linking groups Acid-cleavable linking groups are linking groups that are cleaved under acidic conditions.In a preferred embodiment, acid-cleavable linking groups are cleaved in an acidic environment of about pH 6.5 or less (for example, about 6.0, 5.5, 5.0, or less), or by agents such as enzymes that can act as general acids.In cells, certain low-pH organelles (for example, endosomes and lysosomes) can provide a cleavage environment for acid-cleavable linking groups.Examples of acid-cleavable linking groups include, but are not limited to, hydrazones, esters, and esters of amino acids.Acid-cleavable groups can be represented by the general formula -C=NN- ,, C(O)O, or —OC(O). A preferred embodiment is where the carbon attached to the oxygen of the ester (alkoxy group) is an aryl group, a substituted alkyl group, or a tertiary alkyl group (e.g., dimethyl, pentyl, or t-butyl). These candidates can be evaluated using methods similar to those described above.
[0055] Ester-based linking groups Ester-based cleavable linking groups are cleaved by enzymes such as intracellular esterases and amidases. Examples of ester-based cleavable linking groups include, but are not limited to, alkylene groups, alkenylene groups, and alkynylene groups. Ester-cleavable linking groups have the general formula -C(O)O- or -OC(O)-, and these candidates can be evaluated using methods similar to those described above.
[0056] Peptide-based linking groups Peptide-based cleavable linking groups are cleaved by enzymes such as intracellular peptidases and proteases. Peptide-based cleavable linking groups refer to peptide bonds formed between amino acids to give rise to oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. Peptide-based cleavable groups do not include amide groups (-C(O)NH-). Amide groups can be formed between any alkylene, alkenylene, or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to give rise to peptides and proteins. Peptide-based cleavable groups are generally limited to peptide bonds (i.e., amide bonds) formed between amino acids to give rise to peptides and proteins, and do not include the entire amide functionality. Peptide-based cleavable linking groups have the general formula -NHCHR A C(O)NHCHR B C(O)-(wherein, R A and R Bare the R groups of two adjacent amino acids). These candidates can be evaluated using methods similar to those described above. As used herein, "carbohydrate" refers to either a compound that is itself a carbohydrate, composed of one or more monosaccharide units (which may be linear, branched, or cyclic) having at least six carbon atoms, each with an oxygen, nitrogen, or sulfur atom attached to each carbon atom, or a compound that has as part of it a carbohydrate moiety, composed of one or more monosaccharide units (which may be linear, branched, or cyclic), each with at least six carbon atoms, each with an oxygen, nitrogen, or sulfur atom attached to each carbon atom. Representative carbohydrates include saccharides (monosaccharides, disaccharides, trisaccharides, and oligosaccharides containing about 4-9 monosaccharide units) and polysaccharides (e.g., starch, glycogen, cellulose, and polysaccharide gums). Specific monosaccharides include sugars of C5 or higher (preferably C5-C8); disaccharides and trisaccharides include sugars with two or three monosaccharide units (preferably C5-C8).
[0057] The term "monosaccharide" includes allose, altose, arabinose, cladinose, erythrose, erythrulose, fructose, D-fucitol, L-fucitol, fucosamine, fucose, fuculose, galactosamine, D-galactosaminitol, N-acetyl-galactosamine, galactose, glucosamine, N-acetyl-glucosamine, glucosaminitol, glucose, glucose-6-phosphate, glucose, glucose Monosaccharides include lyceraldehyde, L-glycero-D-mannos-heptose, glycerol, glycerone, gulose, idose, lyxose, mannosamine, mannose, mannose-6-phosphate, psicose, quinovose, quinovosamine, rhamnitol, rhamnosamine, rhamnose, ribose, ribulose, sedoheptulose, sorbose, tagatose, talose, tartaric acid, threose, xylose, and xylulose groups. Monosaccharides can be in the D or L configuration. The monosaccharide may further be a deoxysugar (an alcohol hydroxy group replaced with a hydrogen), an aminosugar (an alcohol hydroxy group replaced with an amino group), a thiosugar (an alcohol hydroxy group replaced with a thiol, or a C=O replaced with a C=S, or a ring oxygen in a cyclic form replaced with a sulfur), a selenosugar, a tellurosugar, an azasugar (a ring carbon replaced with a nitrogen), an iminosugar (a ring oxygen replaced with a nitrogen), a phosphanosugar (a ring oxygen replaced with a phosphorus), a phosphasugar (a ring carbon replaced with a phosphorus), a C-substituted monosaccharide (a hydrogen at a non-terminal carbon atom replaced with a carbon), an unsaturated monosaccharide, an alditol (a carbonyl group replaced with a CHOH group), an aldonic acid (an aldehyde group replaced with a carboxy group), a ketoaldonic acid, a uronic acid, an aldaric acid, and the like. Amino sugars include amino monosaccharides, preferably galactosamine, glucosamine, mannosamine, fucosamine, quinovosamine, neuraminic acid, muramic acid, lactosediamine, acosamine, bacillosamine, daunosamine, desosamine, forosamine, galosamine, kanosamine, kansosamine, mycaminose, mycosamine, perosamine, pneumosamine, purpurosamine, and rhodosamine. It is understood that the monosaccharides can be further substituted.
[0058] The terms "disaccharide," "trisaccharide," and "polysaccharide" refer to abequose, acrabose, amicetose, amylopectin, amylose, apiose, alkanose, ascarylose, ascorbic acid, boivinose, cellobiose, cellotriose, cellulose, chacotriose, chalcose, chitin, colitose, cyclodextrin, cymarose, dextrin, 2-deoxyribose, 2-deoxyglucose, diginose, digitalose, digitoxose, everose, evemitrose, fructooligosaccharide, galto-oligosaccharide, gentianose, gentiobiose, glucan, glucogen, glycogen, hamamelose, heparin, inulin, isolevoglucosenone, isomaltose, These include groups such as sucrose, isomaltotriose, isopanose, kojibiose, lactose, lactosamine, lactosediamine, laminarabiose, levoglucosan, levoglucosenone, β-maltose, maltotriose, mannan-oligosaccharides, manninotriose, melezitose, melibiose, muramic acid, mycarose, mycinose, neuraminic acid, nigerose, nojirimycin, nobiose, oleandrose, panose, paratose, planteose, primeverose, raffinose, rhodinose, rutinose, sarmentose, sedoheptulose, sedoheptulosan, solatriose, sophorose, stachyose, streptose, sucrose, α,α-trehalose, trahalosamine, turanose, tyvelose, xylobiose, and umbelliferose. It is further understood that "disaccharides," "trisaccharides," "polysaccharides," and the like can be further substituted. Disaccharides also include amino sugars and derivatives thereof, particularly mycaminose derivatized at the C-4' position or 4-deoxy-3-aminoglucose derivatized at the C-6' position.
[0059] In one embodiment, the compound has the structure shown in formula (I'): [ka] During the ceremony, A and B are each independently O, N(R N ), or S; X and Y, at each occurrence, independently represent H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -P(Z')(Z'')O-nucleoside, -P(Z')(Z'')O-oligonucleotide, a lipid, PEG, a steroid, a polymer, a nucleotide, a nucleoside, -P(Z')(Z'')OR 1 -Q'-R 2 -OP(Z''')(Z'''')O-oligonucleotide, or oligonucleotide, -P(Z')(Z'')- of formula (I), -P(Z')(Z'')-, or -QR; R is L 1 or having the structure shown in formulas (II) to (V): [ka] q 2A , q 2B , q 3A , q 3B , q4 A , q 4B , q 5A , q 5B , and q 5C represents, independently for each occurrence, 0 to 20, where the repeat units may be the same or different; Q and Q' are each, independently for each occurrence, either absent or -(P 7 -Q 7 -R 7 ) p -T 7 -, or -T 7 -Q 7 -T 7’ -BT 8’ -Q 8 -T 8 and; P 2A , P 2B , P 3A , P 3B , P 4A , P 4B , P 5A , P5B , P 5C , P 7 , T 2A , T 2B , T 3A , T 3B , T 4A , T 4B , T 4A , T 5B , T 5C , T 7 , T 7’ , T 8 , and T 8’ is, each occurrence independently, absent, CO, NH, O, S, OC(O), NHC(O), CH2, CH2NH, or CH2O; B is -CH2-N(B L )-CH2-; B L Ha-T B -Q B -T B’ -R x and; Q 2A , Q 2B , Q 3A , Q 3B , Q 4A , Q 4B , Q 5A , Q 5B , Q 5C , Q 7 , Q 8 , and Q B is, independently for each occurrence, absent, alkylene, or substituted alkylene, where one or more methylenes are selected from O, S, S(O), SO, N(R N ), may be interrupted or terminated by one or more of C(R')=C(R'), C≡C, or C(O); T B and T B’ is, each occurrence independently, absent, CO, NH, O, S, OC(O), OC(O)O, NHC(O), NHC(O)NH, NHC(O)O, CH2, CH2NH, or CH2O; R xis a lipophilic substance (e.g., cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenoic acid, dimethoxytrityl, if or phenoxazine), vitamins (e.g., folic acid, vitamin A, vitamin E, biotin, pyridoxal), peptides, carbohydrates (e.g., monosaccharides, disaccharides, trisaccharides, tetrasaccharides, oligosaccharides, polysaccharides), endosomolytic components, steroids (e.g., uvaol, hesigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, friedelin, epifriedelanol-derivatized lithocholic acid), or cationic lipids; R 1 , R 2 , R 2A , R 2B , R 3A , R 3B , R 4A , R 4B , R 5A , R 5B , R 5C , R 7 are each independently absent or NH, O, S, CH2, C(O)O, C(O)NH, NHCH(R a )C(O), -C(O)-CH(R a )-NH-, CO, CH=NO, [ka] or heterocyclyl; L 1 , L 2A , L 2B , L 3A , L 3B , L 4A , L 4B , L 5A , L 5B , and L 5C is, each occurrence independently, a carbohydrate, e.g., a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, an oligosaccharide, and a polysaccharide; R' and R'' are each independently at each occurrence H, C1-C6 alkyl, OH, SH, or N(R N )2; R N is, independently for each occurrence, H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; R a is H or an amino acid side chain; Z', Z'', Z''', and Z'''' are each, independently for each occurrence, O or S; p is independently 0 to 20 for each occurrence.
[0060] In some embodiments, Formula (I') has the following structure: [ka]
[0061] In some embodiments, Formula (I') has the following structure: [ka]
[0062] In some embodiments, Formula (I') has the following structure: [ka]
[0063] In some embodiments, Formula (I') has the following structure: [ka]
[0064] In some embodiments, Formula (I') has the following structure: [ka]
[0065] In some embodiments, R is: [ka]
[0066] In some embodiments, R is: [ka]
[0067] In some embodiments, R is: [ka]
[0068] In some embodiments, R is: [ka]
[0069] In some embodiments, R is: [ka]
[0070] In some embodiments, R is: [ka]
[0071] In some embodiments, R is: [ka]
[0072] In some embodiments, R is: [ka]
[0073] In some embodiments, R is: [ka]
[0074] In some preferred embodiments, R is: [ka]
[0075] In some preferred embodiments, R is: [ka]
[0076] In some preferred embodiments, formula (I) has the following structure: [ka]
[0077] In some embodiments, R is: [ka]
[0078] In some embodiments, the monomer of formula (I) has the following structure: [ka]
[0079] In some embodiments, the monomer of formula (I) has the following structure: [ka]
[0080] In some embodiments, the monomer of formula (I) has the following structure: [ka]
[0081] In some embodiments, the monomer of formula (I) has the following structure: [ka]
[0082] In some embodiments, the monomer of formula (I) has the following structure: [ka]
[0083] In some embodiments, the monomer of formula (I) has the following structure: [ka]
[0084] In some embodiments, R is: [ka]
[0085] In some embodiments, R is: [ka]
[0086] In some embodiments, R is: [ka]
[0087] In some embodiments, R is: [ka]
[0088] In some embodiments, R is: [ka]
[0089] In some embodiments, R is: [ka]
[0090] In some embodiments, R is: [ka]
[0091] In some embodiments, R is: [ka]
[0092] In some embodiments, R is: [ka]
[0093] In some preferred embodiments, formula (I) has the following structure: [ka]
[0094] In some preferred embodiments, formula (I) has the following structure: [ka]
[0095] In some preferred embodiments, formula (I) has the following structure: [ka]
[0096] In some preferred embodiments, formula (I) has the following structure: [ka]
[0097] In some preferred embodiments, formula (I) has the following structure: [ka]
[0098] In some preferred embodiments, formula (I) has the following structure: [ka]
[0099] In some preferred embodiments, L 2A and L 2B are both the same.
[0100] In some embodiments, L 2A and L 2B are both different.
[0101] In some preferred embodiments, L 3A and L 3B are both the same.
[0102] In some embodiments, L 3A and L 3B are both different.
[0103] In some preferred embodiments, L 4A and L 4B are both the same.
[0104] In some embodiments, L 4A and L 4B are both different.
[0105] In some preferred embodiments, L 5A and L 5B and L 5C are all the same.
[0106] In some embodiments, L 5A and L 5B and L 5C Two of them are the same.
[0107] In some embodiments, L 5A and L 5B is the same.
[0108] In some embodiments, L 5A and L 5C is the same.
[0109] In some embodiments, L 5B and L 5C is the same.
[0110] In another aspect, the invention features an iRNA agent that includes at least one monomer of formula (I).
[0111] In some embodiments, the iRNA agent includes one, two, three, four, or five monomers of formula (I), more preferably one, two, or three monomers of formula (I), more preferably one or two monomers of formula (I), and even more preferably only one monomer of formula (I).
[0112] In some embodiments, the monomers of formula (I) are all on the same strand of the double-stranded iRNA agent.
[0113] In some embodiments, the monomers of formula (I) are on separate strands of a double-stranded iRNA agent.
[0114] In some embodiments, all of the monomers of formula (I) in an iRNA agent are the same.
[0115] In some embodiments, all of the monomers of formula (I) in an iRNA agent are different.
[0116] In some embodiments, only some of the monomers of formula (I) in an iRNA agent are the same.
[0117] In some embodiments, the monomers of formula (I) are adjacent to one another in the iRNA agent.
[0118] In some embodiments, the monomers of formula (I) are not adjacent to one another in the iRNA agent.
[0119] In some embodiments, the monomer of formula (I) is at the 5' end, the 3' end, an internal position, both the 3' end and the 5' end, both the 5' end and an internal position, both the 3' end and an internal position, and all three positions (the 5' end, the 3' end, and an internal position) of the iRNA agent.
[0120] In some preferred embodiments, R x is cholesterol.
[0121] In some preferred embodiments, R x is lithocholic acid.
[0122] In some preferred embodiments, R x is oleyl lithocholic acid.
[0123] In some preferred embodiments, R x has the following structure: [ka]
[0124] In some preferred embodiments, B L has the following structure: [ka]
[0125] In some preferred embodiments, formula (I) has the following structure: [ka]
[0126] In some preferred embodiments, formula (I) has the following structure: [ka]
[0127] In some preferred embodiments, formula (I) has the following structure: [ka]
[0128] In some preferred embodiments, formula (I) has the following structure: [ka] (wherein Y is O or S, and n is 3 to 6).
[0129] In some preferred embodiments, formula (I) has the following structure: [ka] (wherein Y is O or S, and n is 3 to 6).
[0130] In some preferred embodiments, formula (I) has the following structure: [ka]
[0131] In some preferred embodiments, formula (I) has the following structure: [ka] where X is O or S.
[0132] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0133] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0134] In some preferred embodiments, the monomer of formula (I) is attached to the iRNA agent via a linker of formula (VII) below, where R is O or S: [ka]
[0135] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0136] In some preferred embodiments, formula (I) has the following structure: [ka]
[0137] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0138] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0139] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0140] In some preferred embodiments, formula (I) has the following structure: [ka] where R is OH or NHCOOH.
[0141] In some embodiments, an iRNA agent has, in addition to the monomer of formula (I), a monomer having the structure shown in formula (VI): [ka] During the ceremony X 6 and Y 6 is, each occurrence independently, H, OH, hydroxyl protecting group, phosphate group, phosphodiester group, activated phosphate group, activated phosphite group, phosphoramidite, solid support, -P(Z')(Z'')O-nucleoside, -P(Z')(Z'')O-oligonucleotide, lipid, PEG, steroid, polymer, -P(Z')(Z'')OR 1 -Q'-R 2-OP(Z'")(Z"")O-oligonucleotide, nucleotide, or oligonucleotide, -P(Z')(Z")- of formula (I) or -P(Z')(Z")-; Q 6 is not present or -(P 6 -Q 6 -R 6 ) v -T 6 - and; P 6 and T 6 is, each occurrence independently, absent, CO, NH, O, S, OC(O), NHC(O), CH2, CH2NH, or CH2O; Q 6 is, independently for each occurrence, absent or substituted alkylene, wherein one or more methylenes are selected from O, S, S(O), SO, N(R N ), may be interrupted or terminated by one or more of C(R')=C(R'), C≡C, or C(O); R 6 are each independently absent, NH, O, S, CH2, C(O)O, C(O)NH, NHCH(R a )C(O), -C(O)-CH(R a )-NH-, CO, CH=NO, [ka] or heterocyclyl; R' and R'' are each independently at each occurrence H, C1-C6 alkyl, OH, SH, or N(R N )2; R N is, independently for each occurrence, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; R a is H or an amino acid side chain; Z', Z'', Z''', and Z'''' are each, independently for each occurrence, O or S; v, independently for each occurrence, ranges from 0 to 20; RL are lipophilic substances (e.g., cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenoic acid, dimethoxytrityl , or phenoxazine), vitamins (e.g., folic acid, vitamin A, biotin, pyridoxal), peptides, carbohydrates (e.g., monosaccharides, disaccharides, trisaccharides, tetrasaccharides, oligosaccharides, polysaccharides), endosomolytic components, steroids (e.g., uvaol, hesigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, friedelin, epifriedelanol-derivatized lithocholic acid), or cationic lipids.
[0142] In some embodiments, in addition to one or more (e.g., one, two, three, four, or five) monomers of formula (I), one or more (e.g., one, two, three, four, or five) monomers of formula (VI) are present in an iRNA agent.
[0143] In some preferred embodiments, only one monomer of formula (I) and one monomer of formula (VI) are present in the iRNA agent.
[0144] In some embodiments, R L is cholesterol.
[0145] In some embodiments, R L is lithocholic acid.
[0146] In some embodiments, R L is oleyl lithocholic acid.
[0147] In some embodiments, the monomer of formula (I) is covalently bonded to the monomer of formula (VI).
[0148] In some preferred embodiments, the monomer of formula (I) is linked to the monomer of formula (VI) via a phosphate linkage, eg, a phosphodiester linkage, a phosphorothioate linkage, a phosphorodithioate linkage.
[0149] In some preferred embodiments, the monomer of formula (I) is attached to the iRNA agent via a monomer of formula (VI).
[0150] In some embodiments, a monomer of formula (I) is interposed between the iRNA agent and the monomer of formula (VI).
[0151] In some embodiments, the monomer of formula (I) and the monomer of formula (II) are directly bonded to each other.
[0152] In some embodiments, the monomer of formula (I) and the monomer of formula (II) are not directly bonded to each other.
[0153] In some embodiments, the monomer of formula (I) and the monomer of formula (IV) are on separate strands of a double-stranded iRNA agent.
[0154] In some embodiments, the monomer of formula (I) and the monomer of formula (IV) are at opposite ends of the iRNA agent.
[0155] In some embodiments, the monomer of formula (I) and the monomer of formula (IV) are at the same end of the iRNA agent.
[0156] In some embodiments, one of the monomer of formula (I) or the monomer of formula (IV) is at an internal position of the iRNA agent, while the other is at a terminal position of the iRNA agent.
[0157] In some embodiments, the monomer of formula (I) and the monomer of formula (IV) are both at internal positions in the iRNA agent.
[0158] In some preferred embodiments, the monomer of formula (IV) has the following structure: [ka]
[0159] In some embodiments, an iRNA agent of the invention [ka] [ka] [ka] [ka] is selected from the group consisting of where the ligand is a PK modulator, X=O or S, Y=O or S, and PEG is w-OH PEG, w-amino PEG, ω-methoxy PEG, ω-SH PEG, ω-propargyl PEG, ω-azido PEG, and ω-ligand PEG with a molecular weight (MW) of 200 to 100,000.
[0160] Endosomolytic component For macromolecular drugs and hydrophilic drug molecules that cannot easily cross the bilayer membrane, confinement in the endosomal / lysosomal compartment of cells is considered to be the greatest obstacle to their effective delivery to their site of action. In recent years, numerous approaches and strategies have been devised to address this issue. For liposomal formulations, the most common approach is the use of fusogenic lipids in the formulation (Singh, RS, Goncalves, C. et al. (2004). On the Gene Delivery Efficacies of pH-Sensitive Cationic Lipids via Endosomal Protonation. A Chemical Biology Investigation. Chem. Biol. 11, 713-723.). Other components that exhibit pH-sensitive endosomolytic activity through protonation and / or pH-induced conformational changes include charged polymers and peptides.Hoffman, AS, Stayton, PS et al. (2002). Design of "smart" polymers that can direct intracellular drug delivery. Polymers Adv. Technol.13,992-999;Kakudo, Chaki, T., S. et al. (2004). Transferrin-Modified Liposomes Equipped with a pH-Sensitive Fusogenic Peptide:An Artificial Viral-like Delivery System. Biochemistry 436,5618-5628;Yessine, MA and Leroux, JC (2004). Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv. Drug Deliv.Rev.56,999-1021;Oliveira, S., van Rooy, I. et al. (2007). Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of Examples can be found in Oncogenes. Int. J. Pharm. 331, 211-4. These are commonly used in conjunction with drug delivery systems such as liposomes or lipoplexes. For folate receptor-mediated delivery using liposomal formulations, for example, pH-sensitive fusogenic peptides have been incorporated into liposomes to enhance activity by improving drug release during uptake (Turk, MJ, Reddy, JA et al. (2002). Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 1559, 56-68).
[0161] In certain embodiments, the endosomolytic component of the present invention may be a polycationic peptide or peptidomimetic that exhibits pH-dependent membrane activity and / or fusogenicity. Peptidomimetics can be small protein-like chains designed to mimic peptides. Peptidomimetics can be generated by modifying existing peptides to alter the molecular properties or by synthesizing peptide-like molecules using unusual amino acids or their analogs. In certain embodiments, they have improved stability and / or biological activity compared to peptides. In certain embodiments, the endosomolytic component is in an active conformation at endosomal pH (e.g., pH 5-6). An "active" conformation is one in which the endosomolytic component promotes endosome lysis and / or transport of the modular composition of the present invention, or its components, from the endosome to the cytoplasm of the cell.
[0162] Libraries of compounds may be screened for their differential membrane activity at endosomal pH compared to neutral pH using hemolysis assays. Potential candidates isolated in this manner may be used as components of modular compositions of the invention. A method for identifying endosomolytic components for use in the compositions and methods of the invention may include providing a library of compounds; contacting blood cells with members of the library, where the pH of the medium in which the contacting occurs is controlled; and determining whether these compounds induce differential lysis of blood cells at low pH (e.g., about pH 5-6) compared to neutral pH (e.g., about pH 7-8).
[0163] Exemplary endosomolytic components include GALA peptide (Subbarao et al., Biochemistry, 1987, 26:2964-2972), EALA peptide (Vogel et al., J. Am. Chem. Soc., 1996, 118:1581-1586), and their derivatives (Turk et al., Biochem. Biophys. Acta, 2002, 1559:56-68). In certain embodiments, the endosomolytic component may contain a chemical group (e.g., an amino acid) that changes charge or protonation in response to a change in pH. The endosomolytic component may be linear or branched. Exemplary primary sequences of endosomolytic components include H2N-(AALEALAEALEALAEALEALAEAAAAGGC)-CO2H; H2N-(AALAEALAEALAEALAEALAEALAAAAGGC)-CO2H; and H2N-(ALEALAEALEALAEA)-CONH2.
[0164] In certain embodiments, two or more endosomolytic components may be incorporated into an iRNA agent of the present invention. In some embodiments, this involves incorporating two or more of the same endosomolytic components into the iRNA agent in addition to the monomer of formula (I). In other embodiments, this involves incorporating two or more different endosomolytic components into the iRNA agent in addition to the monomer of formula (I).
[0165] These endosomolytic components can mediate escape from endosomes, for example, by changing conformation at endosomal pH. In certain embodiments, endosomolytic components exist in a random coil conformation at neutral pH and can rearrange into an amphipathic helix at endosomal pH. As a result of this conformational transition, these peptides can insert into the lipid membrane of endosomes, allowing the contents of the endosome to leak into the cytoplasm. Because the conformational transition is pH-dependent, endosomolytic components can exhibit little or no fusogenic activity while circulating in the blood (pH approximately 7.4). Fusogenic activity is defined as activity that causes disruption of the lipid membrane by the endosomolytic component. One example of fusogenic activity is disruption of the endosomal membrane by the endosomolytic component, which results in endosome lysis or leakage and transport of one or more components of the modular compositions of the present invention (e.g., nucleic acids) from the endosome to the cytoplasm.
[0166] In addition to the hemolytic assay described herein, suitable endosomolytic components can be tested and identified by those skilled in the art using other methods. For example, the ability of a compound to respond to pH (e.g., change charge depending on the pH) can be tested by conventional methods (e.g., cellular assays). In some embodiments, a test compound is mixed with or contacted with cells, allowing the cells to take up the test compound, for example, by endocytosis. An endosome preparation can then be made from the contacted cells, and this endosome preparation can be compared with an endosome preparation from control cells. A change (e.g., a decrease) in the endosomal fraction from the contacted cells compared to the control cells indicates that the test compound can function as a fusogenic agent. Alternatively, the contacted cells and the control cells can be evaluated, for example, by microscopy (e.g., light or electron microscopy) to determine differences in the endosomal population within the cells. The test compound and / or endosomes can be labeled, for example, to quantify endosomal leakage.
[0167] In another type of assay, the iRNA agent described herein is constructed with one or more test or putative fusogenic agents. The iRNA agent can be labeled for easy visualization. The ability of endosomolytic components to promote escape from endosomes once the iRNA agent is taken up by a cell can be assessed by preparing an endosomal preparation or by microscopy techniques that can visualize the labeled iRNA agent in the cytoplasm of the cell. In some other embodiments, inhibition of gene expression or any other physiological parameter can be used as a surrogate marker for endosomal escape.
[0168] In another embodiment, circular dichroism spectroscopy can be used to identify compounds that exhibit pH-dependent structural transitions.
[0169] A two-step assay can also be performed, in which a first assay assesses the ability of the test compound alone to respond to a change in pH, and a second assay assesses the ability of a modular composition containing the test compound to respond to a change in pH.
[0170] peptide Peptides suitable for use with the present invention can be natural peptides (e.g., tat peptides or antennapedia peptides), synthetic peptides, or peptidomimetics. Furthermore, peptides can be modified, e.g., peptides can contain non-peptide or pseudopeptide bonds and D-amino acids. Peptidomimetics (also referred to herein as oligopeptidomimetics) are molecules that can fold into defined three-dimensional structures similar to natural peptides. The attachment of peptides and peptidomimetics to oligonucleotides can affect the pharmacokinetic distribution of oligonucleotides, for example, by enhancing cellular recognition and uptake. The length of the peptide or peptidomimetic portion can be about 5 to 50 amino acids, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids (see, e.g., Table 1). [Table 1]
[0171] The peptide or peptidomimetic can be, for example, a cell-penetrating peptide, a cationic peptide, an amphipathic peptide, or a hydrophobic peptide (e.g., composed primarily of Tyr, Trp, or Phe). The peptide moiety can be a dendrimeric peptide, a constrained peptide, or a cross-linked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane-translocating sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF, which has the amino acid sequence AAVALLPAVLLALLAP. An RFGF analog containing a hydrophobic MTS (e.g., the amino acid sequence AALLPVLLAAP) can also be a targeting moiety. The peptide moiety can be a "delivery" peptide, capable of transporting large polar molecules, including peptides, oligonucleotides, and proteins, across cell membranes. For example, sequences derived from the HIV Tat protein (GRKKRRQRRRPPQ) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK) have been shown to function as delivery peptides. The peptide or peptidomimetic can be encoded by a random sequence of DNA, such as peptides identified from a phage display library or a one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). The lipid-linked peptide or peptidomimetic is preferably a cell-targeting peptide, such as an arginine-glycine-aspartic acid (RGD) peptide or RGD mimic. The length of the peptide portion can range from about 5 amino acids to about 30 amino acids. The peptide portion can have structural modifications, for example, to increase stability or direct conformational properties. Any of the following structural modifications can be utilized:
[0172] The RGD peptide moiety can be used to target tumor cells, such as endothelial tumor cells or breast cancer tumor cells (Zitzmann et al., Cancer Res., 62:5139-43, 2002). RGD peptides can promote tumor targeting in various tissues, including the lung, kidney, spleen, or liver (Aoki et al., Cancer Gene Therapy 8:783-787, 2001). RGD peptides preferably promote targeting of lipid particles to the kidney. RGD peptides can be linear or cyclic and can be modified (e.g., glycosylated or methylated to promote targeting to specific tissues). For example, glycosylated RGD peptides can be α v Tumor cells that express β3 can be targeted (Haubner et al., Jour. Nucl. Med., 42:326-336, 2001).
[0173] Peptides can be used that target markers that are enriched in proliferating cells. For example, RGD-containing peptides and peptidomimetics target cancer cells, particularly I v Cells that display ν3 integrin can be targeted. Thus, RGD peptides, cyclic peptides containing RGD, RGD peptides containing D-amino acids, and synthetic RGD mimics can be used. In addition to RGD, I v Other moieties that target the -v3 integrin ligand can be used. In general, such ligands can be used to control cell proliferation and angiogenesis.
[0174] A "cell-penetrating peptide" can penetrate cells, such as microbial cells (e.g., bacterial or fungal cells) or mammalian cells (e.g., human cells). Microbial cell-penetrating peptides can be, for example, α-helical linear peptides (e.g., LL-37 or seropin P1), disulfide bond-containing peptides (e.g., α-defensins, β-defensins, or bactenecins), or peptides containing mainly one or two amino acids (e.g., PR-39 or indolicidin). Cell-penetrating peptides can also contain a nuclear localization signal (NLS). For example, cell-penetrating peptides can be bipartite amphipathic peptides, such as MPG, derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).
[0175] iRNA agents An iRNA agent should include a region sufficiently homologous to the target gene and be of sufficient length, in terms of nucleotides, that the iRNA agent, or a fragment thereof, can mediate downregulation of the target gene. (For ease of exposition, the terms nucleotide or ribonucleotide may be used herein in reference to one or more monomeric subunits of an RNA agent. It will be understood that the use of the terms "ribonucleotide" or "nucleotide" herein can also refer to the modified nucleotide, or surrogate replacement moiety at one or more positions, in the case of a modified RNA or nucleotide surrogate.) Thus, an iRNA agent is or includes a region that is at least partially, and in some embodiments, completely, complementary to the target RNA. While perfect complementarity between an iRNA agent and a target need not exist, the correspondence must be sufficient to enable the iRNA agent, or its cleavage products, to direct sequence-specific silencing, e.g., by RNAi cleavage of the target RNA (e.g., mRNA). Complementarity, i.e., the degree of homology with the target strand, is most important in the antisense strand. Although in many cases, perfect complementarity is desired, especially in antisense strand, some embodiments can comprise one or more (to target RNA), or for example, 6, 5, 4, 3, 2 or less mismatches, especially in antisense strand.In particular, mismatches in antisense strand are most tolerated in terminal region, and if present, can be in terminal region(s), for example, within 6, 5, 4 or 3 nucleotides from 5'-end and / or 3'-end.All that is required for sense strand is that it is sufficiently complementary with antisense strand to maintain the overall double-stranded nature of the molecule.
[0176] As discussed elsewhere herein, and in the documents incorporated by reference in their entirety, iRNA agents are often modified or contain nucleoside surrogates. The single-stranded region of an iRNA agent is often modified or contains nucleoside surrogates; for example, an unpaired region or a region of a hairpin structure (e.g., a region connecting two complementary regions) can have a modification or nucleoside surrogate. For example, modifications that stabilize one or more 3' or 5' ends of an iRNA agent against exonucleases or that favor the antisense siRNA agent's entry into RISC are also contemplated. Modifications can include C3 (or C6, C7, C12) amino linkers, thiol linkers, carboxyl linkers, non-nucleotide spacers (C3, C6, C7, C12, abasic, triethylene glycol, hexaethylene glycol), special biotin or fluorescein reagents (which come as phosphoramidites and have an additional DMT-protected hydroxyl group to allow for multiple couplings during RNA synthesis).
[0177] iRNA agents include molecules that are long enough to induce an interferon response (these can be cleaved by Dicer (Bernstein et al., 2001. Nature, 409:363-366) and enter RISC (RNA-induced silencing complex)); and molecules that are short enough not to induce an interferon response (these molecules can also be cleaved by Dicer and / or enter RISC), e.g., molecules sized to enter RISC (e.g., molecules similar to Dicer cleavage products). Molecules that are short enough not to induce an interferon response are referred to herein as "siRNA agents or shorter iRNA agents." As used herein, "siRNA agents or shorter iRNA agents" refers to RNA agents (e.g., double-stranded RNA agents or single-stranded agents) that are short enough not to induce a deleterious interferon response in, for example, human cells, having a duplex region of less than 60, 50, 40, or 30 nucleotide pairs. The siRNA agent, or its cleavage product, can downregulate a target gene, for example, by inducing RNAi against the target RNA, where the target can include an endogenous target RNA or a pathogen target RNA.
[0178] The length of each strand of the siRNA agent can be 30, 25, 24, 23, 22, 21, or 20 nucleotides or less. The length of the strands may be at least 19. For example, the length of each strand can be 21 to 25 nucleotides. The siRNA agent may have a duplex region of 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotide pairs and one or more overhangs, or one or two 3' overhangs of 2 to 3 nucleotides.
[0179] In addition to homology to a target RNA and the ability to downregulate a target gene, an iRNA agent may have one or more of the following properties: (1) The iRNA agent can be of formula VII, VIII, IX, or X, shown below in the section on RNA agents; (2) If single stranded, the iRNA agent can have a 5' modification that includes one or more phosphate groups or one or more analogs of a phosphate group; (3) Despite modifications to a significant number, or even all, of the nucleosides, an iRNA agent may have an antisense strand that is capable of presenting the bases (or modified bases) in the proper three-dimensional conformation to allow for accurate base pairing and formation of a duplex structure with a homologous target RNA sufficient to allow target downregulation, e.g., by cleavage of the target RNA; (4) Despite modifications to a significant number, or even all, of the nucleosides, an iRNA agent can still have "RNA-like" properties. That is, an iRNA agent can have the overall structural, chemical, and physical properties of an RNA molecule, even if it is not limited to, or even partially, ribonucleotide-based content. For example, an iRNA agent can contain, for example, a sense and / or antisense strand in which all nucleotide sugars contain, for example, 2' fluoro instead of 2' hydroxyl. This deoxyribonucleotide-containing agent can still be expected to exhibit RNA-like properties. Without wishing to be bound by theory, electronegative fluorine prefers an axial orientation when attached to the C2' position of ribose. This spatial preference of fluorine may be due to the presence of a C2' sugar. 3’ The endo pucker can be forced to form the same puckering mode observed in RNA molecules, resulting in the A-family helix characteristic of RNA. Furthermore, because fluorine is a good hydrogen bond acceptor, it can participate in the same hydrogen bonding interactions with water molecules, which are known to stabilize RNA structure. The modified moiety at the 2' sugar position can enter into an H-bond that is more characteristic of the OH moiety of ribonucleotides than the H moiety of deoxyribonucleotides. Certain iRNA agents have C-type sugars in all, or at least 50, 75, 80, 85, 90, or 95% of the sugars. 3’ C in sufficient amounts of sugar to exhibit end puckering or to produce the A-family helix characteristic of RNA 3’Show end packer or C 3’ have no more than about 20, 10, 5, 4, 3, 2, or 1 sugar that is not an end-pucker structure. Regardless of the nature of the modification, and although an RNA agent can contain deoxynucleotides or modified deoxynucleotides, particularly in overhangs or other single-stranded regions, it is certain that a DNA molecule, or any molecule in which more than 50, 60, or 70% of the nucleotides in the molecule, or more than 50, 60, or 70% of the nucleotides in a duplex region, are deoxyribonucleotides, or modified deoxyribonucleotides in which the 2' position is deoxy, is excluded from the definition of an RNA agent.
[0180] As used herein, a "single-stranded iRNA agent" refers to an iRNA agent that is composed of a single molecule. A single-stranded iRNA agent may include a duplex region formed by intrastrand pairing; for example, a single-stranded iRNA agent may be or include a hairpin or panhandle structure. A single-stranded iRNA agent may be antisense with respect to a target molecule. In some embodiments, a single-stranded iRNA agent is 5' phosphorylated or includes a phosphoryl analog at the 5' prime end. 5'-phosphate modifications include those that are compatible with RISC-mediated gene silencing.Suitable modifications include 5' monophosphate ((HO)2(O)PO-5'); 5' diphosphate ((HO)2(O)POP(HO)(O)-O-5'); 5' triphosphate ((HO)2(O)PO-(HO)(O)POP(HO)(O)-O-5'); 5'-guanosine cap (7-methylated or unmethylated) (7m-GO-5'-(HO)(O)PO-(HO)(O)POP(HO)( 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (NO-5'-(HO)(O)PO-(HO)(O)POP(HO)(O)-O-5'); 5' monothiophosphate (phosphorothioate; (HO)2(S)PO-5'); 5' monodithiophosphate (phosphorodithioate; (HO)(HS)(S)PO-5'), 5'-ho These modifications include phosphorothiolate ((HO)2(O)PS-5'); any additional combination of oxygen / sulfur substituted monophosphates, diphosphates, and triphosphates (e.g., 5'-α-thiotriphosphate, 5'-γ-thiotriphosphate, etc.), 5'-phosphoramidates ((HO)2(O)P-NH-5', (HO)(NH2)(O)PO-5'), 5'-alkylphosphonates (R = alkyl = methyl, ethyl, isopropyl, propyl, etc., e.g., RP(OH)(O)-O-5', (OH)2(O)P-5'-CH2), and 5'-alkyl ether phosphonates (R = alkyl ether = methoxymethyl (MeOCH2-), ethoxymethyl, etc., e.g., RP(OH)(O)-O-5'). (These modifications can also be used for the antisense strand of a double-stranded iRNA.)
[0181] The single-stranded iRNA agent may be long enough to enter the RISC complex and participate in the cleavage of the target mRNA via RISC.The length of the single-stranded iRNA agent is at least 14 nucleotides, and in other embodiments, at least 15, 20, 25, 29, 35, 40, or 50 nucleotides.In some embodiments, the length of the single-stranded iRNA agent is less than 200, 100, or 60 nucleotides.
[0182] Hairpin iRNA agents have a duplex region equal to or at least 17, 18, 19, 29, 20, 21, 22, 23, 24, or 25 nucleotide pairs. The length of the duplex region is no more than 200, 100, or 50 nucleotide pairs. In some embodiments, the ranges for the length of the duplex region are 15-30, 17-23, 19-23, and 19-21 nucleotide pairs. The hairpin may have a single-stranded overhang or terminal unpaired region, in some embodiments, at the 3' and, in some embodiments, at the antisense side of the hairpin. In some embodiments, the overhang is 2-3 nucleotides in length.
[0183] As used herein, a "double-stranded (ds) iRNA agent" is an iRNA agent that includes two or more, and in some cases two, strands that can form a region of duplex structure by interstrand hybridization.
[0184] The length of the antisense strand of a double-stranded iRNA agent can be equal to or at least 14, 15, 16, 17, 18, 19, 25, 29, 40, or 60 nucleotides. The length of the antisense strand of a double-stranded iRNA agent can be up to 200, 100, or 50 nucleotides. Length ranges can be 17-25, 19-23, and 19-21 nucleotides.
[0185] The length of the sense strand of a double-stranded iRNA agent can be equal to or at least 14, 15, 16, 17, 18, 19, 25, 29, 40, or 60 nucleotides. The length of the sense strand of a double-stranded iRNA agent can be up to 200, 100, or 50 nucleotides. Length ranges can be 17-25, 19-23, and 19-21 nucleotides.
[0186] The length of the double-stranded portion of a double-stranded iRNA agent can be equal to or at least 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 60 nucleotide pairs. The length of the double-stranded portion of a double-stranded iRNA agent can be up to 200, 100, or 50 nucleotide pairs. Ranges of lengths can be 15-30, 17-23, 19-23, and 19-21 nucleotide pairs.
[0187] In many embodiments, the ds iRNA agent is large enough that it can be cleaved by an endogenous molecule (eg, by Dicer) to produce a smaller ds iRNA agent (eg, a siRNA agent).
[0188] It may be desirable to modify one or both of the antisense and sense strands of a double-stranded iRNA agent. The sense and antisense strands may have the same or the same type of modification, or different modifications; for example, in some cases, it may be desirable to modify only the sense strand. For example, it may be desirable to modify only the sense strand to inactivate it, e.g., the sense strand can be modified to inactivate it and prevent the formation of active siRNA / protein or RISC. This can be achieved by modifications that prevent 5'-phosphorylation of the sense strand (e.g., by modification with 5'-O-methylribonucleotides) (see Nykanen et al. (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309-321). Other modifications that prevent phosphorylation can also be used, such as simply replacing 5'-OH with H instead of O-Me. Alternatively, a large bulky group can be added to the 5'-phosphate to convert it into a phosphodiester bond, but this may be less desirable because phosphodiesterase can cleave this bond, releasing the 5'-end of the functional siRNA. Antisense strand modifications include 5' phosphorylation and any other 5' modifications discussed herein, particularly those discussed above in the section on single-stranded iRNA molecules.
[0189] The sense and antisense strands can be selected so that the ds iRNA agent contains a single-stranded or unpaired region at one or both ends of the molecule. Thus, the ds iRNA agent can contain paired sense and antisense strands that contain overhangs, for example, one or two 5' or 3' overhangs, or 3' overhangs of 2-3 nucleotides. Many embodiments have 3' overhangs. Some siRNA agents have single-stranded overhangs, and in some embodiments, 3' overhangs of 1, 2, or 3 nucleotides in length at each end. Overhangs can result from one strand being longer than the other, or from two strands of the same length being zigzagged. The 5' end can be phosphorylated.
[0190] In some embodiments, the length of the duplex region is 15-30 nucleotides, or 18, 19, 20, 21, 22, and 23 nucleotides, for example, in the range of siRNA agents discussed above. The siRNA agent can be similar in length and structure to the product processed from a long ds iRNA by natural Dicer. Also included are embodiments in which the two strands of the siRNA agent are linked (e.g., covalently linked). Hairpins or other single-stranded structures that provide the required duplex region and 3' overhang are also within the scope of the invention.
[0191] The isolated iRNA agent described herein, including ds iRNA agent and siRNA agent, can mediate the silencing of target RNA, for example, mRNA (for example, the transcript of the gene encoding a protein).For convenience, this mRNA is also referred to herein as the mRNA to be silenced.This gene is also referred to as target gene.Generally, the RNA to be silenced is an endogenous gene or a pathogen gene.In addition, it can also target RNA other than mRNA (for example, tRNA) and viral RNA.
[0192] As used herein, the phrase "mediating RNAi" refers to the ability to silence target RNA in a sequence-specific manner. Without wishing to be bound by theory, it is believed that silencing uses the RNAi mechanism or process and a guide RNA (e.g., a 21-23 nucleotide siRNA agent).
[0193] As used herein, " specifically hybridizable " or " complementary " is a term used to indicate a sufficient degree of complementarity between the compound of the present invention and target RNA molecule, so that stable and specific binding occurs.Specific binding requires a sufficient degree of complementarity to avoid non-specific binding of oligomeric compounds to non-target sequences under the conditions where specific binding is desired, i.e., in the case of in vivo assay or therapeutic treatment, under physiological conditions, or in the case of in vitro assay, under the conditions where the assay is performed.Non-target sequences are typically different by at least 5 nucleotides.
[0194] In one embodiment, an iRNA agent is "sufficiently complementary" to a target RNA, e.g., a target mRNA, such that the iRNA agent silences production of a protein encoded by the target mRNA. In another embodiment, the iRNA agent is "exactly complementary" to the target RNA, e.g., the target RNA and iRNA agent anneal to form a hybrid consisting solely of Watson-Crick base pairs in the exact complementary region. A "sufficiently complementary" target RNA can include an internal region (e.g., of at least 10 nucleotides) that is exactly complementary to the target RNA. Furthermore, in some embodiments, the iRNA agent can specifically discriminate between single-nucleotide differences. In this case, the iRNA agent mediates RNAi only if exact complementarity is found in the region (e.g., within 7 nucleotides) of the single-nucleotide difference.
[0195] As used herein, the term "oligonucleotide" refers to a nucleic acid molecule (RNA or DNA) that is, for example, less than 100, 200, 300, or 400 nucleotides in length.
[0196] The RNA agents discussed herein include unmodified RNA, as well as RNA modified, for example, to improve efficacy, and polymers of nucleoside substitutes. Unmodified RNA refers to molecules in which the nucleic acid components, i.e., sugar, base, and phosphate moieties, are the same or essentially the same as those found in nature, e.g., in the human body. In the art, rare or unusual naturally occurring RNAs are often referred to as modified RNAs; see, for example, Limbach et al. (1994) Summary: the modified nucleosides of RNA, Nucleic Acids Res. 22:2183-2196. Such rare or unusual RNAs, often referred to as modified RNAs (typically because they are evidently the result of post-transcriptional modification), are within the scope of the term "unmodified RNA" as used herein. Modified RNA refers to molecules in which one or more nucleic acid components, i.e., sugar, base, and phosphate moieties, are different from those found in nature, e.g., those found in the human body. These are referred to as modified "RNAs," but of course, these include molecules that are not RNAs because they are modified. Nucleoside surrogates are molecules in which the ribophosphate backbone is replaced with a non-ribophosphate construct that allows the bases to be presented in the correct spatial relationship so that hybridization is substantially similar to that seen with a ribophosphate backbone (e.g., an uncharged mimic of the ribophosphate backbone), all of which examples are discussed herein.
[0197] Most of the following discussion refers to single-stranded molecules. Many embodiments of the invention contemplate double-stranded iRNA agents (e.g., partially double-stranded iRNA agents). Thus, double-stranded structures made up of the single-stranded structures described below (e.g., where two separate molecules contact to form a double-stranded region, or where a double-stranded region is formed by intramolecular pairing (e.g., a hairpin structure)) are within the scope of the invention. Lengths are described elsewhere herein.
[0198] Because nucleic acids are polymers of subunits, many of the modifications described below (e.g., modifications of the base, or phosphate moiety, or non-linked O of the phosphate moiety) occur at positions that are repeated within the nucleic acid. While modifications may occur at all of these positions in a nucleic acid, this is often not the case. For example, modifications may occur only at the 3'-terminal position or the 5'-terminal position, or may occur only in terminal regions, e.g., at terminal nucleotide positions or in the last 2, 3, 4, 5, or 10 nucleotides of the chain. Modifications may occur in double-stranded regions, single-stranded regions, or both. Modifications may occur only in double-stranded regions of RNA, or only in single-stranded regions of RNA. For example, phosphorothioate modifications at non-linked O positions may occur at one or both ends, or may occur only in terminal regions, e.g., at terminal nucleotide positions or in the last 2, 3, 4, 5, or 10 nucleotides of the chain, or may occur in double-stranded and single-stranded regions, particularly at the ends. The 5' end(s) can be phosphorylated.
[0199] In some embodiments, it is possible to include specific bases in the overhang or to include modified nucleotides or nucleotide surrogates in the single-stranded overhang (e.g., the 5'-overhang or the 3'-overhang, or both), e.g., to increase stability. For example, it may be desirable to include purine nucleotides in the overhang. In some embodiments, all or some of the bases in the 3'-overhang or the 5'-overhang are modified, e.g., using the modifications described herein. Modifications can include, for example, the use of modifications at the 2'OH group of the ribose sugar, e.g., the use of deoxyribonucleotides (e.g., deoxythymidine) instead of ribonucleotides, and modifications at the phosphate group (e.g., phosphorothioate modifications). The overhang need not be homologous to the target sequence.
[0200] Modifications and nucleotide surrogates are discussed below. [ka]
[0201] The scaffold shown in Formula VII above represents a portion of a ribonucleic acid. The basic components are the ribose sugar, the base, the terminal phosphate, and the phosphate internucleotide linker. When the base is a natural base, such as adenine, uracil, guanine, or cytosine, the sugar is an unmodified 2' hydroxyl ribose sugar (as shown), and W, X, Y, and Z are all O, Formula VII represents a natural, unmodified oligoribonucleotide.
[0202] Unmodified oligoribonucleotide may not be optimal for some applications, for example, unmodified oligoribonucleotide may be easily degraded by, for example, cellular nuclease.Nuclease can hydrolyze the phosphodiester bond of nucleic acid.However, the chemical modification of one or more of the above RNA components can give improved properties, for example, make oligoribonucleotide more stable against nuclease.
[0203] Modified nucleic acids and nucleotide surrogates can include one or more of the following: (i) modification (e.g., substitution) of one or both of the non-linking (X and Y) phosphate oxygens and / or one or more of the linking (W and Z) phosphate oxygens (when the phosphate is at a terminal position, one of positions W or Z does not link the phosphate to an additional element in naturally occurring ribonucleic acids. However, for simplicity of terminology, unless otherwise noted, the W position at the 5' end of a nucleic acid and the terminal Z position at the 3' end of a nucleic acid are within the scope of the term "linking phosphate oxygen" as used herein); (ii) modification (e.g., substitution) of a ribose sugar component (e.g., the 2′ hydroxyl of the ribose sugar); (iii) extensive replacement of the phosphate moiety (bracket I) with a “dephospho” linker; (iv) modification or substitution of naturally occurring bases; (v) substitutions or modifications of the ribose-phosphate backbone (bracket II); (vi) Modification of the 3' or 5' end of the RNA (e.g., removal, modification, or replacement of the terminal phosphate group, or conjugation of a moiety (e.g., a fluorescently labeled moiety) to either the 3' or 5' end of the RNA).
[0204] As used in this context, terms such as substitution, modification, alteration, etc. do not imply a process limitation, e.g., modification does not mean that one must start with a reference ribonucleic acid or a naturally occurring ribonucleic acid and modify it to produce the modified ribonucleic acid; modification simply means a difference from the naturally occurring molecule.
[0205] It is understood that the actual electronic structure of some chemical entities cannot be adequately represented by a single standard form (i.e., Lewis structure). Without wishing to be bound by theory, the actual structure may instead be a hybrid or weighted average of two or more standard forms, collectively known as resonance forms or resonance structures. Resonance structures are not individual chemical entities, but exist only on paper. Resonance structures differ from one another only in the placement or "localization" of bonding and non-bonding electrons for a particular chemical entity. It is possible that one resonance structure contributes to a higher degree of hybridization than another. Therefore, the written and illustrated descriptions of embodiments of the present invention are made in terms of what is recognized in the art as the dominant resonance form for a particular species. For example, any phosphoramidate (non-bonding oxygen replaced by nitrogen) would be represented by X=O and Y=N in the diagram above.
[0206] Specific modifications are discussed in detail below.
[0207] phosphate group The phosphate group is a negatively charged species. The charge is evenly distributed between the two non-bonded oxygen atoms (i.e., X and Y in the above formula 1). However, the phosphate group can be modified by replacing one of the oxygen atoms with a different substituent. One result of this modification to the RNA phosphate backbone may be increased resistance of oligoribonucleotide to nuclease degradation. Therefore, without wishing to be bound by theory, in some embodiments, it may be desirable to introduce a modification that produces either an uncharged linker or a charged linker with asymmetric charge distribution.
[0208] Examples of modified phosphate groups include phosphorothioates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, alkyl or aryl phosphonates, and phosphotriesters. In phosphorodithioates, both non-bonding oxygens are replaced with sulfur. Unlike the situation where only one of X or Y is modified, the phosphorus center in phosphorodithioates is achiral, which prevents the formation of diastereomers of oligoribonucleotides. Diastereomer formation can result in preparations in which the individual diastereomers exhibit different resistance to nucleases. Furthermore, the hybridization affinity of RNA containing chiral phosphate groups may be lower than that of the corresponding unmodified RNA species. Therefore, without wishing to be bound by theory, modifications to both X and Y (e.g., phosphorodithioate formation) that eliminate the chiral center may be desirable, since they cannot produce diastereomeric mixtures. Thus, X can be any one of S, Se, B, C, H, N, or OR (where R is alkyl or aryl). Thus, Y can be any one of S, Se, B, C, H, N, or OR (where R is alkyl or aryl). X and / or Y can be substituted with sulfur.
[0209] The phosphate linker can also be modified by replacing the linking oxygen (i.e., W or Z in Formula 1 above) with nitrogen (bridged phosphoramidate), sulfur (bridged phosphorothioate), and carbon (bridged methylene phosphonate). Substitution can occur at the terminal oxygen (position W (3') or position Z (5')). W can be replaced with carbon or Z can be replaced with nitrogen.
[0210] Candidate agents can be evaluated for suitability as follows.
[0211] sugar group Modified RNAs can include modifications of all or some of the sugar groups of ribonucleic acids. For example, the 2' hydroxyl group (OH) can be modified or replaced with a number of different "oxy" or "deoxy" substituents. Without being bound by theory, enhanced stability is predicted because the hydroxyl can no longer be deprotonated to form a 2' alkoxide ion. The 2' alkoxide can catalyze decomposition by intramolecular nucleophilic attack on the phosphorus atom of the linker. Again, without wishing to be bound by theory, it may be desirable for some embodiments to introduce modifications that do not allow alkoxide formation at the 2' position.
[0212] Examples of "oxy"-2' hydroxyl group modifications include alkoxy or aryloxy (OR, e.g., R = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar); polyethylene glycol (PEG), O(CH2CHO) n CH2CH2OR; "locked" nucleic acids (LNA) in which the 2' hydroxyl is connected to the 4' carbon of the same ribose sugar, for example, by a methylene bridge; O-AMINE (AMINE = NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, polyamino) and aminoalkoxy, O(CH2) n AMINE (e.g., AMINE = NH; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino, ethylenediamine, polyamino). It is noteworthy that oligonucleotides containing only methoxyethyl groups (MOE) (a PEG derivative, OCH2CH2OCH3) exhibit nuclease stability comparable to those modified with the robust phosphorothioate modification.
[0213] "Deoxy" modifications include hydrogen (i.e., deoxyribose sugars, which are particularly relevant in partially dsRNA overhangs); halo (e.g., fluoro); amino (e.g., NH; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid); NH(CHCHNH) n These include CHCH-AMINE (AMINE = NH; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroarylamino), NHC(O)R (R = alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar), cyano; mercapto; alkyl-thio-alkyl; thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl, and alkynyl (which may optionally be substituted, for example, with an amino functional group). Other substituents of certain embodiments include 2'-methoxyethyl, 2'-OCH, 2'-O-allyl, 2'-C-allyl, and 2'-fluoro.
[0214] The sugar group can also contain one or more carbons that have the opposite stereochemical configuration to that of the corresponding carbon in ribose. Thus, modified RNAs can include, for example, nucleotides that contain arabinose as the sugar.
[0215] Modified RNAs can also include "abasic" sugars that lack a nucleobase at C-1'. These abasic sugars can also contain additional modifications at one or more of the constituent sugar atoms.
[0216] To maximize nuclease resistance, the 2' modifications can be used in combination with one or more phosphate linker modifications (e.g., phosphorothioates). So-called "chimeric" oligonucleotides are oligonucleotides that contain two or more different modifications.
[0217] Candidate modifications can be evaluated as follows.
[0218] Phosphate group substitution The phosphate group can be replaced with a non-phosphorus-containing connector (see bracket I in Formula 1). Without wishing to be bound by theory, it is believed that because the charged phosphodiester group is the reactive center in nuclease degradation, replacing it with a neutral structural mimetic should confer enhanced nuclease stability. Again, without wishing to be bound by theory, in certain embodiments, it may be desirable to introduce modifications in which the charged phosphate group is replaced with a neutral moiety.
[0219] Examples of moieties that can replace the phosphate group include siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, and methyleneoxymethylimino. In some embodiments, substitutions may include methylenecarbonylamino and methylenemethylimino groups.
[0220] Candidate modifications can be evaluated as follows.
[0221] Phosphate backbone substitution Oligonucleotide-mimetic scaffolds can also be constructed in which the phosphate linker and ribose sugar are replaced with nuclease-resistant nucleoside or nucleotide surrogates (see bracket II in Formula 1). Without wishing to be bound by theory, it is believed that the absence of a repeatedly charged backbone reduces binding to proteins that recognize polyanions (e.g., nucleases). Again, without wishing to be bound by theory, in some embodiments, it may be desirable to introduce modifications in which the bases are linked by a neutral backbone surrogate.
[0222] Examples include morpholino, cyclobutyl, pyrrolidine, and peptide nucleic acid (PNA) nucleoside surrogates. In certain embodiments, PNA surrogates may be used.
[0223] Candidate modifications can be evaluated as follows.
[0224] terminal modification The 3' and 5' ends of an oligonucleotide can be modified. Such modifications can be made at the 3', 5', or both ends of the molecule. These modifications can include modifying or replacing the entire terminal phosphate or one or more atoms of the terminal phosphate group. For example, the 3' and 5' ends of an oligonucleotide can be conjugated to other functional molecular entities, such as labeling moieties, such as fluorophores (e.g., pyrene, TAMRA, fluorescein, Cy3 dye, or Cy5 dye) or protecting groups (e.g., sulfur-, silicon-, boron-, or ester-based). The functional molecular entities can be attached to the sugar via the phosphate group and / or a spacer. The terminal atom of the spacer can be connected to or replace the linking atom of the phosphate group or the O, N, S, or C group at C-3' or C-5' of the sugar. Alternatively, the spacer can be connected to or replace the terminal atom of a nucleotide surrogate (e.g., PNA). These spacers or linkers include, for example, -(CH2) n -, -(CH2) n N-, -(CH2) n O-, -(CH2) n S-, O(CH2CH2O) nExamples include CH2CH2OH (e.g., n=3 or 6), abasic sugar, amide, carboxy, amine, oxyamine, oxyimine, thioether, disulfide, thiourea, sulfonamide, or morpholino, or biotin and fluorescein reagents. When a "spacer / phosphate-functional molecular entity-spacer phosphate" sequence is interposed between the two strands of an iRNA agent, this sequence can replace the hairpin RNA loop in a hairpin-shaped RNA agent. The 3' end can be an -OH group. Without wishing to be bound by theory, it is believed that conjugation of certain moieties can improve transport, hybridization, and specificity properties. Again, without wishing to be bound by theory, it may be desirable to introduce terminal modifications that improve nuclease resistance. Other examples of terminal modifications include dyes, intercalating agents (e.g., acridine), crosslinkers (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic carriers (e.g., cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithophosphate, and the like). These include: oleic acid, O3-(oleoyl)cholenoic acid, dimethoxytrityl, or phenoxazine), and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bis-imidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles).
[0225] Terminal modification can be added for many reasons, including those discussed elsewhere herein, to adjust activity or to adjust resistance to degradation.Terminal modification useful for adjusting activity includes 5'-end modification with phosphate or phosphate analog.For example, in some embodiments, iRNA agent, particularly antisense strand, is 5'-phosphorylated or contains phosphoryl analog at 5'-prime end.5'-phosphate modification includes those that are compatible with RISC-mediated gene silencing. Suitable modifications include 5' monophosphate ((HO)2(O)PO-5'); 5' diphosphate ((HO)2(O)POP(HO)(O)-O-5'); 5' triphosphate ((HO)2(O)PO-(HO)(O)POP(HO)(O)-O-5'); 5'-guanosine cap (7-methylated or unmethylated) (7m-GO-5'-(HO)(O)PO-(HO)(O)POP(HO)(O)-O-5'); 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (NO-5'-(HO)(O)PO-(HO)(O)POP(HO)(O)-O-5'); 5' monothiophosphate (phosphorothioate; (HO)2(S)PO-5'); 5' monodithiophosphate (phosphorodithioate; (H RP(OH)(O)-O-5', (OH)(O)P-5'-CH), 5'-alkyl ether phosphonates (R=alkyl ether=methoxymethyl (MeOCH-), ethoxymethyl, etc., e.g., RP(OH)(O)-O-5').
[0226] Terminal modifications can also be useful to increase resistance to degradation.
[0227] Terminal modifications can also be useful for monitoring distribution, in which case the added group can include a fluorophore (e.g., fluorescein) or an Alexa dye (e.g., Alexa 488). Terminal modifications can also be useful for enhancing uptake, modifications useful for this purpose include cholesterol. Terminal modifications can also be useful for crosslinking an RNA agent to another moiety, modifications useful for this purpose include mitomycin C.
[0228] Candidate modifications can be evaluated as follows.
[0229] base Adenine, guanine, cytosine, and uracil are the most common bases found in RNA. These bases can be modified or substituted to provide RNA with improved properties. For example, nuclease-resistant oligonucleotides can be prepared using these bases or using synthetic or natural nucleobases (e.g., inosine, thymine, xanthine, hypoxanthine, nubularine, isoguanisine, or tubercidin) and any one of the above modifications. Alternatively, substituted or modified analogs of any of the above bases and "universal bases" can be utilized.Examples include 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and 5-halocytosine, 5-propynyluracil and 5-propynylcytosine, 6-azouracil, 6-azocytosine, and 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5-(2-aminopropanol), ... (propyl)uracil, 5-aminoallyluracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 5-substituted pyrimidines, 6-azapyrimidines, and N-2 substituted protons. Phosphorus, N-6 substituted purines, and O-6 substituted purines (including 2-aminopropyladenine), 5-propynyluracil and 5-propynylcytosine, dihydrouracil, 3-deaza-5-azacytosine, 2-aminopurine, 5-alkyluracil, 7-alkylguanine, 5-alkylcytosine, 7-deazaadenine, N6,N6-dimethyladenine, 2,6-diaminopurine, 5-amino-allyl-uracil, N3-methyluracil , substituted 1,2,4-triazole, 2-pyridinone, 5-nitroindole, 3-nitropyrrole, 5-methoxyuracil, uracil-5-oxyacetic acid, 5-methoxycarbonylmethyluracil, 5-methyl-2-thiouracil, 5-methoxycarbonylmethyl-2-thiouracil, 5-methylaminomethyl-2-thiouracil, 3-(3-amino-3-carboxypropyl)uracil, 3-methylcytosine, 5-methylcytosine, N. 42-acetylcytosine, 2-thiocytosine, N6-methyladenine, N6-isopentyladenine, 2-methylthio-N6-isopentenyladenine, N-methylguanine, or O-alkylated bases. Additional purines and pyrimidines include those disclosed in U.S. Patent No. 3,687,808, those disclosed in "Concise Encyclopedia of Polymer Science and Engineering", pages 858-859, edited by Kroschwitz JI, John Wiley & Sons, 1990, and those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613.
[0230] Generally, base changes are not used to promote stability, but may be useful for other reasons, for example, some (for example, 2,6-diaminopurine and 2-aminopurine) are fluorescent.Modified bases may reduce target specificity.This can be taken into consideration when designing iRNA agents.
[0231] Candidate modifications can be evaluated as follows.
[0232] Evaluation of candidate RNAs A candidate RNA agent (e.g., a modified RNA) can be evaluated for a selected property by exposing the RNA agent or the modified molecule and a control molecule to appropriate conditions and evaluating for the presence of the selected property. For example, resistance to a degradative agent can be evaluated as follows: The candidate modified RNA (and a control molecule, usually in its unmodified form) can be exposed to degradative conditions, such as an environment containing a degradative agent (e.g., a nuclease). For example, a biological sample can be used, such as an environment that may be encountered in therapeutic use, such as blood or a cellular fraction (e.g., a cell-free homogenate or disrupted cells). The candidate and control can then be evaluated for resistance to degradation by any of a number of techniques. For example, the candidate and control can be labeled before exposure, for example, with a radioactive or enzymatic label, or a fluorescent label (e.g., Cy3 or Cy5). The control RNA and modified RNA can be incubated with a degradative agent and, optionally, a control (e.g., an inactivated (e.g., heat-inactivated) degradative agent). Physical parameters (e.g., the size of the modified and control molecules) are then determined. These parameters can be determined by physical methods (e.g., by polyacrylamide gel electrophoresis or size fractionation columns) to assess whether the molecules have maintained their original length, or can be functionally assessed. Alternatively, Northern blot analysis can be used to assay the length of unlabeled modified molecules.
[0233] Functional assays can also be used to evaluate candidate agents. Functional assays can be applied initially, or after a previous non-functional assay (e.g., assays for resistance to degradation) to determine whether modifications alter the molecule's ability to silence gene expression. For example, cells (e.g., mammalian cells, such as mouse or human cells) can be co-transfected with a plasmid expressing a fluorescent protein (e.g., GFP) and a candidate RNA agent homologous to the transcript encoding the fluorescent protein (see, e.g., WO 00 / 44914). For example, a modified dsiRNA homologous to GFP mRNA can be assayed for its ability to inhibit GFP expression by monitoring for a decrease in cellular fluorescence compared to control cells that did not include the candidate dsiRNA in the transfection (e.g., a control in which no RNA agent was added and / or a control in which unmodified RNA was added). The efficacy of a candidate agent on gene expression can be assessed by comparing the fluorescence of cells in the presence of a modified ds iRNA agent and an unmodified ds iRNA agent.
[0234] In an alternative functional assay, a candidate ds iRNA agent homologous to an endogenous mouse gene (e.g., a maternally expressed gene such as c-mos) can be injected into immature mouse oocytes to assess the ability of the iRNA agent to inhibit gene expression in vivo (see, e.g., WO 01 / 36646). Oocyte phenotype (e.g., the ability to maintain metaphase II arrest) can be monitored as an indicator of the RNA agent's inhibition of expression. For example, cleavage of c-mos mRNA by a ds iRNA agent will cause the oocyte to exit metaphase arrest and initiate parthenogenetic development (Colledge et al., Nature 370:65-68, 1994; Hashimoto et al., Nature, 370:68-71, 1994). The effect of the modified RNA agent on target RNA levels can be confirmed by Northern blot to assay for a decrease in the level of target mRNA or by Western blot to assay for a decrease in the level of target protein, compared to a negative control. Controls can include cells to which no RNA agent is added and / or cells to which unmodified RNA is added.
[0235] RNA Structure References All publications, patents, and published patent applications cited herein are hereby incorporated by reference.
[0236] The oligoribonucleotides and oligoribonucleosides used in accordance with the present invention may be synthesized by solid phase synthesis, see, for example, "Oligonucleotides Synthesis, a Practical Approach," edited by M. J. Gait, IRL Press, 1984; "Oligonucleotides and Analogues, A Practical Approach," edited by F. Eckstein, IRL Press, 1991 (especially Chapter 1, "Modern machine-aided methods of oligodeoxyribonucleotide synthesis," Chapter 2, "Oligoribonucleotide synthesis," Chapter 3, "2'-O-Methyloligoribonucleotides: synthesis and applications," Chapter 4, "Phosphorothioate oligonucleotides," Chapter 5, "Synthesis of oligonucleotide phosphorodithioates," Chapter 6, "Synthesis of oligo-2'-deoxyribonucleoside methylphosphonates," and Chapter 7, "Oligodeoxynucleotides containing modified bases"). Other particularly useful synthetic procedures, reagents, blocking groups, and reaction conditions are described in Martin, P., Helv. Chim. Acta, 1995, 78, 486-504; Beaucage, SL and Iyer, RP, Tetrahedron, 1992, 48, 2223-2311, and Beaucage, SL and Iyer, RP, Tetrahedron, 1993, 49, 6123-6194, or the references cited therein. The modifications described in WO 00 / 44895, WO 01 / 75164, or WO 02 / 44321 can be used herein.
[0237] Phosphate Group References The preparation of phosphinate oligoribonucleotides is described in U.S. Patent No. 5,508,270. The preparation of alkylphosphonate oligoribonucleotides is described in U.S. Patent No. 4,469,863. The preparation of phosphoramidite oligoribonucleotides is described in U.S. Patent No. 5,256,775 or U.S. Patent No. 5,366,878. The preparation of phosphotriester oligoribonucleotides is described in U.S. Patent No. 5,023,243. The preparation of boranophosphate oligoribonucleotides is described in U.S. Patent No. 5,130,302 and U.S. Patent No. 5,177,198. The preparation of 3'-deoxy-3'-amino phosphoramidate ribonucleotides is described in U.S. Patent No. 5,476,925. 3'-Deoxy-3'-methylenephosphonate oligoribonucleotides are described in An, H. et al., J. Org. Chem. 2001, 66, 2789-2801. The preparation of sulfur-bridged nucleotides is described in Sproat et al., Nucleosides Nucleotides 1988, 7, 651, and Crossick et al., Tetrahedron Lett. 1989, 30, 4693.
[0238] Sugar Group References Modifications for 2' modifications can be found in Verma, S. et al., Annu. Rev. Biochem. 1998, 67, 99-134 and all references therein. Specific modifications for ribose can be found in the following references: 2'-fluoro (Kawasaki et al., J. Med. Chem., 1993, 36, 831-841), 2'-MOE (Martin, P. Helv. Chim. Acta 1996, 79, 1930-1938), "LNA" (Wengel, J. Acc Chem. Res. 1999, 32, 301-310).
[0239] Phosphate group substitution references Methylenemethylimino-linked oligoribonucleosides (also identified herein as MMI-linked oligoribonucleosides), methylenedimethylhydrazo-linked oligoribonucleosides (also identified herein as MDH-linked oligoribonucleosides), and methylenecarbonylamino-linked oligonucleosides (also identified herein as amide-3-linked oligoribonucleosides), and methyleneaminocarbonyl-linked oligonucleosides (also identified herein as amide-4-linked oligoribonucleosides). Oligonucleotides (also identified as oligonucleosides), as well as mixed backbone compounds having, for example, alternating MMI and PO or PS linkages, can be prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, and 5,489,677, and published international applications PCT / US92 / 04294 and PCT / US92 / 04305 (published as WO 92 / 20822 and WO 92 / 20823, respectively). Formacetal- and thioformacetal-linked oligoribonucleosides can be prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564. Ethylene oxide-linked oligoribonucleosides can be prepared as described in U.S. Pat. No. 5,223,618. Siloxane substitution is described in Cormier, JF et al., Nucleic Acids Res. 1988, 16, 4583. Carbonate substitution is described in Tittensor, JR, J. Chem. Soc. C 1971, 1933. Carboxymethyl substitution is described in Edge, MD, J. Chem. Soc. Perkin Trans. 1 1972, 1991. Carbamate substitution is described in Stirchak, EP, Nucleic Acids Res. 1989, 17, 6129.
[0240] Phosphate-ribose backbone substitution references Cyclobutyl sugar surrogate compounds can be prepared as described in U.S. Pat. No. 5,359,044. Pyrrolidine sugar surrogates can be prepared as described in U.S. Pat. No. 5,519,134. Morpholino sugar surrogates can be prepared as described in U.S. Pat. Nos. 5,142,047 and 5,235,033, as well as other related patent disclosures. Peptide nucleic acids (PNAs) are known per se and can be prepared according to any of the various procedures referenced in "Peptide Nucleic Acids (PNAs): Synthesis, Properties and Potential Applications," Bioorganic & Medicinal Chemistry, 1996, 4, 5-23. They may also be prepared according to U.S. Pat. No. 5,539,083.
[0241] Terminal Modification References Terminal modifications are described in Manoharan, M. et al., Antisense and Nucleic Acid Drug Development 12, 103-128 (2002) and references therein.
[0242] Base References N-2 substituted purine nucleoside amidites can be prepared as described in U.S. Patent No. 5,459,255. 3-deazapurine nucleoside amidites can be prepared as described in U.S. Patent No. 5,457,191. 5,6-substituted pyrimidine nucleoside amidites can be prepared as described in U.S. Patent No. 5,614,617. 5-propynylpyrimidine nucleoside amidites can be prepared as described in U.S. Patent No. 5,484,908. Further references can be found in the above section on base modifications.
[0243] Further RNA agents A particular RNA agent has the following structure (Formula VIII): [ka] During the ceremony, R 1 , R 2 , and R 3are independently H (i.e., abasic nucleotides), adenine, guanine, cytosine, and uracil, inosine, thymine, xanthine, hypoxanthine, nubularine, tubercidin, isoguanisine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and 5-halocytosine, 5-propynyluracil and 5-propynylcytosine, 6-azouracil, 6- Azocytosine, and 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5-(2-aminopropyl)uracil, 5-aminoallyluracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7 -methylguanine, 5-substituted pyrimidines, 6-azapyrimidines, and N-2-, N-6-, and O-6-substituted purines (including 2-aminopropyladenine), 5-propynyluracil and 5-propynylcytosine, dihydrouracil, 3-deaza-5-azacytosine, 2-aminopurine, 5-alkyluracil, 7-alkylguanine, 5-alkylcytosine, 7-deazaadenine, 7-deazaguanine, N6,N6-dimethyladenine, 2,6-diaminopurine, 5-amino-allyl-uracil, N3-methyluracil, substituted 1,2,4-triazoles, 2-pyridinone, 5-nitroindole, 3-nitropyrrole, 5-methoxyuracil, uracil-5-oxyacetic acid, 5-methoxycarbonylmethyluracil, 5-methyl-2-thiouracil, 5-methoxycarbonylmethyl-2-thiouracil, 5-methylaminomethyl-2-thiouracil, 3-(3-amino-3-carboxypropyl)uracil, 3-methylcytosine, 5-methylcytosine, N 4 -acetylcytosine, 2-thiocytosine, N6-methyladenine, N6-isopentyladenine, 2-methylthio-N6-isopentenyladenine, N-methylguanine, or an O-alkylated base; R4 , R 5 , and R 6 are independently OR 8 , O(CH2CH2O) m CH2CH2OR 8 ;O(CH2) n R 9 ;O(CH2) n OR 9 , H; Halo; NH2; NHR 8 ;N(R 8 )2;NH(CH2CH2NH) m CH2CH2NHR 9 ;NHC(O)R 8 ;Cyano;Mercapto, SR 8 alkyl-thio-alkyl; alkyl, aralkyl, cycloalkyl, aryl, heteroaryl, alkenyl, alkynyl, each of which is optionally substituted with halo, hydroxy, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, or ureido; or R 4 , R 5 , or R 6 is R 7 combine together to form a [-O-CH2-] covalent bridge between the 2' and 4' carbons of the sugar; A 1 teeth, [ka] ;H;OH, OCH3, W 1 ; abasic nucleotides or absent; (In some embodiments, A1 may be, particularly for antisense, a 5' monophosphate ((HO)2(O)PO-5'), a 5' diphosphate ((HO)2(O)POP(HO)(O)-O-5'), a 5' triphosphate ((HO)2(O)PO-(HO)(O)POP(HO)(O)-O-5'), a 5'-guanosine cap (7-methylated or unmethylated) (7m-GO-5'-(HO)(O)PO-(HO)(O)POP(HO)(O)-O-5'), a 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (NO-5'-(HO)(O)PO-(HO)(O)POP(HO)(O)-O-5'), a 5' monothiophosphate (phosphorothioate; (HO)2(S)PO-5'), a 5' monodi ... dithioates; (HO)(HS)(S)PO-5'), 5'-phosphorothiolate ((HO)2(O)PS-5'); any further combination of oxygen / sulfur substituted monophosphates, diphosphates, and triphosphates (e.g., 5'-α-thiotriphosphate, 5'-γ-thiotriphosphate, etc.), 5'-phosphoramidates ((HO)2(O)P-NH-5', (HO)(NH2)(O)PO-5'), 5'-alkylphosphonates (R = alkyl = methyl, ethyl, isopropyl, propyl, etc., e.g., RP(OH)(O)-O-5', (OH)2(O)P-5'-CH2), 5'-alkyl ether phosphonates (R = alkyl ether = methoxymethyl (MeOCH2-), ethoxymethyl, etc., e.g., RP(OH)(O)-O-5'); A 2 is: [ka] A 3 is: [ka] A 4 teeth, [ka] ;H;Z 4 ; inverted nucleotide; or absent; W 1 is OH, (CH2) n R 10 , (CH2) n NHR 10 , (CH2) n OR 10 , (CH2) n SR 10 ;O(CH2) n R 10 ;O(CH2) n OR 10 , O(CH2) n NR 10 , O(CH2) n SR 10 ;O(CH2) n SS(CH2) n OR 10 , O(CH2) n C(O)OR 10 , NH(CH2) n R 10 ;NH(CH2) n NR 10 ;NH(CH2) n OR 10 , NH(CH2) n SR 10 ;S(CH2) n R 10 , S(CH2) n NR 10 , S(CH2) n OR 10 , S(CH2) n SR 10 , O(CH2CH2O) m CH2CH2OR 10 ;O(CH2CH2O) m CH2CH2NHR 10 , NH(CH2CH2NH) m CH2CH2NHR 10 ;QR 10 , OQR 10 , N.Q.R. 10 , S.Q.R. 10 , or -O-; W 4 is O, CH2, NH, or S; X 1 , X 2 , X 3 , and X 4 is, independently for each occurrence, O or S; Y 1 , Y 2 , Y 3 , and Y 4 are independently expressed as OH and O - , OR 8 , S, Se, BH3 - ,H,NHR 9 , N(R 9 ) 2, alkyl, cycloalkyl, aralkyl, aryl, or heteroaryl, each of which may be optionally substituted; Z 1 , Z 2 , and Z 3 is, each occurrence independently, O, CH2, NH, or S; Z 4 is OH, (CH2) n R 10 , (CH2) n NHR 10 , (CH2) n OR 10 , (CH2) n SR 10 ;O(CH2) n R 10 ;O(CH2) n OR 10 , O(CH2) n NR 10 , O(CH2) n SR 10 , O(CH2) n SS(CH2) n OR 10 , O(CH2) n C(O)OR 10 ;NH(CH2) n R 10 ;NH(CH2) n NR 10 ;NH(CH2) n OR 10 , NH(CH2) n SR 10 ;S(CH2) n R10 , S(CH2) n NR 10 , S(CH2) n OR 10 , S(CH2) n SR 10 , O(CH2CH2O) m CH2CH2OR 10 , O(CH2CH2O) m CH2CH2NHR 10 , NH(CH2CH2NH) m CH2CH2NHR 10 ;QR 10 , OQR 10 , N.Q.R. 10 , S.Q.R. 10 and; x is between 5 and 100 and is selected to accommodate the length of an RNA agent described herein; R 7 is H; or R 4 , R 5 , or R 6 combine together to form a [-O-CH2-] covalent bridge between the 2' and 4' carbons of the sugar; R 8 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, amino acid, or sugar; R 9 is NH2, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid; R 10Fluorophores (pyrene, TAMRA, fluorescein, Cy3 dye, or Cy5 dye); sulfur protecting groups, silicon protecting groups, boron protecting groups, or ester protecting groups; intercalating agents (e.g., acridine), crosslinking agents (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic carriers (e.g., cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, mitomycin C), ristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenoic acid, dimethoxytrityl, or phenoxazine), and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl; radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles); or RNA agents; m is 0 to 1,000,000; n is 0 to 20.
[0244] Q is a spacer selected from the group consisting of an abasic sugar, an amide, a carboxy, an oxyamine, an oxyimine, a thioether, a disulfide, a thiourea, a sulfonamide, or a morpholino, or a biotin or fluorescein reagent.
[0245] Certain RNA agents in which the entire phosphate group is replaced have the following structure (Formula IX): [ka] During the ceremony, A 10 ~A 40 is LGL;A 10 and / or A 40 may be absent (where L is a linker, one or both L may be present or absent, CH2(CH2) g ;N(CH2) g ;O(CH2) g ;S(CH2) g selected from the group consisting of G is a functional group selected from the group consisting of siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, and methyleneoxymethylimino; R 10 , R 20 , and R 30are, independently for each occurrence, H (i.e., abasic nucleotides), adenine, guanine, cytosine, and uracil, inosine, thymine, xanthine, hypoxanthine, nubularine, tubercidin, isoguanisine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and 5-halocytosine, 5-propynyluracil and 5-propynylcytosine, 6 -azouracil, 6-azocytosine, and 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5-(2-aminopropyl)uracil, 5-aminoallyluracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosine, 7-methylguanine, 5-substituted pyrimidines, 6-azapyrimidines, and N-2-, N-6-, and O-6-substituted purines (including 2-aminopropyladenine), 5-propynyluracil and 5-propynylcytosine, dihydrouracil, 3-deaza-5-azacytosine, 2-aminopurine, 5-alkyluracil, 7-alkylguanine, 5-alkylcytosine, 7-deazaadenine, N6,N6-dimethyladenine, 2,6-diaminopurine, 5-amino-allyl-uracil, N3-methyluracil, substituted 1,2,4-triazoles, 2-pyridinone, 5-nitroindole, 3-nitropyrrole, 5-methoxyuracil, uracil-5-oxyacetic acid, 5-methoxycarbonylmethyluracil, 5-methyl-2-thiouracil, 5-methoxycarbonylmethyl-2-thiouracil, 5-methylaminomethyl-2-thiouracil, 3-(3-amino-3-carboxypropyl)uracil, 3-methylcytosine, 5-methylcytosine, N 4 -acetylcytosine, 2-thiocytosine, N6-methyladenine, N6-isopentyladenine, 2-methylthio-N6-isopentenyladenine, N-methylguanine, or an O-alkylated base; R40 , R 50 , and R 60 are independently OR 8 , O(CH2CH2O) m CH2CH2OR 8 ;O(CH2) n R 9 ;O(CH2) n OR 9 , H; Halo; NH2; NHR 8 ;N(R 8 )2;NH(CH2CH2NH) m CH2CH2NHR 9 ;NHC(O)R 8 ;Cyano;Mercapto, SR 8 alkyl-thio-alkyl; alkyl, aralkyl, cycloalkyl, aryl, heteroaryl, alkenyl, alkynyl, each of which is optionally substituted with halo, hydroxy, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, or ureido; or R 4 , R 5 , or R 6 combines with R7 to form a [-O-CH2-] covalent bridge between the 2' and 4' carbons of the sugar; x is 5 to 100, or selected to fit the length of an RNA agent described herein; R 70 is H; or R 40 , R 50 , or R 60combine together to form a [-O-CH2-] covalent bridge between the 2' and 4' carbons of the sugar; R 8 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, amino acid, or sugar; R 9 is NH2, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or an amino acid; m is 0 to 1,000,000; n is 0 to 20; g is 0 to 2.
[0246] A particular nucleoside surrogate has the following structure (Formula X): [ka] During the ceremony, S is a nucleoside surrogate selected from the group consisting of mophilino, cyclobutyl, pyrrolidine, and peptide nucleic acid; L is a linker and CH2(CH2) g ;N(CH2) g ;O(CH2) g ;S(CH2) g ;-C(O)(CH2) n - may be selected from the group consisting of or absent; M may be an amide bond; a sulfonamide; a sulfinate; a phosphate group; a modified phosphate group as described herein, or may be absent; R 100 , R 200 , and R 300are, independently for each occurrence, H (i.e., abasic nucleotides), adenine, guanine, cytosine, and uracil, inosine, thymine, xanthine, hypoxanthine, nubularine, tubercidin, isoguanisine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and 5-halocytosine, 5-propynyluracil and 5-propynylcytosine, 6 -azouracil, 6-azocytosine, and 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5-(2-aminopropyl)uracil, 5-aminoallyluracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted adenines and 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, and other 8-substituted guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosine, 7-methylguanine, 5-substituted pyrimidines, 6-azapyrimidines, and N-2-, N-6-, and O-6-substituted purines (including 2-aminopropyladenine), 5-propynyluracil and 5-propynylcytosine, dihydrouracil, 3-deaza-5-azacytosine, 2-aminopurine, 5-alkyluracil, 7-alkylguanine, 5-alkylcytosine, 7-deazaadenine, N6,N6-dimethyladenine, 2,6-diaminopurine, 5-amino-allyl-uracil, N3-methyluracil, substituted 1,2,4-triazoles, 2-pyridinone, 5-nitroindole, 3-nitropyrrole, 5-methoxyuracil, uracil-5-oxyacetic acid, 5-methoxycarbonylmethyluracil, 5-methyl-2-thiouracil, 5-methoxycarbonylmethyl-2-thiouracil, 5-methylaminomethyl-2-thiouracil, 3-(3-amino-3-carboxypropyl)uracil, 3-methylcytosine, 5-methylcytosine, N 4 -acetylcytosine, 2-thiocytosine, N6-methyladenine, N6-isopentyladenine, 2-methylthio-N6-isopentenyladenine, N-methylguanine, or an O-alkylated base; x is 5 to 100, or selected to fit the length of an RNA agent described herein; g is 0 to 2.
[0247] definition The term "halo" refers to any radical of fluorine, chlorine, bromine, or iodine. The term "alkyl" refers to saturated and unsaturated non-aromatic hydrocarbon chains, which may be straight or branched, containing the specified number of carbon atoms and which may optionally be interrupted by N, O, or S, including, but not limited to, propyl, allyl, or propargyl. For example, C1-C 10 means that the group may have 1 to 10 (inclusive) carbon atoms in it. The term "alkoxy" refers to an -O-alkyl group. The term "alkylene" refers to a divalent alkyl (i.e., -R-). The term "alkylenedioxo" refers to a divalent species of the structure -ORO- (where R represents alkylene). The term "aminoalkyl" refers to an alkyl substituted with an amino. The term "mercapto" refers to an -SH group. The term "thioalkoxy" refers to an -S-alkyl group.
[0248] The term "aryl group" refers to a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system in which 0, 1, 2, 3, or 4 atoms of each ring can be replaced by substituents. Examples of aryl groups include phenyl, naphthyl, and the like. The term "arylalkyl" or "aralkyl" refers to an alkyl substituted with an aryl. The term "arylalkoxy" refers to an alkoxy substituted with an aryl.
[0249] The term "cycloalkyl" as used herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, e.g., 3 to 8 carbons, and e.g., 3 to 6 carbons, and the cycloalkyl groups may further be optionally substituted. Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
[0250] The term "heteroaryl" refers to a 5- to 8-membered aromatic monocyclic ring system, an 8- to 12-membered aromatic bicyclic ring system, or an 11- to 14-membered aromatic tricyclic ring system having 1 to 3 heteroatoms in the monocyclic ring, 1 to 6 heteroatoms in the bicyclic ring, or 1 to 9 heteroatoms in the tricyclic ring, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1 to 3, 1 to 6, or 1 to 9 N, O, or S heteroatoms in the monocyclic, bicyclic, or tricyclic ring, respectively), wherein 0, 1, 2, 3, or 4 atoms in each ring may be optionally substituted. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like. The term "heteroarylalkyl" or "heteroaralkyl" refers to an alkyl substituted with a heteroaryl. The term "heteroarylalkoxy" refers to an alkoxy substituted with a heteroaryl.
[0251] The term "heterocyclyl" refers to a 5- to 8-membered non-aromatic monocyclic ring system, an 8- to 12-membered non-aromatic bicyclic ring system, or an 11- to 14-membered non-aromatic tricyclic ring system having 1 to 3 heteroatoms in the monocyclic ring, 1 to 6 heteroatoms in the bicyclic ring, or 1 to 9 heteroatoms in the tricyclic ring, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1 to 3, 1 to 6, or 1 to 9 N, O, or S heteroatoms in the monocyclic, bicyclic, or tricyclic ring, respectively), in which 0, 1, 2, or 3 atoms in each ring are optionally substituted. Examples of heterocyclyl groups include trizolyl, tetrazolyl, piperazinyl, pyrrolidinyl, dioxanyl, morpholyl, tetrahydrofuranyl, and the like.
[0252] The term "oxo" refers to an oxygen atom which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur.
[0253] The term "acyl" refers to an alkylcarbonyl, cycloalkoxycarbonyl, arylcarbonyl, heterocyclylcarbonyl, or heteroarylcarbonyl substituent, any of which may be further substituted by substituents.
[0254] The term "substituted" refers to the replacement of one or more hydrogen radicals in a given structure with a specified substituent group, including, but not limited to, halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic. It is understood that the substituent group can be further substituted.
[0255] Palindrome An iRNA agent of the invention can target two or more RNA regions. For example, an iRNA agent can include a first sequence and a second sequence that are sufficiently complementary to each other to hybridize. The first sequence can be complementary to a first target RNA region, and the second sequence can be complementary to a second target RNA region. The first and second sequences of an iRNA agent can be on different RNA strands, and the mismatch between the first and second sequences can be less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1%. The first and second sequences of an iRNA agent can be on the same RNA strand, and in related embodiments, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, or more than 1% of the iRNA agent can be in bimolecular form. The first and second sequences of an iRNA agent can be fully complementary to each other.
[0256] The first target RNA region can be encoded by a first gene and the second target RNA region can be encoded by a second gene, or the first target RNA region and the second target RNA region can be different regions of RNA derived from a single gene. The first sequence and the second sequence can differ by at least one nucleotide.
[0257] The first and second target RNA regions can be on transcripts encoded by first and second sequence variants (e.g., first and second alleles) of a gene. The sequence variants can be, for example, mutations or polymorphisms. The first target RNA region can include nucleotide substitutions, insertions, or deletions compared to the second target RNA region, or the second target RNA region can be a mutant or variant of the first target region.
[0258] The first and second target RNA regions can include viral or human RNA regions. The first and second target RNA regions can be located on mutated oncogene transcripts or can contain different mutations in tumor suppressor gene transcripts. Furthermore, the first and second target RNA regions can correspond to genetic mutation hotspots.
[0259] The compositions of the invention can include a mixture of iRNA agent molecules. For example, an iRNA agent can contain a first sequence and a second sequence that are sufficiently complementary to each other to hybridize, and further, the first sequence can be complementary to a first target RNA region, and the second sequence can be complementary to a second target RNA region. The mixture can also include at least one additional iRNA agent species that includes a third sequence and a fourth sequence that are sufficiently complementary to each other to hybridize, where the third sequence can be complementary to a third target RNA region, and the fourth sequence can be complementary to a fourth target RNA region. Furthermore, the first sequence or the second sequence can be sufficiently complementary to the third sequence or the fourth sequence to hybridize to each other. The first sequence and the second sequence can be on the same or different RNA strands, and the third sequence and the fourth sequence can be on the same or different RNA strands.
[0260] The target RNA regions can be mutant sequences of viral or human RNA, and in certain embodiments, at least two target RNA regions can be mutant transcripts of oncogenes or tumor suppressor genes. The target RNA regions can correspond to hotspots of genetic mutations.
[0261] Methods of making iRNA agent compositions can include obtaining or providing information about a region of the RNA of a target gene (e.g., a viral or human gene, or an oncogene or tumor suppressor gene, e.g., p53) that has a high variability or mutation frequency (e.g., in humans). It can further include obtaining or providing information about multiple RNA targets within that region, where each RNA target corresponds to a different variant or mutant of the gene (e.g., a region containing codons encoding p53 248Q and / or p53 249S). An iRNA agent can be constructed such that a first sequence is complementary to a first target of the multiple variant RNA targets (e.g., encoding 249Q), a second sequence is complementary to a second target of the multiple variant RNA targets (e.g., encoding 249S), and the first and second sequences can be sufficiently complementary to hybridize.
[0262] For example, to identify common mutations in a target gene, sequence analysis can be used to identify regions of the target gene that have a high degree of variability or mutation frequency. Regions of the target gene that have a high degree of variability or mutation frequency can be identified by obtaining or providing genotype information about the target gene from a population.
[0263] By providing an iRNA agent having a first sequence and a second sequence that are sufficiently complementary to hybridize with each other, expression of a target gene can be modulated (e.g., down-regulated or silenced). Furthermore, the first sequence can be complementary to a first target RNA region, and the second sequence can be complementary to a second target RNA region.
[0264] The iRNA agent can include a first sequence complementary to a first variant RNA target region and a second sequence complementary to a second variant RNA target region. The first and second variant RNA target regions can correspond to first and second variants or first and second mutants of a target gene (e.g., a viral gene, a tumor suppressor gene, or an oncogene). The first and second variant RNA target regions can include allelic variants, mutations (e.g., point mutations), or polymorphisms of the target gene. The first and second variant RNA target regions can correspond to genetic hotspots.
[0265] A plurality of iRNA agents (eg, a panel or bank) can be provided.
[0266] Other embodiments In another embodiment, the iRNA agent is produced in a cell in vivo, e.g., from an exogenous DNA template delivered to the cell. For example, the DNA template can be inserted into a vector and used as a gene therapy vector. The gene therapy vector can be delivered to a subject, e.g., by intravenous injection, local administration (U.S. Pat. No. 5,328,470), or stereotactic injection (see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). Pharmaceutical preparations of gene therapy vectors can include the gene therapy vector in an acceptable diluent, or can include a slow-release matrix in which the gene delivery vehicle is embedded. For example, the DNA template can include two transcription units: one that produces a transcript containing the upper strand of the iRNA agent, and one that produces a transcript containing the lower strand of the iRNA agent. When the template is transcribed, the iRNA agent is produced and processed into an siRNA agent fragment that mediates gene silencing.
[0267] Antagomir Antagomirs are RNA-like oligonucleotides with various modifications for protection from RNase and pharmacological properties (for example, enhanced uptake into tissues and cells).Antagomirs differ from ordinary RNA, for example, by complete 2'-methylation of sugars, phosphorothioate backbone, and, for example, cholesterol moiety at the 3'-end.Antagomirs can be used to efficiently silence endogenous miRNA, thereby preventing miRNA-induced gene silencing.An example of antagomir-mediated miRNA silencing is the silencing of miR-122 described in Krutzfeldt et al., Nature, 2005, 438:685-689 (which is expressly incorporated herein by reference in its entirety).
[0268] Decoy oligonucleotides Because transcription factors can recognize their relatively short binding sequences even in the absence of surrounding genomic DNA, short oligonucleotides bearing the consensus binding sequence of a specific transcription factor can be used as tools to manipulate gene expression in living cells. In this strategy, such "decoy oligonucleotides" are delivered into cells and then recognized and bound by the target factor. Once the decoy occupies the DNA binding site of the transcription factor, the transcription factor is unable to subsequently bind to the promoter region of the target gene. Decoys can be used as therapeutic agents to inhibit the expression of genes activated by the transcription factor or to upregulate genes repressed by transcription factor binding. An example of the use of decoy oligonucleotides can be found in Mann et al., J. Clin. Invest., 2000, 106:1071-1075, which is expressly incorporated herein by reference in its entirety.
[0269] antisense oligonucleotides Antisense oligonucleotides are single-stranded DNA or RNA that are at least partially complementary to a selected sequence. In the case of antisense RNA, they bind to complementary RNA strands, thereby preventing the translation of the complementary RNA strand. Antisense DNA can also be used to target specific, complementary (coding or non-coding) RNA. When binding occurs, this DNA / RNA hybrid can be degraded by the enzyme RNase H. An example of the use of antisense oligonucleotides can be found in Dias et al., Mol. Cancer Ther., 2002, 1:347-355, which is expressly incorporated herein by reference in its entirety.
[0270] Aptamers Aptamers are nucleic acid molecules that bind to specific target molecules (single or multiple). Aptamers can be RNA-based or DNA-based, and can contain riboswitches. Riboswitches are parts of mRNA that can directly bind to small target molecules and affect gene activity by binding to the target. Therefore, mRNAs containing riboswitches are directly involved in regulating their own activity depending on the presence or absence of their target molecules.
[0271] Physiological effects The iRNA agents described herein can be designed so that determining therapeutic toxicity is made easier by complementarity of the iRNA agent with both human and non-human animal sequences. By these methods, the iRNA agent can be designed to complement human-derived nucleic acid sequences. andThe iRNA agent can consist of a sequence that is fully complementary to a nucleic acid sequence from at least one non-human animal, e.g., a non-human mammal (e.g., a rodent, ruminant, or primate). For example, the non-human mammal can be a mouse, rat, dog, pig, goat, sheep, cow, monkey, pygmy chimpanzee (Pan paniscus), common chimpanzee (Pan troglodytes), rhesus monkey (Macaca mulatto), or cynomolgus monkey (Cynomolgus monkey). The sequence of the iRNA agent can be complementary to a sequence within a homologous gene (e.g., an oncogene or tumor suppressor gene) in a non-human mammal and a human. By determining the toxicity of the iRNA agent in a non-human mammal, the toxicity of the iRNA agent in a human can be estimated. For more rigorous toxicity testing, the iRNA agent can be complementary to a human and two or more (e.g., two, three, or more) non-human animals.
[0272] The methods described herein can be used to correlate any physiological effect of an iRNA agent on a human, e.g., any undesirable effect (e.g., a toxic effect), or any beneficial or desired effect.
[0273] Increased cellular uptake of ds iRNA The methods of the invention include administering an iRNA agent and a drug that affects the uptake of the iRNA agent into a cell. The drug can be administered before, after, or simultaneously with the iRNA agent. The drug can be covalently attached to the iRNA agent. The drug can be, for example, lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-κB. The drug can have a transient effect on the cell.
[0274] The drug can increase intracellular uptake of the iRNA agent, for example, by disrupting the cytoskeleton of the cell (e.g., by disrupting the cell's microtubules, microfilaments, and / or intermediate filaments). The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.
[0275] Drugs can also increase the cellular uptake of iRNA agents, for example, by activating an inflammatory response. Exemplary drugs that may have such an effect include tumor necrosis factor alpha (TNFα), interleukin-1β, or gamma interferon.
[0276] iRNA conjugates An iRNA agent can be conjugated (e.g., covalently linked) to a second agent. For example, an iRNA agent used to treat a particular disorder can be conjugated to a second therapeutic agent (e.g., an agent other than the iRNA agent). The second therapeutic agent can be a therapeutic agent for treating the same disorder. For example, in the case of an iRNA used to treat a disorder characterized by unwanted cell proliferation (e.g., cancer), the iRNA agent can be conjugated to a second agent with anti-cancer activity. For example, the iRNA agent can be conjugated to an agent that stimulates the immune system (e.g., a CpG motif), or more generally, to an agent that activates toll-like receptors and / or increases the production of gamma interferon.
[0277] iRNA production iRNAs can be produced in large quantities by a variety of methods, including organic synthesis and RNA cleavage (e.g., in vitro cleavage).
[0278] organic synthesis iRNA can be made by separately synthesizing each respective strand of a double-stranded RNA molecule, after which the component strands can be annealed.
[0279] Large bioreactors (e.g., OligoPilot II from Pharmacia Biotec AB, Uppsala, Sweden) can be used to produce large quantities of specific RNA strands for a given iRNA. The OligoPilot II reactor can efficiently attach nucleotides using only a 1.5 molar excess of phosphoramidite nucleotides. Ribonucleotide amidites are used to create the RNA strands. Standard monomer addition cycles can be used to synthesize 21- to 23-nucleotide strands for iRNAs. Typically, the two complementary strands are produced separately and then annealed, for example, after release from the solid support and deprotection.
[0280] Organic synthesis can be used to produce distinct iRNA species. The complementarity of an iRNA species to a specific target gene can be precisely specified. For example, an iRNA species can be complementary to a region containing a polymorphism (e.g., a single nucleotide polymorphism). Furthermore, the location of the polymorphism can be precisely defined. In some embodiments, the polymorphism is in an internal region, for example, at least 4, 5, 7, or 9 nucleotides from one or both termini.
[0281] ds iRNA cleavage iRNAs can also be generated by cleaving larger ds iRNAs. Cleavage can be mediated in vitro or in vivo. For example, the following method can be used to generate iRNAs by in vitro cleavage.
[0282] In vitro transcription. ds iRNA is produced by transcribing a nucleic acid (DNA) segment in both directions. For example, the HiScribe™ RNAi Transcription Kit (New England Biolabs) provides a vector and a method for producing ds iRNA for a nucleic acid segment cloned into this vector flanked by T7 promoters. Separate templates are generated for T7 transcription of the two complementary strands for the ds iRNA. These templates are transcribed in vitro by adding T7 RNA polymerase to produce the ds iRNA. Similar methods using PCR and / or other RNA polymerases (e.g., T3 polymerase or SP6 polymerase) can also be used. In one embodiment, the RNA produced by this method is carefully purified to remove endotoxins that may contaminate recombinant enzyme preparations.
[0283] In vitro cleavage. For example, ds iRNA can be cleaved in vitro to iRNA using Dicer or comparable RNase III-based activity.For example, ds iRNA can be incubated in an in vitro extract from Drosophila or with purified components (for example, purified RNase or RISC complex (RNA-induced silencing complex)).For example, see Ketting et al. Genes Dev 2001 Oct 15;15(20):2654-9: and Hammond Science 2001 Aug 10;293(5532):1146-50. Cleavage of a ds iRNA typically produces multiple iRNA species, each of which is a specific 21-23 nt fragment of the original ds iRNA molecule. For example, there may be iRNAs that contain sequences complementary to overlapping and flanking regions of the original ds iRNA molecule.
[0284] Regardless of the synthesis method, the iRNA preparation can be prepared in a solution (e.g., aqueous and / or organic solution) suitable for formulation. For example, the iRNA preparation can be precipitated and redissolved in pure double-distilled water, and then lyophilized. The dried iRNA can then be resuspended in a solution suitable for the intended formulation process.
[0285] Formulation The iRNA agents described herein can be formulated for administration to a subject.
[0286] For ease of exposition, the formulations, compositions, and methods in this section are discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these formulations, compositions, and methods can be practiced with other iRNA agents, e.g., modified iRNA agents, and such practice is within the scope of the invention.
[0287] Formulated iRNA compositions can be in a variety of states. In some instances, the composition is at least partially crystalline, uniformly crystalline, and / or anhydrous (e.g., less than 80%, less than 50%, less than 30%, less than 20%, or less than 10% water). In other instances, the iRNA is in an aqueous phase, e.g., in a solution that includes water.
[0288] Aqueous phase compositions or crystalline compositions can be incorporated into, for example, a delivery vehicle, such as a liposome (particularly for aqueous phase) or a particle (e.g., a microparticle, as may be appropriate for crystalline compositions). Typically, iRNA compositions are formulated in a manner compatible with the intended method of administration (see below).
[0289] In certain embodiments, the composition is prepared by at least one of the following methods: spray drying, freeze drying, vacuum drying, evaporation, fluidized bed drying, or a combination of these techniques, or sonication with lipids, freeze drying, condensation, and other self-assembly.
[0290] The iRNA preparation can be formulated in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes the iRNA (e.g., a protein that complexes with the iRNA to form an iRNP). Additional agents include chelating agents, e.g., EDTA (e.g., Mg 2+ (for removing divalent cations such as ), salts, RNase inhibitors (e.g., broad specificity RNase inhibitors such as RNAsin), etc.
[0291] In one embodiment, the iRNA preparation includes another iRNA agent, e.g., a second iRNA that can mediate RNAi for a second gene or for the same gene. Still other preparations can include at least 3, 5, 10, 20, 50, or 100 or more different iRNA species. Such iRNAs can mediate RNAi for a similar number of different genes.
[0292] In one embodiment, the iRNA preparation includes at least a second therapeutic agent (e.g., an agent other than RNA or DNA). For example, an iRNA composition for treating a viral disease (e.g., HIV) may include a known antiviral agent (e.g., a protease inhibitor or reverse transcriptase inhibitor). In another example, an iRNA composition for treating cancer may further include a chemotherapeutic agent.
[0293] Exemplary formulations are discussed below.
[0294] Liposomes For ease of exposition, the formulations, compositions, and methods in this section are discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these formulations, compositions, and methods can be practiced with other iRNA agents, e.g., modified iRNA agents, and such practice is within the scope of the present invention. Preparations of iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNA encoding iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof), can be formulated for delivery in membranous molecular assemblies (e.g., liposomes or micelles). As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer (e.g., one bilayer or multiple bilayers). Liposomes include unilamellar and multilamellar vesicles, which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the iRNA composition. The lipophilic material separates the aqueous interior from the aqueous exterior and typically does not contain an iRNA composition, although in some instances it may. Liposomes are useful for transporting and delivering active ingredients to the site of action. Because the liposome membrane is structurally similar to a biological membrane, when the liposome is applied to a tissue, the liposome bilayer fuses with the cell membrane bilayer. As the liposome and cell fusion proceeds, the aqueous contents of the interior, including the iRNA, are delivered into the cell, where the iRNA can specifically bind to the target RNA and mediate RNAi. In some cases, liposomes can also be specifically targeted, for example, to direct the iRNA to a specific cell type.
[0295] Liposomes containing iRNA can be prepared by a variety of methods.
[0296] In one example, the lipid components of the liposome are dissolved in a detergent to form micelles with the lipid components. For example, the lipid components can be amphipathic cationic lipids or lipid conjugates. The detergent can have a high critical micelle concentration and can be non-ionic. Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The iRNA preparation is then added to the micelles containing the lipid components. The cationic groups on the lipids interact with the iRNA and condense around the iRNA to form liposomes. After condensation, the detergent is removed, for example, by dialysis, to obtain a liposome preparation of the iRNA.
[0297] If necessary, a carrier compound that promotes condensation can be added during the condensation reaction, for example, by controlled addition. For example, the carrier compound can be a polymer other than nucleic acid (e.g., spermine or spermidine). The pH can also be adjusted to favor condensation.
[0298] Further description of methods for producing stable polynucleotide delivery vehicles that incorporate polynucleotide / cationic lipid complexes as a structural component of the delivery vehicle is provided, for example, in WO 96 / 37194. Liposome formation can also include one or more embodiments of the exemplary methods described in Felgner, PL et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987; U.S. Pat. No. 4,897,355; U.S. Pat. No. 5,171,678; Bangham et al. M. Mol. Biol. 23:238, 1965; Olson et al. Biochim. Biophys. Acta 557:9, 1979; Szoka et al. Proc. Natl. Acad. Sci. 75:4194, 1978; Mayhew et al. Biochim. Biophys. Acta 775:169, 1984; Kim et al. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga et al. Endocrinol. 115:757, 1984. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw extrusion (see, e.g., Mayer et al., Biochim. Biophys. Acta 858:161, 1986). Microfluidization can be used when consistently small (50-200 nm) and relatively uniform aggregates are desired (Mayhew et al., Biochim. Biophys. Acta 775:169, 1984). These methods are easily adapted to package iRNA preparations into liposomes.
[0299] Liposomes that are pH-sensitive or negatively charged entrap nucleic acid molecules rather than complexing with them. Because both the nucleic acid molecule and the lipid are similarly charged, repulsion occurs rather than complexation. Nevertheless, some nucleic acid molecules are trapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the foreign gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 19, (1992) 269-274).
[0300] One major type of liposome composition includes phospholipids other than naturally occurring phosphatidylcholine. For example, neutral liposome compositions can be formed from dimyristoylphosphatidylcholine (DMPC) or dipalmitoylphosphatidylcholine (DPPC). Anionic liposome compositions are usually formed from dimyristoylphosphatidylglycerol, while anionic fusogenic liposomes are primarily formed from dioleoylphosphatidylethanolamine (DOPE). Another type of liposome composition is formed from phosphatidylcholine (PC), such as soybean PC and egg PC. Another type is formed from a mixture of phospholipids and / or phosphatidylcholine and / or cholesterol.
[0301] Other exemplary methods for introducing liposomes into cells in vitro and in vivo include U.S. Pat. No. 5,283,185; U.S. Pat. No. 5,171,678; WO 94 / 00569; WO 93 / 24640; WO 91 / 16024; Felgner, J. Biol. Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci. 90:11307, 1993; Nabel, Human Gene Ther. 3:649, 1992; Gershon, Biochem. 32:7143, 1993; and Strauss EMBO J. 11:417, 1992.
[0302] In one embodiment, cationic liposomes are used.Cationic liposomes have the advantage of being able to fuse with the cell membrane.Non-cationic liposomes cannot fuse with the plasma membrane efficiently, but can be taken up by macrophages in vivo and can be used to deliver iRNA to macrophages.
[0303] Additional advantages of liposomes include the fact that liposomes derived from natural phospholipids are biocompatible and biodegradable, liposomes can incorporate a wide range of water- and lipid-soluble drugs, and liposomes protect iRNAs encapsulated in the internal liposome compartment from metabolism and degradation (Rosoff, "Pharmaceutical Dosage Forms," Lieberman, Rieger, and Banker (eds.), 1988, Vol. 1, p. 245). Important considerations in preparing liposome formulations are the lipid surface charge, vesicle size, and aqueous volume of the liposomes.
[0304] The positively charged synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), can be used to form small liposomes that spontaneously interact with nucleic acids and fuse with the negatively charged lipids in the plasma membrane of tissue culture cells, thereby forming lipid-nucleic acid complexes that can result in delivery of iRNA (see, e.g., Felgner, PL et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987 and U.S. Pat. No. 4,897,355 for a description of DOTMA and its use with DNA).
[0305] The DOTMA analogue 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with phospholipids to form vesicles that complex with DNA. Lipofectin™ (Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for delivering highly anionic nucleic acids into living tissue culture cells, including positively charged DOTMA liposomes that spontaneously interact with negatively charged polynucleotides to form complexes. When sufficiently positively charged liposomes are used, the net charge on the resulting complex is also positive. The positively charged complexes thus prepared spontaneously bind to negatively charged cell surfaces and fuse with the plasma membrane, effectively delivering functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane ("DOTAP") (Boehringer Mannheim, Indianapolis, Indiana), differs from DOTMA in that the oleoyl moiety is attached by an ester rather than an ether bond.
[0306] Other reported cationic lipid compounds include, for example, those conjugated to one of two types of lipids and conjugated to various moieties including carboxyspermine, including compounds such as 5-carboxyspermylglycine dioctaoleoylamide ("DOGS") (Transfectam™, Promega, Madison, Wisconsin) and dipalmitoylphosphatidylethanolamine 5-carboxyspermylamide ("DPPES") (see, e.g., U.S. Pat. No. 5,171,678).
[0307] Another cationic lipid conjugate is a lipid derivatized with cholesterol ("DC-Chol") formulated in liposomes in combination with DOPE (see Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991). Lipopolylysine, prepared by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou et al., Biochim. Biophys. Acta 1065:8, 1991). For certain cell lines, these liposomes containing conjugated cationic lipids are said to exhibit lower toxicity and provide more efficient transfection than DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, California) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Maryland). Other cationic lipids suitable for delivery of oligonucleotides are described in WO 98 / 39359 and WO 96 / 37194.
[0308] Liposome formulations are particularly suitable for topical administration, and liposomes offer several advantages over other formulations. Such advantages include reduced side effects associated with high systemic absorption of administered drugs, increased accumulation of administered drugs in desired targets, and the ability to administer iRNA to the skin. In some implementations, liposomes are also used to deliver iRNA to epithelial cells and enhance the penetration of iRNA into dermal tissues (e.g., skin). For example, liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been demonstrated (e.g., Weiner et al., Journal of Drug Targeting, 1992, Vol. 2, 405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, RJ and Fould-Fogerite, S., Biotechniques 6:682-690, 1988; Itani, T. et al., Gene 56:267-276, 1987; Nicolau, C. et al., Meth. Enz. 149:157-176, 1987; Straubinger, RM and Papahadjopoulos, D., Meth. Enz. 101:512-527, 1983; Wang, C.Y. and Huang, L., Proc. Natl. Acad. Sci. USA 84:7851-7855, 1987).
[0309] Nonionic liposome systems, particularly those containing nonionic surfactants and cholesterol, have also been investigated to determine their usefulness in delivering drugs to the skin. Nonionic liposome formulations containing Novasome® I (glyceryl dilaurate / cholesterol / polyoxyethylene-10-stearyl ether) and Novasome® II (glyceryl distearate / cholesterol / polyoxyethylene-10-stearyl ether) have been used to deliver drugs to the dermis of mouse skin. Such formulations containing iRNA are useful for treating skin disorders.
[0310] Liposomes containing iRNA can be highly deformable. Such deformability can allow liposomes to penetrate through pores smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposome. Transfersomes can be prepared by adding a surface edge activator (usually a surfactant) to a standard liposome composition. Transfersomes containing iRNA can be delivered by subcutaneous injection to deliver iRNA to keratinocytes in the skin, for example. To cross intact mammalian skin, lipid vesicles must pass through a series of micropores, each less than 50 nm in diameter, under the influence of a suitable transdermal gradient. Furthermore, due to the properties of lipids, these transfersomes can be self-optimizing (e.g., adapting to the shape of the pores within the skin), self-repairing, and often self-reloading, reaching their target without fragmentation.
[0311] surfactant For ease of exposition, the formulations, compositions, and methods in this section will be discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these formulations, compositions, and methods can be implemented with other iRNA agents, e.g., modified iRNA agents, and such implementations are within the scope of the present invention. Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes (see above). Compositions of iRNA (or precursors, e.g., larger ds iRNAs that can be processed into iRNAs, or DNA encoding iRNAs or precursors) can include surfactants. In one embodiment, iRNAs are formulated as emulsions containing surfactants. The most common way to classify and rank the properties of the many different types of surfactants (both natural and synthetic) is by using the hydrophilic / lipophilic balance (HLB). The nature of the hydrophilic group provides the most useful means for categorizing different surfactants used in formulations (Rieger, "Pharmaceutical Dosage Forms", Marcel Dekker, Inc., New York, NY, 1988, p. 285).
[0312] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical products and are usable over a wide range of pH values. Generally, their HLB values range from 2 to approximately 18, depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers (e.g., fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated / propoxylated block polymers) also fall into this category. Polyoxyethylene surfactants are the most common of the nonionic surfactants.
[0313] If a surfactant molecule has a negative charge when dissolved or dispersed in water, it is classified as anionic. Anionic surfactants include carboxylates (e.g., soaps), acyl lactylates, acyl amides of amino acids, esters of sulfuric acid (e.g., alkyl sulfates and ethoxylated alkyl sulfates), sulfonates (e.g., alkyl benzene sulfonates), acyl isethionates, acyltaurates, and sulfosuccinates, as well as phosphates. The most important anionic surfactants are alkyl sulfates and soaps.
[0314] If a surfactant molecule carries a positive charge when dissolved or dispersed in water, it is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. Quaternary ammonium salts are the most commonly used of this class.
[0315] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines, and phosphatides.
[0316] The use of surfactants in drug products, formulations, and emulsions has been reviewed (Rieger, "Pharmaceutical Dosage Forms," Marcel Dekker, Inc., New York, NY, 1988, p. 285).
[0317] Micelles and other membrane-like formulations For ease of exposition, micelles and other formulations, compositions, and methods in this section are discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these micelles and other formulations, compositions, and methods can be practiced with other iRNA agents, e.g., modified iRNA agents, and such practice is within the scope of the present invention. Compositions of iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNA encoding iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof), can be provided as micellar formulations. A "micelle" is defined herein as a specific type of molecular assembly in which amphiphilic molecules are arranged in a spherical structure so that all of the hydrophobic portions of the amphiphilic molecules face inward and the hydrophilic portions are in contact with the surrounding aqueous phase. The opposite arrangement exists when the environment is hydrophobic.
[0318] Mixed micelle formulations suitable for transdermal delivery contain an aqueous solution of the iRNA composition and an alkali metal C8-C 22 It can be prepared by mixing alkyl sulfate with a micelle-forming compound.Exemplary micelle-forming compounds include lecithin, hyaluronic acid, hyaluronic acid pharmaceutically acceptable salts, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleate, monolaurate, borage oil, evening primrose oil, menthol, trihydroxyoxocholanylglycine and its pharmaceutically acceptable salts, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ether and its analogs, polidocanol alkyl ether and its analogs, chenodeoxycholate, deoxycholate, and mixtures thereof.The micelle-forming compound can be added simultaneously with or after the addition of alkali metal alkyl sulfate.Mixed micelles can be formed by mixing virtually any type of components, but to provide smaller micelles, they can be formed by vigorous mixing.
[0319] In one method, a first micelle composition containing an iRNA composition and at least an alkali metal alkyl sulfate is prepared. This first micelle composition is then mixed with at least three micelle-forming compounds to form a mixed micelle composition. In another method, the mixed micelle composition is prepared by mixing the iRNA composition, the alkali metal alkyl sulfate, and at least one micelle-forming compound, and then adding the remaining micelle-forming compounds while vigorously mixing.
[0320] Phenol and / or m-cresol may be added to the mixed micelle composition to stabilize the formulation and protect against bacterial growth. Alternatively, phenol and / or m-cresol may be added together with the micelle-forming components. An isotonicity agent, such as glycerin, may also be added after the mixed micelle composition is formed. To deliver the micelle formulation as a spray, the formulation can be placed in an aerosol dispenser, which is then filled with a propellant. The propellant, under pressure, is in liquid form in the dispenser. The ratio of components is adjusted so that there is one aqueous phase and one propellant phase, i.e., one phase. If two phases are present, the dispenser must be shaken before dispensing a portion of the contents through the metered valve, for example. The medicinal dose is expelled from the metered valve as a fine spray.
[0321] Propellants can include hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether, and diethyl ether. In some embodiments, HFA 134a (1,1,1,2-tetrafluoroethane) can be used.
[0322] The specific concentrations of the essential components can be determined by relatively straightforward experimentation. For oral absorption, it is often desirable to increase the dosage, e.g., at least two or three times, the dosage for administration by injection or via the digestive tract.
[0323] particle For ease of exposition, the particles, formulations, compositions, and methods in this section are primarily discussed with respect to unmodified iRNA agents. However, it will be understood that these particles, formulations, compositions, and methods can be implemented with other iRNA agents, e.g., modified iRNA agents, and such implementations are within the scope of the present invention. In another embodiment, preparations of iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNA encoding iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof) can be incorporated into particles (e.g., microparticles). Microparticles can be produced by spray drying, but may also be produced by other methods, including lyophilization, evaporation, fluidized-bed drying, vacuum drying, or a combination of these techniques. For further explanation, see below.
[0324] Sustained-release formulations. The iRNA agents described herein, e.g., double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNAs that encode iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof), can be formulated for controlled release (e.g., sustained release). Controlled release can be achieved by placing the iRNA within a structure or material that slows its release. For example, the iRNA can be placed within a porous matrix or an erodible matrix, either of which allows for release of the iRNA over an extended period of time.
[0325] Polymer particles (e.g., polymer microparticles) can be used as a sustained-release reservoir of iRNA, which is taken up by cells only upon release from the microparticles by biodegradation. Therefore, the polymer particles in this embodiment should be large enough to prevent phagocytosis (e.g., larger than 10 μm or larger than 20 μm). Such particles can be produced by the same methods used to make smaller particles, but with less vigorous mixing of the first and second emulsions. That is, lower homogenization speeds, vortex mixing speeds, or sonication settings can be used to obtain particles approximately 100 μm in diameter rather than 10 μm. Mixing times can also be varied.
[0326] Larger microparticles can be formulated as suspensions, powders, or implantable solids, so that they can be delivered by intramuscular, subcutaneous, intradermal, intravenous, or intraperitoneal injection, by inhalation (intranasal or pulmonary), orally, or by implantation.These particles are useful for the delivery of any iRNA when a relatively long-term sustained release is desired.The degradation rate, and therefore the release rate, varies depending on the polymer formulation.
[0327] Microparticles may contain pores, voids, depressions, defects, or other interstitial spaces that allow the liquid suspension medium to freely penetrate or perfuse the microparticle boundaries. For example, porous spray-dried microspheres with holes can be formed.
[0328] Polymer particles containing iRNA (e.g., siRNA) can be produced, for example, using a double emulsion technique. First, the polymer is dissolved in an organic solvent. The polymer can be lactic acid / glycolic acid copolymer (PLGA) with a lactic acid / glycolic acid weight ratio of 65:35, 50:50, or 75:25. A sample of nucleic acid suspended in aqueous solution is then added to the polymer solution, and the two solutions are mixed to form a first emulsion. The solutions can be mixed by vortexing or shaking, and the mixture can be sonicated. Any method that minimizes damage to the nucleic acid in the form of nicking, shearing, or degradation while still allowing for the formation of a suitable emulsion is acceptable. For example, acceptable results can be obtained with a Vibra-cell model VC-250 sonicator equipped with a 1 / 8-inch microtip probe at setting #3.
[0329] spray drying An iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) can be prepared by spray drying. The spray-dried iRNA can be administered to a subject or subjected to further formulation. A pharmaceutical composition of an iRNA can be prepared by spray-drying a homogenous aqueous mixture containing the iRNA under conditions sufficient to provide a dispersible powdered composition (e.g., a pharmaceutical composition). The material for spray drying can also include one or more pharmaceutically acceptable excipients or a dispersibility-enhancing amount of a physiologically acceptable water-soluble protein. The spray-dried product can be a dispersible powder containing the iRNA.
[0330] Spray drying is a process that converts liquid or slurry materials into dry, particulate form.Spray drying can be used to provide powder materials for various routes of administration, including inhalation.See, for example, M. Sacchetti and M. M. Van Oort: Inhalation Aerosols: Physical and Biological Basis for Therapy, edited by A. J. Hickey, Marcel Dekkar, New York, 1996.
[0331] Spray drying can involve atomizing a solution, emulsion, or suspension to form a fine mist of droplets and drying the droplets. The mist can be projected into a drying chamber (e.g., a container, tank, tube, or coil) where it is contacted with a drying gas. The mist can include a solid or liquid pore-forming agent. The solvent and pore-forming agent evaporate from the droplets into the drying gas, solidifying the droplets and simultaneously forming pores throughout the solid. The solid (typically in the form of a powdery particle) is then separated from the drying gas and recovered.
[0332] Spray drying involves combining a highly dispersed liquid and a sufficient volume of air (e.g., hot air) to result in evaporation and drying of the liquid droplets. The preparation to be spray-dried can be any solution, naturally a suspension, a slurry, a colloidal dispersion, or a paste that can be atomized using the selected spray drying equipment. Typically, the feed is sprayed into a warm, filtered air stream that evaporates the solvent and carries the dried product to a collector. The spent air is then exhausted along with the solvent. Several different types of equipment can be used to provide the desired product. For example, commercially available spray dryers manufactured by Buchi or Nipro can efficiently produce particles of the desired size.
[0333] Spray-dried powder particles are generally spherical in shape, fairly uniform in size, and often may be dimpled. Some degree of irregularity may be present, depending on the pharmaceutical agent incorporated and the spray-drying conditions. In many cases, dispersion stability of spray-dried microspheres appears to be more effective with the use of a swelling agent (or foaming agent) in their production. Some embodiments may include emulsions with a swelling agent as either the dispersed or continuous phase (the other phase being aqueous in nature). The swelling agent is dispersed with a surfactant solution, e.g., using a commercially available microfluidizer at pressures of about 5,000 to 15,000 psi. This process results in the formation of emulsions that may be stabilized by the incorporated surfactant, typically comprising submicron droplets of a water-immiscible foaming agent dispersed in an aqueous continuous phase. The formation of such dispersions using this and other techniques is common and well known to those skilled in the art. The blowing agent can be a fluorinated compound (e.g., perfluorohexane, perfluorooctyl bromide, perfluorodecalin, perfluorobutylethane) that vaporizes during the spray-drying process, leaving behind aerodynamically light microspheres that are typically hollow and porous. As discussed in more detail below, other suitable blowing agents include chloroform, Freons, and hydrocarbons. Nitrogen gas and carbon dioxide are also contemplated as suitable blowing agents.
[0334] Although the porous microstructure can be formed using a foaming agent as described above, it will be understood that in some cases, a foaming agent is not required and the aqueous dispersion of the drug and surfactant is directly spray-dried. In such cases, the formulation is amenable to process conditions (e.g., elevated temperature) that generally lead to the formation of hollow, relatively porous microparticles. Furthermore, the drug may possess special physicochemical properties (e.g., high crystallinity, high melting temperature, surface activity, etc.) that are particularly suitable for use in such techniques.
[0335] The porous microstructure may optionally be associated with or contain one or more surfactants. Furthermore, a miscible surfactant may optionally be combined with the liquid phase of the suspension medium. Those skilled in the art will appreciate that the use of a surfactant may further increase dispersion stability, simplify formulation procedures, or increase bioavailability upon administration. Of course, combinations of surfactants are contemplated within the scope of the present invention, including the use of one or more surfactants in the liquid phase and one or more surfactants associated with the porous microstructure. "Associated with or comprising" means that the structural matrix or porous microstructure may incorporate, adsorb, absorb, be coated with, or be formed by a surfactant.
[0336] Surfactants suitable for use include any compound or composition that facilitates the formation and maintenance of a stabilized respirable dispersion by forming a layer at the interface between the structural matrix and the suspending medium. The surfactant may comprise a single compound or any combination of compounds (e.g., as in the case of cosurfactants). In particular, certain surfactants are substantially insoluble in the propellant, are non-fluorinated, and are selected from the group consisting of saturated and unsaturated lipids, nonionic surfactants, nonionic block copolymers, ionic surfactants, and combinations of such agents. It should be emphasized that, in addition to the surfactants described above, suitable (i.e., biocompatible) fluorinated surfactants are compatible with the teachings herein and may be used to provide the desired stabilized preparations.
[0337] Lipids, including phospholipids from both natural and synthetic sources, can be used at various concentrations to form the structural matrix. Typically, compatible lipids include those with a gel to liquid crystal phase transition above about 40° C. In some embodiments, the incorporated lipids are relatively long chain (i.e., C6-C 22), and may include phospholipids. Exemplary phospholipids useful in the disclosed stabilized preparations include egg phosphatidylcholine, dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, short-chain phosphatidylcholine, phosphatidylethanolamine, dioleylphosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, glycolipids, ganglioside GM1, sphingomyelin, phosphatidic acid, cardiolipin, lipids with polymer chains (e.g., polyethylene glycol, chitin, hyaluronic acid, or polyvinylpyrrolidone), lipids with sulfonated monosaccharides, disaccharides, and polysaccharides, fatty acids (e.g., palmitic acid, stearic acid, and oleic acid), cholesterol, cholesterol esters, and cholesterol hemisuccinate. Due to their excellent biocompatibility, phospholipids and combinations of phospholipids and poloxamers are particularly suitable for use in the stabilized dispersions disclosed herein.
[0338] Suitable nonionic surfactants include sorbitan trioleate (Spans™ 85), sorbitan sesquioleate, sorbitan monooleate, sorbitan monolaurate, sorbitan esters including polyoxyethylene(20) sorbitan monolaurate and polyoxyethylene(20) sorbitan monooleate, oleyl polyoxyethylene(2) ether, stearyl polyoxyethylene(2) ether, lauryl polyoxyethylene(4) ether, glycerol esters, and sucrose esters. Other suitable nonionic surfactants can be readily identified using McCutcheon's Emulsifiers and Detergents (McPublishing Co., Glen Rock, NJ). Specific block copolymers include diblock and triblock copolymers of polyoxyethylene and polyoxypropylene, including poloxamer 188 (Pluronic® F68), poloxamer 407 (Pluronic® F-127), and poloxamer 338. Ionic surfactants (e.g., sodium sulfosuccinate) and fatty acid soaps may also be utilized. In certain embodiments, the microstructure may include oleic acid or its alkali salt.
[0339] In addition to the surfactants mentioned above, cationic surfactants or lipids can be particularly used in the delivery of iRNA agents, such as double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNA encoding iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof). Examples of suitable cationic lipids include DOTMA, i.e., N-[-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride, DOTAP, i.e., 1,2-dioleyloxy-3-(trimethylammonio)propane, and DOTB (1,2-dioleyl-3-(4'-trimethylammonio)butanoyl-sn-glycerol). Polycationic amino acids (e.g., polylysine) and polyarginine are also contemplated.
[0340] Regarding the spraying process, spraying methods such as rotary atomization, pressure atomization, and two-fluid atomization can be used. Examples of the equipment used in these processes include "Parubis [sound rendering] Mini Spray GA-32" and "Parubis Spray Dryer DL-41" manufactured by Yamato Chemical Co., Ltd., or "Spray Dryer CL-8", "Spray Dryer L-8", "Spray Dryer FL-12", "Spray Dryer FL-16" or "Spray Dryer FL-20" manufactured by Okawara Kakoki Co., Ltd. can be used for the spraying method using a rotating disk atomizer.
[0341] There are no particular limitations on the gas used to dry the sprayed material, but it is recommended to use air, nitrogen gas, or an inert gas. The inlet temperature of the gas used to dry the sprayed material is a temperature that does not cause thermal deactivation of the sprayed material. The temperature range can vary from about 50°C to about 200°C, for example, from about 50°C to 100°C. The outlet temperature of the gas used to dry the sprayed material can vary from about 0°C to about 150°C, for example, from 0°C to 90°C, for example, from 0°C to 60°C.
[0342] Spray drying is performed under conditions that result in a substantially amorphous powder of uniform composition with a respirable particle size, low moisture content, and readily aerosolizable fluid properties. In some cases, the particle size of the resulting powder is such that greater than about 98% of the agglomerates have a diameter of about 10 μm or less, and about 90% of the agglomerates have a diameter of less than 5 μm. Alternatively, about 95% of the agglomerates have a diameter of less than 10 μm, and about 80% of the particle agglomerates have a diameter of less than 5 μm.
[0343] The pharmaceutical-based dispersible dry powder containing the iRNA preparation may optionally be combined with a pharmaceutical carrier or excipient suitable for respiratory and pulmonary administration. Such a carrier may simply serve as a bulking agent if it is desired to reduce the iRNA concentration in the powder delivered to the patient, but may also serve to enhance the stability of the iRNA composition and improve the dispersibility of the powder in a powder dispersion device, providing more efficient and reproducible delivery of the iRNA and improving handling characteristics of the iRNA, such as flowability and consistency, for ease of manufacturing and powder filling.
[0344] Such carrier materials may be combined with the drug prior to spray drying, i.e., by adding the carrier material to the purified bulk solution. In this way, the carrier particles are simultaneously formed with the drug particles, resulting in a homogeneous powder. Alternatively, the carrier may be prepared separately in dry powder form and combined with the dry powder drug by blending. Powder carriers are usually crystalline (to avoid water absorption), but in some cases may be amorphous or a mixture of crystalline and amorphous. The size of the carrier particles may be selected to improve the flowability of the drug powder and is typically in the range of 25 μm to 100 μm. The carrier material may also be crystalline lactose having a size within the above range.
[0345] The powder prepared by any of the above methods is recovered from the spray dryer in a conventional manner for subsequent use. For pharmaceutical and other uses, it is often desirable to break up any agglomerates formed by sieving or other conventional techniques. For pharmaceutical use, dry powder formulations are usually measured into single doses, and these single doses are sealed in packages. Such packages are particularly useful for dispersion in dry powder inhalers, as described in more detail below. Alternatively, the powder may be packaged in a multi-dose container.
[0346] Methods for spray drying hydrophobic and other drugs and ingredients are described in U.S. Patent Nos. 5,000,888, 5,026,550, 4,670,419, 4,540,602, and 4,486,435. Bloch and Speison (1983) Pharm. Acta. Helv 58:14-22 teach the spray drying of hydrochlorothiazide and chlorthalidone (lipophilic drugs) with a hydrophilic adjuvant (pentaerythritol) in azeotropic solvents of dioxane-water and 2-ethoxyethanol-water. A number of Japanese patent application abstracts relate to spray drying of hydrophilic-hydrophobic product combinations, including JP 806766, JP 7-242568, JP 7-101884, JP 7-101883, JP 7-1018982, JP 7-101881, and JP 4-036233. Other foreign patent applications related to spray drying of hydrophilic-hydrophobic product combinations include FR 2594693, DE 2209477, and WO 88 / 07870.
[0347] Freeze drying Preparations of iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNA encoding iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof) can be made by lyophilization. Lyophilization is a freeze-drying process in which water is sublimated from the composition after it has been frozen. A particular advantage associated with the lyophilization process is that biologics and pharmaceuticals that are relatively unstable in aqueous solution can be dried without elevated temperatures (thereby eliminating deleterious thermal effects) and then stored in a dry state where stability issues are less likely to be an issue. With respect to the present invention, such techniques are particularly compatible with incorporating nucleic acids into porous microstructures without compromising biological activity. Methods for providing lyophilized microparticles are known in the art, and it will be apparent that providing dispersion-compatible microstructures in accordance with the teachings herein will not require undue experimentation. Thus, to the extent that a lyophilization process can be used to provide microstructures with the desired porosity and size, it is expressly contemplated that the lyophilization process is compatible with the teachings herein and is within the scope of the present invention.
[0348] gene In one aspect, the invention features a method for treating a subject at risk for or suffering from a disease that may benefit from administration of an iRNA agent of the invention. The method includes administering an iRNA agent of the invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered depends on the disease being treated.
[0349] In certain embodiments, the iRNA agent silences a growth factor gene or growth factor receptor gene, a kinase (e.g., a protein tyrosine kinase, a protein serine kinase, or a protein threonine kinase) gene, an adaptor protein gene, a gene encoding a G protein superfamily molecule, or a gene encoding a transcription factor.
[0350] In some embodiments, the iRNA agent silences the PDGFβ gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted PDGFβ expression (e.g., testicular and lung cancer).
[0351] In some embodiments, the iRNA agent silences the Erb-B gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted Erb-B expression (e.g., breast cancer).
[0352] In some embodiments, the iRNA agent silences the Src gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted Src expression (e.g., colon cancer).
[0353] In some embodiments, the iRNA agent silences the CRK gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted CRK expression (e.g., colon cancer and lung cancer).
[0354] In some embodiments, the iRNA agent silences the GRB2 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted GRB2 expression (e.g., squamous cell carcinoma).
[0355] In another embodiment, the iRNA agent silences the RAS gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted RAS expression (e.g., pancreatic, colon, and lung cancer, and chronic leukemia).
[0356] In another embodiment, the iRNA agent silences the MEKK gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted MEKK expression (e.g., squamous cell carcinoma, melanoma, or leukemia).
[0357] In another embodiment, the iRNA agent silences the JNK gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted JNK expression (e.g., pancreatic or breast cancer).
[0358] In some embodiments, the iRNA agent silences the RAF gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted RAF expression (e.g., lung cancer or leukemia).
[0359] In some embodiments, the iRNA agent silences the Erk1 / 2 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted Erk1 / 2 expression (e.g., lung cancer).
[0360] In another embodiment, the iRNA agent silences the PCNA (p21) gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted PCNA expression (e.g., lung cancer).
[0361] In some embodiments, the iRNA agent silences the MYB gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted MYB expression (e.g., colon cancer or chronic myeloid leukemia).
[0362] In some embodiments, the iRNA agent silences the c-MYC gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted c-MYC expression (e.g., Burkitt's lymphoma or neuroblastoma).
[0363] In another embodiment, the iRNA agent silences the JUN gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted JUN expression (e.g., ovarian, prostate, or breast cancer).
[0364] In another embodiment, the iRNA agent silences the FOS gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted FOS expression (e.g., skin cancer or prostate cancer).
[0365] In some embodiments, the iRNA agent silences the BCL-2 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted BCL-2 expression (e.g., lung cancer, prostate cancer, or non-Hodgkin's lymphoma).
[0366] In some embodiments, the iRNA agent silences the cyclin D gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted cyclin D expression (e.g., esophageal and colon cancer).
[0367] In some embodiments, the iRNA agent silences the VEGF gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted VEGF expression (e.g., esophageal and colon cancer).
[0368] In some embodiments, the iRNA agent silences the EGFR gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted EGFR expression (e.g., breast cancer).
[0369] In another embodiment, the iRNA agent silences the cyclin A gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted cyclin A expression (e.g., lung cancer and cervical cancer).
[0370] In another embodiment, the iRNA agent silences the cyclin E gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted cyclin E expression (e.g., lung cancer and breast cancer).
[0371] In another embodiment, the iRNA agent silences the WNT-1 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted WNT-1 expression (e.g., basal cell carcinoma).
[0372] In another embodiment, the iRNA agent silences the β-catenin gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted β-catenin expression (e.g., adenocarcinoma or hepatocellular carcinoma).
[0373] In another embodiment, the iRNA agent silences the c-MET gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted c-MET expression (e.g., hepatocellular carcinoma).
[0374] In another embodiment, the iRNA agent silences the PKC gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted PKC expression (e.g., breast cancer).
[0375] In some embodiments, the iRNA agent silences the NFKB gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted NFKB expression (e.g., breast cancer).
[0376] In some embodiments, the iRNA agent silences the STAT3 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted STAT3 expression (e.g., prostate cancer).
[0377] In another embodiment, the iRNA agent silences the survivin gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted survivin expression (e.g., cervical cancer or pancreatic cancer).
[0378] In another embodiment, the iRNA agent silences the Her2 / Neu gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted Her2 / Neu expression (e.g., breast cancer).
[0379] In another embodiment, the iRNA agent silences the topoisomerase I gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted topoisomerase I expression (e.g., ovarian and colon cancer).
[0380] In some embodiments, the iRNA agent silences the topoisomerase IIα gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted topoisomerase IIα expression (e.g., breast cancer and colon cancer).
[0381] In some embodiments, the iRNA agent silences a mutation in the p73 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted p73 expression (e.g., colorectal adenocarcinoma).
[0382] In some embodiments, the iRNA agent silences a mutation in the p21(WAF1 / CIP1) gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted p21(WAF1 / CIP1) expression (e.g., liver cancer).
[0383] In some embodiments, the iRNA agent silences a mutation in the p27(KIP1) gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted p27(KIP1) expression (e.g., liver cancer).
[0384] In some embodiments, the iRNA agent silences a mutation in the PPMID gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted PPMID expression (e.g., breast cancer).
[0385] In some embodiments, the iRNA agent silences a mutation in a RAS gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted RAS expression (e.g., breast cancer).
[0386] In another embodiment, the iRNA agent silences a mutation in the caveolin I gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted caveolin I expression (e.g., esophageal squamous cell carcinoma).
[0387] In another embodiment, the iRNA agent silences a mutation in the MIB I gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted MIB I expression (e.g., male breast cancer (MBC)).
[0388] In another embodiment, the iRNA agent silences a mutation in the MTAI gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted MTAI expression (e.g., ovarian cancer).
[0389] In another embodiment, the iRNA agent silences a mutation in the M68 gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted M68 expression (e.g., human adenocarcinoma of the esophagus, stomach, colon and rectum).
[0390] In certain embodiments, iRNA agents silence mutations in tumor suppressor genes and thus can be used as a method to promote apoptotic activity in combination with chemotherapeutic drugs.
[0391] In some embodiments, the iRNA agent silences a mutation in the p53 tumor suppressor gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted p53 expression (e.g., gallbladder cancer, pancreatic cancer, and lung cancer).
[0392] In some embodiments, the iRNA agent silences a mutation in DN-p63, a member of the p53 family, and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted DN-p63 expression (e.g., squamous cell carcinoma).
[0393] In some embodiments, the iRNA agent silences a mutation in the pRb tumor suppressor gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted pRb expression (e.g., oral squamous cell carcinoma).
[0394] In some embodiments, the iRNA agent silences a mutation in the APC1 tumor suppressor gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted APC1 expression (e.g., colon cancer).
[0395] In some embodiments, the iRNA agent silences a mutation in the BRCA1 tumor suppressor gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted BRCA1 expression (e.g., breast cancer).
[0396] In some embodiments, the iRNA agent silences a mutation in the PTEN tumor suppressor gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted PTEN expression (e.g., hamartoma, glioma, prostate cancer, and endometrial cancer).
[0397] In some embodiments, the iRNA agent silences an MLL fusion gene (e.g., MLL-AF9) and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted MLL fusion gene expression (e.g., acute leukemia).
[0398] In another embodiment, the iRNA agent silences the BCR / ABL fusion gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted BCR / ABL fusion gene expression (e.g., acute and chronic leukemia).
[0399] In another embodiment, the iRNA agent silences the TEL / AML1 fusion gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted TEL / AML1 fusion gene expression (e.g., childhood acute leukemia).
[0400] In another embodiment, the iRNA agent silences the EWS / FLI1 fusion gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted EWS / FLI1 fusion gene expression (e.g., Ewing's sarcoma).
[0401] In another embodiment, the iRNA agent silences the TLS / FUS1 fusion gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted TLS / FUS1 fusion gene expression (e.g., myxoid liposarcoma).
[0402] In another embodiment, the iRNA agent silences the PAX3 / FKHR fusion gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted PAX3 / FKHR fusion gene expression (e.g., myxoid liposarcoma).
[0403] In another embodiment, the iRNA agent silences the AML1 / ETO fusion gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted AML1 / ETO fusion gene expression (e.g., acute leukemia).
[0404] disease angiogenesis In another aspect, the invention features a method of treating a subject (e.g., a human) at risk for or suffering from a disease or disorder (e.g., cancer) that may benefit from inhibiting angiogenesis. The method includes administering an iRNA agent of the invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered will depend on the type of angiogenesis-related gene being treated.
[0405] In some embodiments, the iRNA agent silences the αv-integrin gene and thus can be used to treat a subject having or at risk for a disorder characterized by unwanted αv-integrin expression (e.g., a brain tumor or a tumor of epithelial origin).
[0406] In some embodiments, the iRNA agent silences the Flt-1 receptor gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted Flt-1 receptor expression (e.g., cancer and rheumatoid arthritis).
[0407] In some embodiments, the iRNA agent silences the tubulin gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted tubulin expression (e.g., cancer and retinal neovascularization).
[0408] In some embodiments, the iRNA agent silences the tubulin gene and thus can be used to treat subjects having or at risk for disorders characterized by unwanted tubulin expression (e.g., cancer and retinal neovascularization).
[0409] Viral diseases In another aspect, the invention features a method for treating a subject infected with a virus, or a subject at risk for or suffering from a disorder or disease associated with a viral infection. The method includes administering an iRNA agent of the invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered depends on the type of viral disease being treated. In some embodiments, the nucleic acid can target a viral gene. In other embodiments, the nucleic acid can target a host gene.
[0410] Thus, the present invention provides methods for treating patients infected with human papillomavirus (HPV) or at risk of or suffering from disorders mediated by HPV (e.g., cervical cancer). HPV is involved in 95% of cervical cancers, and therefore antiviral therapy is an attractive method for treating these cancers and other symptoms of viral infection. In some embodiments, the expression of an HPV gene is reduced. In another embodiment, the HPV gene is one of the E2, E6, or E7 group. In some embodiments, the expression of a human gene required for HPV replication is reduced.
[0411] The present invention also provides methods of treating patients infected with human immunodeficiency virus (HIV) or at risk for or afflicted with an HIV-mediated disorder, such as acquired immune deficiency syndrome (AIDS). In some embodiments, expression of an HIV gene is reduced. In another embodiment, the HIV gene is CCR5, Gag, or Rev. In some embodiments, expression of a human gene required for HIV replication is reduced. In another embodiment, the gene is CD4 or Tsg101.
[0412] The present invention also provides methods for treating patients infected with hepatitis B virus (HBV) or at risk for or afflicted with HBV-mediated disorders (e.g., cirrhosis and hepatocellular carcinoma). In some embodiments, expression of an HBV gene is reduced. In another embodiment, the targeted HBV gene encodes one of the following groups: the tail region, the pre-cregious (pre-c) region, or the cregious (c) region of the HBV core protein. In another embodiment, the targeted HBV-RNA sequence consists of the poly(A) tail. In one embodiment, expression of a human gene required for HBV replication is reduced.
[0413] The present invention also provides methods of treating a patient infected with Hepatitis A Virus (HAV), or at risk for or afflicted with a disorder mediated by HAV, in some embodiments, by reducing the expression of a human gene required for HAV replication.
[0414] The present invention also provides methods for treating patients infected with hepatitis C virus (HCV) or at risk for or afflicted with an HCV-mediated disorder (e.g., cirrhosis). In some embodiments, expression of an HCV gene is reduced. In another embodiment, expression of a human gene required for HCV replication is reduced.
[0415] The present invention also provides methods of treating patients infected with any of a group of hepatitis virus strains, including hepatitis D, E, F, G, or H, or at risk for or afflicted with a disorder mediated by any of these hepatitis strains. In some embodiments, expression of the hepatitis D gene, the hepatitis E gene, the hepatitis F gene, the hepatitis G gene, or the hepatitis H gene is reduced. In another embodiment, expression of a human gene required for hepatitis D, E, F, G, or H replication is reduced.
[0416] The methods of the present invention also provide for treating patients infected with respiratory syncytial virus (RSV) or at risk for or suffering from disorders mediated by RSV (e.g., lower respiratory tract infections and childhood asthma in infants, pneumonia and other complications in the elderly, etc.). In some embodiments, the expression of an RSV gene is reduced. In another embodiment, the targeted HBV gene encodes one of the group of genes N, L, or P. In some embodiments, the expression of a human gene required for RSV replication is reduced.
[0417] The methods of the present invention provide for treating patients infected with herpes simplex virus (HSV) or at risk for or afflicted with disorders mediated by HSV (e.g., genital herpes and cold sores, as well as diseases that result in life-threatening or visual impairment primarily in immunocompromised patients). In some embodiments, expression of an HSV gene is reduced. In another embodiment, the targeted HSV gene encodes a DNA polymerase or helicase-primase. In some embodiments, expression of a human gene required for HSV replication is reduced.
[0418] The present invention also provides methods for treating patients infected with herpes cytomegalovirus (CMV) or at risk for or afflicted with a CMV-mediated disorder (e.g., a pathological condition in patients with congenital viral infections and immunocompromised states). In some embodiments, expression of a CMV gene is reduced. In some embodiments, expression of a human gene required for CMV replication is reduced.
[0419] The methods of the present invention also provide methods for treating patients infected with herpes Epstein-Barr virus (EBV) or at risk for or afflicted with EBV-mediated disorders (e.g., NK / T-cell lymphoma, non-Hodgkin's lymphoma, and Hodgkin's disease). In some embodiments, the expression of an EBV gene is reduced. In some embodiments, the expression of a human gene required for EBV replication is reduced.
[0420] The methods of the present invention also provide for treating patients infected with Kaposi's sarcoma-associated herpesvirus (KSHV) (also known as human herpesvirus type 8) or at risk for or afflicted with a KSHV-mediated disorder (e.g., Kaposi's sarcoma, multicentric Castleman's disease, and AIDS-associated primary effusion lymphoma). In some embodiments, the expression of a KSHV gene is reduced. In some embodiments, the expression of a human gene required for KSHV replication is reduced.
[0421] The present invention also includes methods of treating patients infected with JC virus (JCV) or diseases or disorders associated with this virus (e.g., progressive multifocal leukoencephalopathy (PML)). In some embodiments, expression of a JCV gene is reduced. In certain embodiments, expression of a human gene required for JCV replication is reduced.
[0422] The methods of the present invention also provide for treating patients infected with a myxovirus or at risk for or suffering from a myxovirus-mediated disorder (e.g., influenza). In some embodiments, the expression of a myxovirus gene is reduced. In some embodiments, the expression of a human gene required for myxovirus replication is reduced.
[0423] The methods of the present invention also provide for treating patients infected with rhinovirus or at risk for or suffering from a rhinovirus-mediated disorder (e.g., the common cold). In some embodiments, the expression of a rhinovirus gene is reduced. In some embodiments, the expression of a human gene required for rhinovirus replication is reduced.
[0424] The methods of the present invention also provide for treating patients infected with a coronavirus or at risk for or suffering from a coronavirus-mediated disorder (e.g., the common cold). In some embodiments, the expression of a coronavirus gene is reduced. In some embodiments, the expression of a human gene required for coronavirus replication is reduced.
[0425] The methods of the present invention also provide for treating patients infected with the flavivirus West Nile virus, or patients at risk for or suffering from a disorder mediated by West Nile virus. In some embodiments, the expression of a West Nile virus gene is reduced. In another embodiment, the West Nile virus gene is one of a group including E, NS3, or NS5. In some embodiments, the expression of a human gene required for West Nile virus replication is reduced.
[0426] The methods of the present invention also provide for treating patients infected with St. Louis encephalitis flavivirus or at risk for or suffering from a disorder or disease associated with the virus (e.g., viral hemorrhagic fever or neurological disease). In some embodiments, the expression of a St. Louis encephalitis gene is reduced. In some embodiments, the expression of a human gene required for St. Louis encephalitis virus replication is reduced.
[0427] The methods of the present invention also provide for treating patients infected with tick-borne encephalitis flaviviruses or at risk for or suffering from disorders mediated by tick-borne encephalitis viruses (e.g., viral hemorrhagic fevers and neurological diseases). In some embodiments, the expression of a tick-borne encephalitis virus gene is reduced. In some embodiments, the expression of a human gene required for tick-borne encephalitis virus replication is reduced.
[0428] The methods of the present invention also provide methods for treating patients infected with Murray Valley encephalitis flavivirus, which commonly causes viral hemorrhagic fever and neurological disease. In some embodiments, the expression of a Murray Valley encephalitis virus gene is reduced. In some embodiments, the expression of a human gene required for Murray Valley encephalitis virus replication is reduced.
[0429] The present invention also includes methods of treating patients infected with dengue flavivirus or diseases or disorders associated with this virus (e.g., dengue hemorrhagic fever). In some embodiments, the expression of a dengue virus gene is reduced. In some embodiments, the expression of a human gene required for dengue virus replication is reduced.
[0430] The methods of the present invention also provide for treating patients infected with Simian Virus 40 (SV40) or at risk for or suffering from a disorder mediated by SV40 (e.g., tumor formation). In some embodiments, the expression of an SV40 gene is reduced. In some embodiments, the expression of a human gene required for SV40 replication is reduced.
[0431] The present invention also includes methods of treating patients infected with human T-cell leukemia virus (HTLV) or diseases or disorders associated with this virus (e.g., leukemia and myelopathy). In some embodiments, expression of an HTLV gene is reduced. In another embodiment, the HTLV1 gene is a Tax transcriptional activator. In some embodiments, expression of a human gene required for HTLV replication is reduced.
[0432] The methods of the present invention also provide for treating patients infected with Moloney murine leukemia virus (Mo-MuLV) or at risk for or suffering from a disorder mediated by Mo-MuLV (e.g., T-cell leukemia). In some embodiments, expression of a Mo-MuLV gene is reduced. In some embodiments, expression of a human gene required for Mo-MuLV replication is reduced.
[0433] The methods of the present invention also provide for treating patients infected with encephalomyocarditis virus (EMCV) or at risk for or suffering from disorders mediated by EMCV (e.g., myocarditis). EMCV causes myocarditis in mice and pigs and can infect human cardiomyocytes. Therefore, this virus is of concern for patients undergoing xenotransplantation. In some embodiments, the expression of an EMCV gene is reduced. In some embodiments, the expression of a human gene required for EMCV replication is reduced.
[0434] The present invention also includes methods of treating patients infected with measles virus (MV), at risk for, or afflicted with a disorder mediated by MV (e.g., measles). In some embodiments, the expression of an MV gene is reduced. In some embodiments, the expression of a human gene required for MV replication is reduced.
[0435] The present invention also includes methods of treating patients infected with varicella-zoster virus (VZV) or at risk for or afflicted with a VZV-mediated disorder, such as chickenpox or herpes zoster (also called shingles). In some embodiments, the expression of a VZV gene is reduced. In some embodiments, the expression of a human gene required for VZV replication is reduced.
[0436] The present invention also includes methods for treating patients infected with adenovirus or at risk for or suffering from an adenovirus-mediated disorder (e.g., respiratory tract infection). In some embodiments, the expression of an adenoviral gene is reduced. In some embodiments, the expression of a human gene required for adenovirus replication is reduced.
[0437] The present invention also includes methods of treating patients infected with Yellow Fever Virus (YFV) or at risk for or suffering from a disorder mediated by YFV (e.g., respiratory tract infection). In some embodiments, expression of a YFV gene is reduced. In another embodiment, the gene may be one of a group including the E, NS2A, or NS3 genes. In some embodiments, expression of a human gene required for YFV replication is reduced.
[0438] The methods of the present invention also provide for treating patients infected with poliovirus or at risk for or suffering from a disorder mediated by poliovirus (e.g., polio). In some embodiments, the expression of a poliovirus gene is reduced. In some embodiments, the expression of a human gene required for poliovirus replication is reduced.
[0439] The methods of the present invention also provide for treating patients infected with a poxvirus or at risk for or suffering from a poxvirus-mediated disorder (e.g., smallpox). In some embodiments, the expression of a poxvirus gene is reduced. In some embodiments, the expression of a human gene required for poxvirus replication is reduced.
[0440] Other pathogens In another aspect, the invention features a method of treating a subject infected with a pathogen (e.g., a bacterial, amoebic, parasitic, or fungal pathogen). The method includes administering an iRNA agent of the invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered depends on the type of pathogen being treated. In some embodiments, the nucleic acid can target a pathogen gene. In other embodiments, the nucleic acid can target a host gene.
[0441] The target gene can be one involved in growth, cell wall synthesis, protein synthesis, transcription, energy metabolism (eg, the Krebs cycle), or toxin production.
[0442] Thus, the present invention provides methods for treating patients infected with malaria-causing malaria parasites. In some embodiments, the expression of a malaria parasite gene is reduced. In another embodiment, the gene is apical membrane antigen 1 (AMA1). In some embodiments, the expression of a human gene required for malaria parasite replication is reduced.
[0443] The present invention also includes methods for treating patients infected with Mycobacterium ulcerans or for treating a disease or disorder associated with this pathogen (e.g., Buruli ulcer). In some embodiments, the expression of a Mycobacterium ulcerans gene is reduced. In some embodiments, the expression of a human gene required for Mycobacterium ulcerans replication is reduced.
[0444] The present invention also includes methods of treating patients infected with Mycobacterium tuberculosis or a disease or disorder associated with this pathogen (e.g., tuberculosis). In some embodiments, the expression of a Mycobacterium tuberculosis gene is reduced. In some embodiments, the expression of a human gene required for Mycobacterium tuberculosis replication is reduced.
[0445] The present invention also includes methods of treating patients infected with Mycobacterium leprae or a disease or disorder associated with this pathogen (e.g., leprosy). In some embodiments, the expression of a Mycobacterium leprae gene is reduced. In some embodiments, the expression of a human gene required for Mycobacterium leprae replication is reduced.
[0446] The present invention also includes methods of treating patients infected with the bacterium Staphylococcus aureus, or diseases or disorders associated with this pathogen (e.g., skin and mucosal infections). In some embodiments, expression of a Staphylococcus aureus gene is reduced. In some embodiments, expression of a human gene required for Staphylococcus aureus replication is reduced.
[0447] The present invention also includes methods of treating patients infected with the bacterium Streptococcus pneumoniae, or a disease or disorder associated with this pathogen (e.g., pneumonia or childhood lower respiratory tract infection). In some embodiments, the expression of a Streptococcus pneumoniae gene is reduced. In some embodiments, the expression of a human gene required for Streptococcus pneumoniae replication is reduced.
[0448] The present invention also includes methods of treating patients infected with the bacterium Streptococcus pyogenes, or a disease or disorder associated with this pathogen (e.g., streptococcal pharyngitis or scarlet fever). In some embodiments, the expression of a Streptococcus pyogenes gene is reduced. In some embodiments, the expression of a human gene required for Streptococcus pyogenes replication is reduced.
[0449] The present invention also includes methods of treating patients infected with the bacterium Chlamydia pneumoniae, or a disease or disorder associated with this pathogen (e.g., pneumonia or childhood lower respiratory tract infection). In some embodiments, the expression of a Chlamydia pneumoniae gene is reduced. In some embodiments, the expression of a human gene required for Chlamydia pneumoniae replication is reduced.
[0450] The present invention also includes methods of treating patients infected with the bacterium Mycoplasma pneumoniae, or a disease or disorder associated with this pathogen (e.g., pneumonia or childhood lower respiratory tract infection). In some embodiments, the expression of a Mycoplasma pneumoniae gene is reduced. In some embodiments, the expression of a human gene required for Mycoplasma pneumoniae replication is reduced.
[0451] Immune disorders In one aspect, the invention features a method of treating a subject (e.g., a human) at risk for or afflicted with a disease or disorder characterized by an unwanted immune response (e.g., an inflammatory disease or disorder, or an autoimmune disease or disorder). The method includes administering an iRNA agent of the invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered will depend on the type of immune disorder being treated.
[0452] In some embodiments, the disease or disorder is ischemia or reperfusion injury, e.g., acute myocardial infarction, unstable angina, cardiopulmonary bypass, surgical intervention (e.g., angioplasty (e.g., percutaneous transluminal coronary angioplasty)), response to a transplanted organ or tissue (e.g., transplanted cardiac tissue or vascular tissue), or ischemia or reperfusion injury associated with thrombolysis.
[0453] In some embodiments, the disease or disorder is restenosis, eg, restenosis associated with surgical intervention (eg, angioplasty (eg, percutaneous transluminal coronary angioplasty)).
[0454] In certain embodiments, the disease or disorder is inflammatory bowel disease, eg, Crohn's disease or ulcerative colitis.
[0455] In certain embodiments, the disease or disorder is inflammation associated with infection or injury.
[0456] In certain embodiments, the disease or disorder is asthma, lupus, multiple sclerosis, diabetes (eg, type 2 diabetes), arthritis (eg, rheumatoid arthritis or psoriatic arthritis).
[0457] In certain other embodiments, the iRNA agent silences an integrin or its co-ligand, eg, VLA4, VCAM, ICAM.
[0458] In certain other embodiments, the iRNA agent silences a selectin or its co-ligand, eg, P-selectin, E-selectin (ELAM), I-selectin, P-selectin glycoprotein-1 (PSGL-1).
[0459] In certain other embodiments, the iRNA agent silences a component of the complement system, eg, C3, C5, C3aR, C5aR, C3 convertase, C5 convertase.
[0460] In certain other embodiments, the iRNA agent silences a chemokine or its receptor, e.g., TNFI, TNFJ, IL-1I, IL-1J, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-6, IL-8, TNFRI, TNFRII, IgE, SCYA11, CCR3.
[0461] In other embodiments, the iRNA agent silences GCSF, Gro1, Gro2, Gro3, PF4, MIG, pro-platelet basic protein (PPBP), MIP-1I, MIP-1J, RANTES, MCP-1, MCP-2, MCP-3, CMBKR1, CMBKR2, CMBKR3, CMBKR5, AIF-1, or I-309.
[0462] pain In one aspect, the invention features a method of treating a subject (e.g., a human) at risk for or suffering from acute or chronic pain. The method includes administering an iRNA agent of the invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered depends on the type of pain being treated.
[0463] In certain other embodiments, the iRNA agent silences a component of an ion channel.
[0464] In certain other embodiments, the iRNA agent silences a neurotransmitter receptor or ligand.
[0465] In one aspect, the invention features a method of treating a subject (e.g., a human) at risk for or afflicted with a neurological disease or disorder. The method includes providing an iRNA agent, wherein the iRNA is homologous to and capable of silencing, e.g., by cleavage, a gene that mediates the neurological disease or disorder, and administering it to the subject, thereby treating the subject.
[0466] Neurological disorders In some embodiments, the disease or disorder is a neurological disorder, including Alzheimer's disease or Parkinson's disease. The method includes administering an iRNA agent of the present invention to a subject in need thereof, thereby treating the subject. The iRNA agent administered depends on the type of neurological disorder being treated.
[0467] In certain other embodiments, the iRNA agent silences an amyloid-family gene (eg, APP), a presenilin gene (eg, PSEN1 and PSEN2), or I-synuclein.
[0468] In some embodiments, the disease or disorder is a neurodegenerative trinucleotide repeat disorder (e.g., Huntington's disease, dentatorubral-pallidoluysian atrophy, or spinocerebellar ataxia (e.g., SCA1, SCA2, SCA3 (Machado-Joseph disease), SCA7, or SCA8)).
[0469] In certain other embodiments, the iRNA agent silences HD, DRPLA, SCA1, SCA2, MJD1, CACNL1A4, SCA7, SCA8.
[0470] Loss of heterozygosity Loss of heterozygosity (LOH) can result in hemizygosity of a sequence (e.g., a gene) in the LOH region. This can result in significant genetic differences between normal cells and diseased cells (e.g., cancer cells) and provides useful differentiation between normal and diseased cells (e.g., cancer cells). This difference can arise because a gene or other sequence is heterozygous in euploid cells but hemizygous in cells with LOH. Regions of LOH often contain genes whose loss promotes unwanted growth, e.g., tumor suppressor genes, and other sequences, including, for example, other genes (in some cases, genes essential for normal function (e.g., proliferation)). The methods of the present invention rely, in part, on specifically cleaving or silencing one allele of an essential gene with an iRNA agent of the present invention. The iRNA agent is selected to target a single allele of the essential gene found in cells with LOH but not to silence the other allele present in cells that do not exhibit LOH. In effect, the iRNA agent distinguishes between the two alleles and preferentially silences the selected allele. Essentially, a polymorphism (eg, a SNP in an essential gene affected by LOH) is used as a target for disorders characterized by cells with LOH (eg, cancer cells with LOH).
[0471] Those skilled in the art can identify essential genes that are adjacent to tumor suppressor genes and within LOH regions that include tumor suppressor genes. The gene encoding the large subunit of human RNA polymerase II (POLR2A), which is located adjacent to the tumor suppressor gene p53, is one such gene. Such genes are often present within LOH regions in cancer cells. Other genes present within LOH regions and that are lost in many cancer cell types include a group that includes replication protein A70kDa subunit, replication protein A32-kDa, ribonucleotide reductase, thymidylate synthase, TATA-associated factor 2H, ribosomal protein S14, eukaryotic initiation factor 5A, alanyl-tRNA synthetase, cysteinyl-tRNA synthetase, NaK ATPase, alpha-1 subunit, and transferrin receptor.
[0472] Thus, the present invention features a method for treating a disorder characterized by LOH (e.g., cancer). The method optionally includes determining the genotype of the allele of a gene in the LOH region, determining the genotype of both alleles of this gene in normal cells, providing an iRNA agent that preferentially cleaves or silences the allele found in LOH cells, and administering the iRNA to a subject, thereby treating the disorder.
[0473] The invention also includes iRNA agents disclosed herein, eg, iRNA agents that can preferentially silence (eg, cleave) one allele of a polymorphic gene.
[0474] In another aspect, the present invention provides a method for cleaving or silencing two or more genes with an iRNA agent. In these embodiments, the iRNA agent is selected to have sufficient homology to the sequence found in two or more genes. For example, the sequence AAGCTGCCCTGGACATGGAGAT is conserved between mouse lamin B1, lamin B2, keratin complex 2-gene 1, and lamin A / C. Therefore, an iRNA agent targeting this sequence will effectively silence the entire group of these genes.
[0475] The invention also includes iRNA agents disclosed herein that are capable of silencing more than one gene.
[0476] Delivery route For ease of explanation, the formulations, compositions and methods in this section are mainly discussed with respect to unmodified iRNA agents.However, it can be understood that these formulations, compositions and methods can be implemented with respect to other iRNA agents, for example, modified iRNA agents, and such implementation is within the scope of the present invention.The composition comprising iRNA can be delivered to a subject by various routes.Exemplary routes include intravenous route, topical route, rectal route, anal route, vaginal route, nasal route, pulmonary route and ocular route.
[0477] The iRNA molecules of the present invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically contain one or more iRNAs and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use of conventional media and agents in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[0478] The pharmaceutical compositions of the present invention can be administered in a number of ways, depending on whether local or systemic treatment is desired and on the area to be treated. Administration can be topical (including ophthalmic, vaginal, rectal, nasal, or transdermal), oral, or parenteral. Parenteral administration includes intravenous infusion, subcutaneous, intraperitoneal, or intramuscular injection, or intrathecal or intraventricular administration.
[0479] The route and site of administration may be selected to enhance targeting. For example, if muscle cells are to be targeted, intramuscular injection into the muscle of interest would be a logical choice. Lung cells can be targeted by administering iRNA in aerosol form. Vascular endothelial cells can be targeted by coating a balloon catheter with iRNA and mechanically introducing DNA.
[0480] Preparations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders.Conventional pharmaceutical carriers, aqueous bases, powder bases, or oily bases, thickeners, etc. may be necessary or desirable.Coated condoms, gloves, etc. may also be useful.
[0481] Compositions for oral administration include powders or granules, aqueous suspensions or solutions, syrups, elixirs or non-aqueous media, tablets, capsules, lozenges, or troches. For tablets, usable carriers include lactose, sodium citrate, and phosphate salts. Various disintegrants (e.g., starch) and lubricants (e.g., magnesium stearate, sodium lauryl sulfate, and talc) are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high-molecular-weight polyethylene glycol. When aqueous suspensions are required for oral use, the nucleic acid composition can be combined with emulsifying and suspending agents. If desired, certain sweeteners and / or flavoring agents can be added.
[0482] Compositions for intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents, and other suitable additives.
[0483] Formulations for parenteral administration may include sterile aqueous solutions, which may also contain buffers, diluents, and other suitable additives. Intraventricular injection may be facilitated, for example, by an intraventricular catheter attached to a reservoir. For intravenous use, the total concentration of solutes may be controlled so that the preparation is isotonic.
[0484] For ocular administration, ointments or droppable solutions may be delivered by ocular delivery systems known to those skilled in the art, such as applicators or eye droppers. Such compositions may contain mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose, or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA, or benzylcuronium chloride, and conventional amounts of diluents and / or carriers.
[0485] Local delivery For ease of exposition, the formulations, compositions, and methods in this section are discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these formulations, compositions, and methods can be implemented with other iRNA agents, e.g., modified iRNA agents, and such implementation is within the scope of the present invention. In some embodiments, an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) is delivered to a subject via topical administration. "Topical administration" refers to delivery to a subject by directly contacting the formulation with a surface of the subject. While the most common form of topical delivery is to the skin, the compositions disclosed herein can also be applied directly to other surfaces of the body (e.g., the eye, mucous membranes, surfaces of body cavities, or internal surfaces).
[0486] As mentioned above, the most common local delivery is to the skin.This term includes, but is not limited to, several administration routes, including topical and transdermal.These administration modes typically involve penetration of the skin's permeability barrier and efficient delivery to target tissue or target layer.Topical administration can be used as a means for the composition to penetrate the epidermis and dermis, and ultimately achieve systemic delivery.Topical administration can also be used as a means for selectively delivering oligonucleotide to the target epidermis or dermis, or to a specific layer thereof, or to the underlying tissue.
[0487] As used herein, the term "skin" refers to the epidermis and / or dermis of an animal. Mammalian skin consists of two main distinct layers. The outer layer of skin is called the epidermis. The epidermis is composed of the stratum corneum, stratum granulosum, stratum spinosum, and stratum basale, with the stratum corneum being at the surface of the skin and the stratum basale being at the deepest part of the epidermis. The epidermis is 50 μm to 0.2 mm thick, depending on the location on the body.
[0488] Beneath the epidermis lies the dermis, which is significantly thicker than the epidermis. The dermis is composed primarily of collagen in the form of fibrous bundles that provide support for, among other things, blood vessels, lymphatic capillaries, glands, nerve endings, and immunologically active cells.
[0489] One of the main functions of the skin as an organ is to regulate the entry of substances into the body. The primary permeability barrier of the skin is provided by the stratum corneum, which is formed from many layers of cells in various states of differentiation. The intercellular spaces in the stratum corneum are filled with various lipids arranged in a lattice, which provide a seal to further enhance the skin's permeability barrier.
[0490] The permeability barrier provided by the skin is largely impermeable to molecules having a molecular weight greater than about 750 Da. In order for large molecules to cross the skin's permeability barrier, mechanisms other than normal osmosis must be used.
[0491] Several factors determine the permeability of the skin to the administered drug. These factors include the characteristics of the treated skin, the characteristics of the delivery agent, the interactions between the drug and the delivery agent and between the drug and the skin, the dosage of the applied drug, the form of treatment, and the post-treatment administration schedule. In order to selectively target the epidermis and dermis, it may be possible to formulate the composition with one or more penetration enhancers, which allow the drug to penetrate into preselected layers.
[0492] Transdermal delivery is a useful route for administering lipid-soluble therapeutic agents. The dermis is more permeable than the epidermis, and therefore absorption through abraded, burned, or peeled skin is much more rapid. Inflammation and other physiological conditions that increase blood flow to the skin also enhance transdermal absorption. Absorption through this route can be enhanced by using an oily vehicle (ointment) or by using one or more penetration enhancers. Other effective methods for delivering the compositions disclosed herein via the transdermal route include skin hydration and the use of controlled-release topical patches. The transdermal route provides a potentially effective means for delivering the compositions disclosed herein for systemic and / or local treatment.
[0493] Additionally, iontophoresis (the movement of ionic solutes through biological membranes under the influence of an electric field) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 163), phonophoresis, or sonophoresis (the use of ultrasound to enhance the absorption of various therapeutic agents across biological membranes, particularly the skin and cornea) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 166), as well as optimizing vehicle properties for dosing location and retention at the administration site (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 168), may be useful methods for enhancing transport of topically administered compositions across skin and mucosal sites.
[0494] The provided compositions and methods can be used to investigate the function of various proteins and genes in vitro in cultured or preserved dermal tissues and in animals. Thus, the present invention can be applied to investigate the function of any gene. The methods of the present invention can also be used therapeutically or prophylactically. For example, to treat animals known to suffer from or suspected of suffering from diseases such as psoriasis, lichen planus, toxic epidermal necrolysis, erythema multiforme, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, Kaposi's sarcoma, pulmonary fibrosis, Lyme disease, and viral, fungal, and bacterial skin infections.
[0495] pulmonary delivery For ease of exposition, the formulations, compositions, and methods in this section will be discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these formulations, compositions, and methods can be implemented with other iRNA agents, e.g., modified iRNA agents, and such implementations are within the scope of the present invention. Compositions containing iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents (e.g., precursors, e.g., larger iRNA agents that can be processed into siRNA agents, or DNA encoding iRNA agents, e.g., double-stranded iRNA agents, or siRNA agents, or precursors thereof), can be administered to a subject by pulmonary delivery. Pulmonary delivery compositions can be delivered by the patient inhaling a dispersion, so that the composition (e.g., iRNA) in the dispersion reaches the lungs, where it can be readily absorbed directly into the blood circulation through the alveolar region. Pulmonary delivery can be effective for both systemic and local delivery to treat lung diseases.
[0496] Pulmonary delivery can be achieved by a variety of techniques, including the use of nebulized, aerosolized, micelle-based, and dry powder-based formulations. Delivery can be achieved using liquid nebulizers, aerosol-based inhalers, and dry powder dispersion devices. Metered-dose devices may also be used. One advantage of using nebulizers or inhalers is that these devices are self-contained, minimizing the potential for contamination. Dry powder dispersion devices, for example, deliver drugs that can be easily formulated as dry powders. iRNA compositions can be stably stored as lyophilized or spray-dried powders, alone or in combination with a suitable powder carrier. Delivery of compositions for inhalation may be mediated by a dose-timing element, such as a timer, dose meter, time meter, or time indicator, which, when incorporated into the device, allows for tracking of dosage, monitoring compliance, and / or reminding the patient to take a dose during administration of the aerosol pharmaceutical.
[0497] The term "powder" refers to a composition consisting of finely dispersed solid particles that are free-flowing and readily dispersible in an inhalation device, and that can subsequently be inhaled by a subject to reach the lungs and penetrate into the alveoli. Thus, the powder is said to be "respirable." For example, the average particle size is less than about 10 μm in diameter and is distributed in a relatively uniform spherical shape. In some embodiments, the diameter is less than about 7.5 μm, and in some embodiments, less than about 5.0 μm. Typically, the particle size distribution is from about 0.1 μm to about 5 μm in diameter, and sometimes from about 0.3 μm to about 5 μm.
[0498] The term "dry" means that the composition has a moisture content of less than about 10% by weight (% w), typically less than about 5% w, and sometimes less than about 3% w. A dry composition may be one in which the particles are readily dispersible in an inhalation device to form an aerosol.
[0499] The term "therapeutically effective amount" is the amount present in a composition needed to provide a desired level of drug in the subject being treated to obtain the desired physiological response.
[0500] The term "physiologically effective amount" is the amount delivered to a subject to obtain a desired palliative or therapeutic effect.
[0501] The term "pharmaceutically acceptable carrier" means that the carrier can be taken up into the lungs without significant adverse toxicological effects on the lungs.
[0502] Types of pharmaceutical excipients useful as carriers include stabilizers (e.g., human serum albumin (HSA)), bulking agents (e.g., carbohydrates, amino acids, and polypeptides), pH adjusters or buffers, salts (e.g., sodium chloride), etc. These carriers may be in crystalline or amorphous form, or a mixture of the two.
[0503] Particularly useful bulking agents include compatible carbohydrates, polypeptides, amino acids, or combinations thereof. Suitable carbohydrates include monosaccharides (e.g., galactose, D-mannose, sorbose), disaccharides (e.g., lactose, trehalose), cyclodextrins (e.g., 2-hydroxypropyl-β-cyclodextrin), and polysaccharides (e.g., raffinose, maltodextrin, dextran), alditols (e.g., mannitol, xylitol), and the like. The carbohydrate group includes lactose, trehalose, raffinose, maltodextrin, and mannitol. Suitable polypeptides include aspartame. Amino acids include alanine and glycine, and in some embodiments, glycine is used.
[0504] Minor additives may be included in the compositions of the present invention to improve conformational stability and powder dispersibility during spray drying. These additives include hydrophobic amino acids such as tryptophan, tyrosine, leucine, and phenylalanine.
[0505] Suitable pH adjusters or buffers include organic salts prepared from organic acids and organic bases, such as sodium citrate, sodium ascorbate, and the like; in some embodiments, sodium citrate is used.
[0506] Pulmonary administration of micellar iRNA formulations can be achieved with a metered dose spray device using propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether, and other non-CFC and CFC propellants.
[0507] Oral or nasal delivery For ease of explanation, the formulations, compositions, and methods in this section will be primarily discussed with respect to unmodified iRNA agents. However, it will be understood that these formulations, compositions, and methods can be implemented with respect to other iRNA agents, such as modified iRNA agents, and such implementation is within the scope of the present invention. Both oral and nasal membranes offer advantages over other administration routes. For example, drugs administered through these membranes have a rapid onset of action, provide therapeutic plasma levels, avoid the first-pass effect of hepatic metabolism, and avoid exposing the drug to the harsh gastrointestinal (GI) environment. Additional advantages include the easy accessibility of these membrane sites, allowing drugs to be easily applied, localized, and removed.
[0508] In oral delivery, the composition can be targeted to the surface of the oral cavity, for example, the sublingual mucosa (including the membrane on the ventral surface of the tongue and the floor of the oral cavity) or the buccal mucosa that constitutes the inner membrane of the cheek.The sublingual mucosa is relatively permeable, which allows many drugs to be absorbed quickly and have acceptable bioavailability.In addition, the sublingual mucosa is convenient, acceptable, and easily accessible.
[0509] The ability of molecules to permeate through the oral mucosa appears to be related to molecular size, lipid solubility, and ionization of peptide proteins. Small molecules, less than 1,000 daltons, appear to cross the mucosa rapidly. As molecular size increases, permeability decreases rapidly. Lipid-soluble compounds are more permeable than non-lipid-soluble molecules. Maximum absorption occurs when the molecule is non-ionized or neutral in charge. Therefore, charged molecules present the greatest challenge for absorption through the oral mucosa.
[0510] Alternatively, the iRNA pharmaceutical composition may be administered to the oral cavity by spraying the mixed micelle pharmaceutical formulation and propellant into a human's oral cavity from a metered dose dispenser, rather than by inhalation. In one embodiment, the dispenser is first shaken before spraying the pharmaceutical formulation and propellant into the oral cavity.
[0511] Device For ease of exposition, the devices, formulations, compositions, and methods in this section are discussed primarily with respect to unmodified iRNA agents. However, it will be understood that these devices, formulations, compositions, and methods can be implemented with other iRNA agents, e.g., modified iRNA agents, and such implementations are within the scope of the present invention. An iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof), can be disposed on or within a device, e.g., a device implanted or otherwise placed in a subject. Exemplary devices include devices introduced into the vascular system (e.g., devices inserted into the lumen of vascular tissue) or devices that themselves form part of a blood vessel, including stents, catheters, heart valves, and other vascular devices. These devices (e.g., catheters or stents) can be placed in blood vessels in the lungs, heart, or legs.
[0512] Other devices include non-vascular devices, such as devices implanted in the peritoneum, or in organ or glandular tissue (e.g., artificial organs), which can release therapeutic substances in addition to iRNA, for example, the device can release insulin.
[0513] Other devices include artificial joints (eg, hip joints) and other orthopedic implants.
[0514] In one embodiment, a unit dose or fixed dose of the composition comprising the iRNA is delivered by an implanted device. The device may include a sensor that monitors a parameter within the subject. For example, the device may include a pump and, optionally, associated electronics.
[0515] Tissues (e.g., cells or organs) can be treated ex vivo with an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent which can be processed into an siRNA agent, or a DNA which encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof), and then administered or implanted into a subject.
[0516] The tissue can be autologous, allogeneic, or xenogeneic tissue. For example, the tissue can be treated to reduce graft-versus-host disease. In other embodiments, the tissue is allogeneic tissue and is treated to treat disorders characterized by undesired gene expression in the tissue. For example, tissue, such as hematopoietic cells (e.g., bone marrow hematopoietic cells), can be treated to inhibit undesired cell proliferation.
[0517] The introduction of processed tissue, whether autologous or transplanted, can be combined with other treatments.
[0518] In some implementations, the iRNA-treated cells are isolated from other cells by, for example, a semi-permeable porous barrier that prevents the cells from leaving the implant but allows molecules from within the body to reach the cells and molecules produced by the cells to enter the body. In one embodiment, the porous barrier is formed from alginate.
[0519] In one embodiment, a contraceptive device is coated with or contains an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent which can be processed into an siRNA agent, or a DNA which encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof). Exemplary devices include condoms, diaphragms, IUDs (implantable intrauterine devices), sponges, vaginal condoms, and birth control devices. In one embodiment, the iRNA is selected to inactivate sperm or eggs. In another embodiment, the iRNA is selected to be complementary to the RNA of a virus or pathogen (e.g., an STD). In some examples, the iRNA composition can include a spermicide.
[0520] Dosage In one aspect, the invention features a method of administering to a subject (e.g., a human subject) an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent. The method includes administering a unit dose of an iRNA agent, e.g., an siRNA agent, e.g., a double-stranded siRNA agent, where (a) the double-stranded portion is 19-25 nucleotides (nt) in length, e.g., 21-23 nt, (b) is complementary to a target RNA (e.g., an endogenous target RNA or a pathogen target RNA), and optionally (c) includes at least one 1-5 nucleotide 3' overhang. In one embodiment, the unit dose is less than 1.4 mg / kg body weight, or less than 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005, or 0.00001 mg / kg body weight, and less than 200 nmol of RNA agent (e.g., about 4.4 x 10 16 copies), or less than 1,500, 750, 300, 150, 75, 15, 7.5, 1.5, 0.75, 0.15, 0.075, 0.015, 0.0075, 0.0015, 0.00075, or 0.00015 nmol of RNA agent per kg of body weight.
[0521] The specified amount can be an amount that is effective for treating or preventing disease or disorder, for example, disease or disorder related to target RNA.The unit dose can be administered, for example, by injection (for example, intravenous or intramuscular), inhalation administration, or topical application.In some embodiments, the dosage can be less than 2, 1, or 0.1 mg per kg of body weight.
[0522] In some embodiments, the unit dose is administered less frequently than once a day, for example, less than every 2, 4, 8, or 30 days. In other embodiments, the unit dose is not administered frequently (e.g., not administered at a regular frequency). For example, the unit dose may be administered once.
[0523] In one embodiment, an effective dose is administered with other conventional therapeutic modalities. In one embodiment, the subject has a viral infection, and the modality is an antiviral agent other than an iRNA agent (e.g., a double-stranded iRNA agent or an siRNA agent). In another embodiment, the subject has atherosclerosis, and an effective dose of an iRNA agent (e.g., a double-stranded iRNA agent or an siRNA agent) is administered in combination, for example, after surgical intervention (e.g., angioplasty).
[0524] In one embodiment, a subject is administered an initial dose and one or more maintenance doses of an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof). The maintenance dose is typically less than the initial dose (e.g., one-half less than the initial dose). A maintenance dosing regimen involves treating a subject with a dose ranging from 0.01 μg to 1.4 mg per kg of body weight per day, e.g., 10, 1, 0.1, 0.01, 0.001, or 0.00001 mg per kg of body weight per day. A maintenance dose is administered, for example, no more than once every 5, 10, or 30 days. Furthermore, the treatment regimen is sustained for a period of time, depending on the nature of the particular disease, its severity, and the overall condition of the patient. In some embodiments, dosage can be delivered only once a day, for example, once every 24, 36, 48 hours or more, for example, once every 5 or 8 days.After treatment, patient can be monitored for changes in patient's condition and alleviation of the symptoms of disease state.If patient does not respond well to the current dosage level, the dosage of compound can be increased, or if the symptoms of disease state are alleviated, disease state is eliminated, or if undesirable side effects are observed, the dosage can be reduced.
[0525] An effective dose can be administered in a single dose or in two or more doses, as desired or deemed appropriate under the particular circumstances. Where it is desirable to facilitate repeated or frequent infusions, it may be desirable to implant a delivery device (e.g., a pump, a semi-permanent stent (e.g., intravenous, intraperitoneal, intracapsular, or intra-articular)) or a reservoir.
[0526] In one embodiment, an iRNA agent pharmaceutical composition comprises multiple iRNA agent species. In another embodiment, an iRNA agent species has a sequence that is non-overlapping and non-adjacent to another iRNA agent species with respect to a naturally occurring target sequence. In another embodiment, the multiple iRNA agent species are specific for different naturally occurring target genes. In another embodiment, the iRNA agent is allele-specific.
[0527] In some cases, patients are treated with iRNA agents in conjunction with other therapeutic modalities.For example, patients receiving treatment for viral diseases, such as HIV-related diseases (e.g., AIDS), can be administered iRNA agents specific to target genes essential for the virus in conjunction with known viral agents (e.g., protease inhibitors or reverse transcriptase inhibitors).In another example, in other embodiments, patients receiving treatment for cancer can be administered iRNA agents specific to targets essential for tumor cell growth in conjunction with chemotherapy.
[0528] Following successful treatment, it may be desirable to administer maintenance therapy to patients to prevent recurrence of the disease state, in which case the compounds of the invention are administered at a maintenance dose of 0.01 μg to 100 g per kg of body weight (see U.S. Pat. No. 6,107,094).
[0529] The concentration of the iRNA agent composition is an amount sufficiently effective to treat or prevent a disorder or to regulate a physiological condition in humans. The concentration or amount of iRNA agent administered will depend on the parameters determined for the iRNA agent and the method of administration (e.g., nasal, buccal, pulmonary). For example, nasal formulations tend to require much lower concentrations of some components to avoid irritation or burning of the nasal passages. It may be desirable to dilute an oral formulation up to 10-100 times to provide a suitable nasal formulation.
[0530] Certain factors may affect the dosage required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the subject's general health and / or age, and the presence of other diseases. Furthermore, treatment of a subject with a therapeutically effective amount of an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) can include a single treatment or, e.g., a series of treatments. It will also be understood that the effective dosage of an iRNA agent (e.g., an siRNA agent) used for treatment may increase or decrease during a particular treatment. Dosage variations are possible and may become apparent from the results of diagnostic assays such as those described herein. For example, the subject can be monitored after administration of an iRNA agent composition. Based on information from the monitoring, an additional amount of an iRNA agent composition can be administered.
[0531] Dosing depends on the severity and responsiveness of the disease state to be treated, with treatment courses lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal administration schedules can be calculated from measurements of drug accumulation in the patient's body. One of ordinary skill in the art can readily determine optimal dosages, methods of administration, and repetition frequencies. Optimal dosages may vary depending on the relative potency of individual compounds and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models. In some embodiments, animal models include transgenic animals expressing a human gene (e.g., a gene that produces a target RNA). The transgenic animal can be deficient in the corresponding endogenous RNA. In another embodiment, the composition for testing comprises an iRNA agent that is complementary, at least in an internal region, to a sequence conserved between the target RNA of the animal model and the human target RNA.
[0532] The inventors have discovered that the iRNA agents described herein can be administered to mammals, particularly large mammals (e.g., non-human primates or humans), in a number of ways.
[0533] In one embodiment, administration of an iRNA agent (e.g., a double-stranded iRNA agent, or siRNA agent) composition is parenteral, e.g., intravenous (e.g., as a bolus or as a diffuse infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intracerebroventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral, or ocular. Administration can be by the subject or by another person (e.g., a health care provider). The pharmaceutical agent can be provided in a metered dose or in a dispenser that delivers a metered amount. Selected modes of delivery are discussed in more detail below.
[0534] The invention provides methods, compositions, and kits for rectal administration or delivery of the iRNA agents described herein.
[0535] Thus, an iRNA agent described herein, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof), e.g., a therapeutically effective amount of an iRNA agent described herein, e.g., an iRNA agent having a double-stranded region of less than 40 nucleotides, e.g., less than 30 nucleotides, and having one or two single-stranded 3' overhangs of 1-3 nucleotides, can be administered rectally (e.g., introduced via the rectum into the lower or upper colon). This approach is particularly useful in treating inflammatory disorders, disorders characterized by unwanted cell proliferation, e.g., polyps or colon cancer.
[0536] Medicaments can be delivered to sites within the colon by introducing a dispensing device, for example, a flexible, camera-guided device similar to those used to examine the colon or remove polyps, which includes a means for delivering the medication.
[0537] For rectal administration of an iRNA agent, an enema is used. The iRNA agent in the enema can be dissolved in saline or a buffer solution. Alternatively, a suppository can be used for rectal administration, and the suppository can contain other ingredients, such as excipients (e.g., cocoa butter or hydropropylmethylcellulose).
[0538] Any of the iRNA agents described herein can be administered orally, for example, in the form of a tablet, capsule, gel cap, lozenge, pastille, or liquid syrup. Additionally, the compositions can be applied topically to the surfaces of the oral cavity.
[0539] Any iRNA agent described herein can be administered into the oral cavity.For example, the pharmaceutical agent can be sprayed into the oral cavity, or can be directly applied to the surface of the oral cavity, for example, in the form of liquid, solid or gel.This administration is particularly desirable for treating inflammation in the oral cavity (for example, gums or tongue), and for example, in one embodiment, oral administration is carried out by spraying into the oral cavity from a dispenser, for example, a metered dose dispenser that dispenses pharmaceutical composition and propellant, without inhalation.
[0540] Any of the iRNA agents described herein can be administered to ocular tissues. For example, the pharmaceutical agent can be applied to the eye or adjacent tissues (e.g., the inside of the eyelid). The pharmaceutical agent can be applied topically, for example, by spraying, as drops, as an eyewash, or as an ointment. Administration can be performed by the subject or by another person (e.g., a healthcare provider). The pharmaceutical agent can be provided in a fixed dose or in a dispenser that delivers a fixed amount. The pharmaceutical agent can also be administered inside the eye and can be introduced by a needle or other delivery device that can introduce the pharmaceutical agent to a selected area or structure. Ocular treatment is particularly desirable for treating inflammation of the eye or adjacent tissues.
[0541] Any of the iRNA agents described herein can be administered directly to the skin. For example, pharmaceutical agents can be topically applied or delivered to a skin layer, for example, by using a microneedle or series of microneedles that penetrate the skin but not, for example, the underlying muscle tissue. Administration of the iRNA agent composition can be topical. Topical application can deliver the composition, for example, to the dermis or epidermis of a subject. Topical administration can be in the form of a transdermal patch, ointment, lotion, cream, gel, drops, suppository, spray, liquid, and powder. Compositions for topical administration can be formulated as liposomes, micelles, emulsions, or other lipid-soluble molecular aggregates. Transdermal administration can be applied using at least one penetration enhancer, such as iontophoresis, phonophoresis, or sonophoresis.
[0542] Any of the iRNA agents described herein can be administered to the pulmonary system. Pulmonary administration can be achieved by inhalation or by introducing a delivery device into the pulmonary system, for example, by introducing a delivery device capable of dispensing a pharmaceutical agent. Some embodiments may use a method of pulmonary delivery by inhalation. The pharmaceutical agent can be provided in a dispenser that delivers the pharmaceutical agent (e.g., a wet or dry pharmaceutical agent in a form small enough to be inhaled). The device can deliver a metered amount of the pharmaceutical agent. The pharmaceutical agent can be administered by the subject or another person.
[0543] Pulmonary delivery is effective not only for disorders that directly affect lung tissue, but also for disorders that affect other tissues.
[0544] The iRNA agent can be formulated as a liquid or non-liquid (eg, powder, crystal), or as an aerosol for pulmonary delivery.
[0545] Any of the iRNA agents described herein can be administered intranasally. Nasal administration can be achieved by introducing a delivery device into the nose, for example, by introducing a delivery device capable of dispensing a pharmaceutical agent. Nasal delivery methods include sprays, aerosols, liquids (e.g., via nasal drops), or topical administration to the surface of the nasal cavity. The pharmaceutical agent can be provided, for example, in a dispenser that delivers a wet or dry pharmaceutical agent in a form small enough to be inhaled. The device can deliver a metered amount of pharmaceutical agent. The pharmaceutical agent can be administered by the subject or another person.
[0546] Nasal delivery is effective not only for disorders that directly affect nasal tissue, but also for disorders that affect other tissues.
[0547] The iRNA agent can be formulated as a liquid or non-liquid (eg, powder, crystal), or for nasal delivery.
[0548] The iRNA agent can be packaged within a natural viral capsid, within an artificial capsid or structure derived therefrom produced chemically or enzymatically.
[0549] A dosage of a pharmaceutical composition containing an iRNA agent can be administered to alleviate the symptoms of a disease state (e.g., cancer, or cardiovascular disease). A subject can be treated with the pharmaceutical composition by any of the methods described above.
[0550] Gene expression in a subject can be modulated by administering a pharmaceutical composition that includes an iRNA agent.
[0551] A subject can be treated by administering a composition of a defined amount of an iRNA agent, e.g., a double-stranded iRNA agent, or an siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent), in powder form, e.g., a collection of fine particles, such as crystalline particles. The composition can include multiple iRNA agents, e.g., specific for one or more different endogenous target RNAs. The method can include other features described herein.
[0552] A subject can be treated by administering a defined amount of an iRNA agent composition prepared by a method including spray drying (i.e., atomizing a liquid solution, emulsion, or suspension, immediately exposing the droplets to a drying gas, and collecting the resulting porous powder particles). The composition can include multiple iRNA agents, e.g., specific for one or more different endogenous target RNAs. The method can include other features described herein.
[0553] An iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent which can be processed into an siRNA agent, or a DNA which encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) can be provided in powder, crystalline, or other finely divided form, with or without a carrier (e.g., microparticles or nanoparticles suitable for inhalation or other pulmonary delivery). This can include providing an aerosol preparation, e.g., an aerosolized spray-dried composition. The aerosol composition can be provided in or dispensed by a metered-dose delivery device.
[0554] A subject can be treated for a treatable condition by inhalation, e.g., by aerosolizing a composition of a spray-dried iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA that encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) and inhaling the aerosolized composition. The iRNA agent can be an siRNA. The composition can include multiple iRNA agents, e.g., specific for one or more different endogenous target RNAs. The method can include other features described herein.
[0555] A subject can be treated by administering a composition including an effective / defined amount of an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent which can be processed into an siRNA agent, or a DNA which encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof), where the composition is prepared by a method including spray drying, freeze drying, vacuum drying, evaporation, fluidized bed drying, or a combination of these techniques.
[0556] In another aspect, the invention features a method that includes assessing a parameter related to transcript abundance in a cell of a subject, comparing the assessed parameter to a reference value, and administering to the subject an iRNA agent (or a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or DNA encoding the iRNA agent or precursor thereof) if the assessed parameter has a preselected relationship to the reference value (e.g., is high). In one embodiment, the iRNA agent includes a sequence complementary to the assessed transcript. For example, the parameter can be a direct measurement of transcript levels, a measurement of protein levels, a measurement of a symptom or characteristic of a disease or disorder (e.g., cell proliferation rate and / or tumor mass, viral load).
[0557] In another aspect, the invention features a method that includes administering to a subject a first quantity of a composition that includes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA that encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof), where the iRNA agent includes a strand that is substantially complementary to a target nucleic acid, and assessing activity associated with a protein encoded by the target nucleic acid and using this assessment to determine whether to administer a second quantity. In some embodiments, the method includes administering a second quantity of the composition, where the timing or dosage of administration for the second quantity is a function of the assessment. The method can include other features described herein.
[0558] In another aspect, the invention features a method of administering to a subject a source of a double-stranded iRNA agent (ds iRNA agent). The method includes administering or implanting a source of a ds iRNA agent, e.g., an siRNA agent, that (a) includes a double-stranded region 19-25 nucleotides in length, e.g., 21-23 nucleotides, (b) is complementary to a target RNA (e.g., an endogenous RNA or a pathogen RNA), and, optionally, (c) includes at least one 3' overhang 1-5 nt in length. In one embodiment, the source releases the ds iRNA agent over an extended period of time, e.g., the source is a controlled- or delayed-release source (e.g., a microparticle that slowly releases the ds iRNA agent). In other embodiments, the source is a pump, e.g., a pump that includes a sensor or a pump that can release one or more unit doses.
[0559] In one aspect, the invention features a pharmaceutical composition that includes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA that encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) that includes a nucleotide sequence complementary (e.g., substantially and / or exactly complementary) to a target RNA. The target RNA can be a transcript of an endogenous human gene. In one embodiment, the iRNA agent (a) is 19-25 nucleotides in length, e.g., 21-23 nucleotides, (b) is complementary to an endogenous target RNA, and optionally (c) includes at least one 3' overhang 1-5 nt in length. In one embodiment, the pharmaceutical composition can be an emulsion, microemulsion, cream, jelly, or liposome.
[0560] In one example, the pharmaceutical composition comprises an iRNA agent mixed with a topical delivery agent. The topical delivery agent can be a plurality of microscopic vesicles. The microscopic vesicles can be liposomes. In some embodiments, the liposomes are cationic liposomes.
[0561] In another aspect, a pharmaceutical composition includes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent or precursor thereof, such as a double-stranded iRNA agent or siRNA agent) admixed with a topical penetration enhancer. In one embodiment, the topical penetration enhancer is a fatty acid. Fatty acids include arachidonic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicapric acid, tricapric acid, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitine, acylcholine, or C 1-10 It can be an alkyl ester, a monoglyceride, a diglyceride, or a pharmaceutically acceptable salt thereof.
[0562] In another embodiment, the topical penetration enhancer is a bile salt, which can be cholic acid, dehydrocholic acid, deoxycholic acid, glycolic acid, glycolic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate, polyoxyethylene-9-lauryl ether, or a pharmaceutically acceptable salt thereof.
[0563] In another embodiment, the penetration enhancer is a chelating agent, which can be EDTA, citric acid, salicylic acid, N-acyl derivatives of collagen, laureth-9, N-aminoacyl derivatives of β-diketones, or mixtures thereof.
[0564] In another embodiment, the penetration enhancer is a surfactant, such as an ionic or nonionic surfactant, which can be sodium lauryl sulfate, polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether, an emulsion of a perfluoro compound, or a mixture thereof.
[0565] In another embodiment, the penetration enhancer can be selected from the group consisting of unsaturated cyclic ureas, 1-alkyl-alkones, 1-alkenylazacyclo-alacanones, steroidal anti-inflammatory agents, and mixtures thereof. In yet another embodiment, the penetration enhancer can be a glycol, pyrrole, azone, or a terpene.
[0566] In one aspect, the invention features a pharmaceutical composition including an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA encoding an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof), in a form suitable for oral delivery. In one embodiment, oral delivery can be used to deliver the iRNA agent composition to a cell or region of the gastrointestinal tract, e.g., the small intestine, the large intestine (e.g., to treat colon cancer), etc. The oral delivery form can be a tablet, capsule, or gel capsule. In one embodiment, the iRNA agent of the pharmaceutical composition modulates expression of a cell adhesion protein, modulates the growth rate of a cell, or has biological activity against a eukaryotic pathogen or retrovirus. In another embodiment, the pharmaceutical composition includes an enteric material that substantially prevents dissolution of the tablet, capsule, or gel capsule in a mammalian stomach. In some embodiments, the enteric material is a coating. The coating agent can be acetate phthalate, propylene glycol, sorbitan monooleate, cellulose acetate trimellitate, hydroxypropylmethylcellulose phthalate, or cellulose acetate phthalate.
[0567] In another embodiment, the oral dosage form of the pharmaceutical composition includes a penetration enhancer. The penetration enhancer can be a bile salt or a fatty acid. The bile salt can be ursodeoxycholic acid, chenodeoxycholic acid, or a salt thereof. The fatty acid can be capric acid, lauric acid, or a salt thereof.
[0568] In another embodiment, the oral dosage form of the pharmaceutical composition includes an excipient. In one example, the excipient is polyethylene glycol. In another example, the excipient is Precirol.
[0569] In another embodiment, the oral dosage form of the pharmaceutical composition includes a plasticizer. The plasticizer can be diethyl phthalate, triacetin dibutyl sebacate, dibutyl phthalate, or triethyl citrate.
[0570] In one aspect, the invention features a pharmaceutical composition including an iRNA agent and a delivery vehicle. In one embodiment, the iRNA agent (a) is 19-25 nucleotides in length, e.g., 21-23 nucleotides, (b) is complementary to an endogenous target RNA, and optionally (c) includes at least one 1-5 nucleotide 3' overhang.
[0571] In one embodiment, a delivery vehicle can deliver an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA that encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) to a cell by a local route of administration. The delivery vehicle can be a microscopic vesicle. In one example, the microscopic vesicle is a liposome. In some embodiments, the liposome is a cationic liposome. In another example, the microscopic vehicle is a micelle. In one aspect, the invention features a pharmaceutical composition including an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent (e.g., a precursor, e.g., a larger iRNA agent that can be processed into an siRNA agent, or a DNA that encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof) in an injectable dosage form. In one embodiment, pharmaceutical compositions in injectable dosage form include sterile aqueous solutions or dispersions and sterile powders. In some embodiments, the sterile solution may include diluents such as water, saline, fixed oils, polyethylene glycol, glycerin, or propylene glycol.
[0572] In one aspect, the invention features a pharmaceutical c...
Claims
1. A compound having the structure shown in formula (I'): [Case 1] [In the formula, A and B are each independently selected from O, N(R N ), or S; one of X and Y is H, a phosphate group, a phosphite group, or a phosphoramidite, and the other of X and Y is a protecting group; R is L 1 or the following formula (II) to (V): [Case 2] having the structure shown in q 2A , q 2B , q 3A , q 3B , q 4A , q 4B , q 5A , q 5B , and q 5C is, independently for each occurrence, 0 to 20, where the repeat units may be the same or different; Q is not present or -(P 7 -Q 7 -R 7 ) p -T 7 - or -T 7 -Q 7 -T 7’ -B'-T 8’ -Q 8 -T 8 - and P 2A , P 2B , P 3A , P 3B , P 4A , P 4B , P 5A , P 5B , P 5C , P 7 , T 2A , T 2B , T 3A , T 3B , T 4A , T 4B , T 5A , T 5B , T 5C , T 7 , T 7’ , T 8 , and T 8’ are each independently absent, CO, NH, O, S, OC(O), NHC(O), CH 2 , C.H. 2 NH, or CH 2 O; B' is -CH 2 -N(B L )-CH 2 - and B L is -T B -Q B -T B’ -R X and Q 2A , Q 2B , Q 3A , Q 3B , Q 4A , Q 4B , Q 5A , Q 5B , Q 5C , Q 7 , Q 8 , and Q B is, independently for each occurrence, absent, alkylene, or substituted alkylene, where one or more methylenes are selected from O, S, S(O), SO 2 , N(R N ), C(R')=C(R'', C≡C, or C(O); T B and T B’ are each independently absent, CO, NH, O, S, OC(O), OC(O)O, NHC(O), NHC(O)NH, NHC(O)O, CH 2 , C.H. 2 NH, or CH 2 O; R Xis a lipophilic substance selected from the group consisting of cholesterol, cholic acid, adamantane acetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl radical, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl radical, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, and phenoxazine, or a cationic lipid selected from the group consisting of DOTMA, DOTAP, DOTB, DOGS, DPPES, DC-Chol, DMRIE, DMRIE-HP, and DOSPA; R 2A , R 2B , R 3A , R 3B , R 4A , R 4B , R 5A , R 5B , R 5C , and R 7 is independently absent or NH, O, S, CH 2 , C(O)O, C(O)NH, NHCH(R a )C(O), C(O)-CH(R a )-NH, CO, CH=N-O, [C3] or heterocyclyl; L 1 , L 2A , L 2B , L 3A , L 3B , L 4A , L 4B , L 5A , L 5B , and L 5C is, independently for each occurrence, a carbohydrate, or a derivative thereof having a hydroxyl protecting group, said carbohydrate being galactose or N-acetylgalactosamine (GalNAc); R′ and R″ are each independently selected from H, C, 1 -C 6 Alkyl, OH, SH, or N(R N ) 2 and R N is independently for each occurrence methyl, ethyl, propyl, isopropyl, butyl, or benzyl; R a is H or an amino acid side chain; and p, independently for each occurrence, is 0 to 20.
2. A and B are each O; one of X and Y is H and the other of X and Y is a protecting group; R has the structure shown in formula (V); Q is -P 7 -Q 7 -T 7 - and Q 7 is alkylene; L 5A , L 5B , and L 5C is, independently for each occurrence, a derivative of said carbohydrate having a hydroxyl protecting group The compound of claim 1.
3. X is H and Y is a protecting group; Q is -P 7 -Q 7 -T 7 - and P 7 is C(O) and Q 7 is alkylene, and T 7 is C(O)NH; The compound according to claim 2.
4. The compound according to any one of claims 1 to 3, wherein the carbohydrate is N-acetylgalactosamine (GalNAc).
5.
4. 2. The compound of claim 1 selected from the group consisting of:
6.
5. 3. The compound of claim 2,
7.
6. 2. The compound of claim 1,
8.
7. 2. The compound of claim 1,
9.
8. 2. The compound of claim 1,
10. A compound represented by the following formula: [C9]
11. A method of making compound 117, comprising the steps of: [C10] Hydroxyproline Compound 115: [C11] is hydrolyzed to give the hydroxyproline compound 116: [C12] forming Hydroxyproline compound 116 was reacted with ligand moiety compound 110: [C13] or a salt thereof under conditions effective to produce compound 117. A method comprising:
12. 12. The method of claim 11, wherein the hydrolyzing step is carried out in the presence of LiOH in THF / DCM / water, followed by neutralization with acetic acid.
13. 12. The method of claim 11, wherein the step of reacting the hydroxyproline compound 116 with the ligand moiety compound 110 is carried out in the presence of HBTU / DIEA in DMF or TBTU / HOBt / DIEA in DMF.
14. GalNAc acid 103: [C14] to branched linker compound 108: [C15] or a salt thereof, and a ligand moiety compound 109: [C16] reacting under conditions effective to form hydrogenating said ligand moiety 109 under conditions effective to form ligand moiety 110. The method of claim 11 further comprising:
15. 15. The method of claim 14, wherein the step of reacting GalNAc acid 103 with branched linker compound 108 is carried out in the presence of HBTU / DIEA / HOBt in DMF.
16. The step of hydrogenating the ligand moiety compound 109 comprises hydrogenating the ligand moiety compound 109 with H in the presence of Pd / C, methanol, and acetic acid. 2 The method of claim 14, which is carried out using
17. GalNAc derivative compound 102: [C17] under conditions effective to form GalNAc acid compound 103.
18. The step of hydrogenating the GalNAc derivative compound 102 comprises hydrogenating the compound 102 with H in the presence of Pd / C, methanol, and acetic acid. 2 The method of claim 17, which is carried out using
19. Branched Linker Compound 106: [C18] and a linker compound: [C19] to produce branched linker compound 107: [C20] forming deprotecting the N-protecting group of branched linker compound 107 under conditions effective to form branched linker compound 108. The method of claim 14 further comprising:
20. 20. The method of claim 19, wherein the step of reacting the branched linker compound 106 with the linker compound is carried out in the presence of HBTU / DIEA in DMF.
21. 20. The method of claim 19, wherein the deprotecting step is carried out in the presence of TFA / DCM.
Citation Information
Patent Citations
Conjugates of hydroxyalkyl starches with proteins
JP2007527891A
Nanoparticles comprising RNA ligands
WO2005116226A2
Chemically modified oligonucleotides
WO2006020768A2
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
WO2006078278A2
